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Abstract 
Aplastic anaemia (AA) is a disorder resulting in pancytopenia and hypocellular bone 
marrow. Although the immunological nature of AA pathogenesis is widely accepted, 
there is an increasing recognition that a significant number of AA patients might present 
dysfunctional haematopoietic stem or progenitor cells. In this study, induced pluripotent 
stem cell (iPSC) technology was used to reprogram fibroblasts from four paediatric 
severe AA (SAA) patients and three unaffected controls. SAA-iPSC lines were 
successfully differentiated into erythroid and myeloid progenitors and cells. Two key 
differences were observed in three of the four SAA patients: (1) SAA-iPSC generated 
a reduced number of erythroid and myeloid cells and (2) SAA-iPSC failed to elongate 
their telomeres during the reprogramming process. These deficiencies comprise two 
key features of AA and indicate that the iPSC model closely mimics the disease 
phenotype. These deficiencies also suggest that some (but not all SAA) may be 
characterised by an underlying genetic predisposition which impacts the proliferation 
and/or differentiation of erythroid and myeloid cells. 
 
A detailed flow cytometric analysis indicated a significant reduction in the fraction of 
proliferative iPSC-derived-haematopoietic progenitors in three SAA patients. Likewise, 
significant levels of replicative stress-associated DNA damage were observed in iPSC-
derived-haematopoietic progenitors from one of the SAA patients, which may suggest 
an impaired DNA damage response in the face of replicative stress. 
 
Finally, thrombopoietin-receptor agonist eltrombopag was investigated in the iPSC 
model system and was shown to have no significant effect on the, proliferation, DNA 
repair and erythroid/myeloid colony-forming potential of SAA-iPSC derived 
haematopoietic progenitors under normal or stress conditions.  
 
In summary, the data generated from this study highlights the utility of patient specific 
iPSC in providing a disease model for SAA, in identifying likely constitutional cases for 
further genetic studies and predicting patient specific responses to available and future 
drugs.  
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1 Chapter 1. Introduction 
1.1 Aplastic anaemia 
1.1.1 Definition 
Aplastic anaemia is a rare and heterogeneous disorder defined as a clinical syndrome 
that results from a marked reduction of marrow blood cell production and characterized 
by low blood cell counts (pancytopenia) and hypocellular bone marrow (Figure 1) in 
the absence of neoplasia and reticulin fibrosis (Killick et al., 2016).  
 
Figure 1. Normal and aplastic anaemia bone marrow biopsies. 
(A) Normal bone marrow characterised by presence of haematopoietic cells and fat cells; (B) Aplastic 
anaemia bone marrow with extremely reduced number of haematopoietic cells and elevated presence 
of fat cells. Reproduced from Raghupathy et al. 2012 (Raghupathy and Derman, 2012) 
1.1.2 Classification of aplastic anaemia 
According to its aetiology, aplastic anaemia can be classified as inherited or acquired 
(Table 1). Inherited syndromes represent a 15-20% of aplastic anaemia cases the 
most common being Fanconi anaemia (FA) followed by telomeropathies such as 
dyskeratosis congenita (DC). On the other hand, aplastic anaemia might be acquired 
by exposure to environmental factors such as radiotherapy, drugs, toxins or viruses 
that would lead to the destruction of the haematopoietic stem cells (HSC) in the bone 
marrow. However, they account for a small fraction of the cases and no causal 
aetiology to the pathogenesis of acquired aplastic anaemia has been found for any of 
these agents (Young et al., 2008). To date 70-80% of the total cases of diagnosed 
aplastic anaemia account for idiopathic cases where the aetiology remains unknown 
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or poorly understood (Marsh et al., 2009). In this study we will focus on the study of 
the potential pathogenic mechanisms associated with idiopathic aplastic anaemia (AA).  
 
Aetiology Syndrome Cause associated 
Inherited 
Fanconi Anaemia (FA) 
Mutations in FANC 
complementation groups 
Dyskeratosis congenita (DC) 
Mutations in DKC1, TERC, TERT, 
NOP10, ACD, NOLA2, NOLA3, 
TCAB1, TINF2, RTEL1 genes 
Schwachman-Diamond 
syndrome (SDS) 
Mutations in SBDS gene 
Congenital amegakaryocytic 
thrombocytopenia (CAMT) 
Mutations in MPL gene 
Acquired 
Acquired aplastic anaemia 
Environmental factors (irradiation, 
drugs, chemicals, viruses) 
Idiopathic aplastic anaemia 
(AA) 
Unknown 
 
Table 1. Classification of aplastic anaemia according to aetiology 
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1.1.3 Epidemiology and clinical presentation of AA 
1.1.3.1 Epidemiology  
The incidence rate of AA is 2-3 per million per year in Europe and North America and 
2-3 fold higher in East Asia (Montane et al., 2008). Incidence of AA follows a bimodal 
distribution, with peaks among young adults (from 10 to 25 years) and elderly patients 
(over 60 years), and incidence ratio of approximately of one between male and female 
in all modern studies (Young and Kaufman, 2008).  
1.1.3.2 Clinical presentation  
Patients with AA show a clinical presentation related to anaemia due to the low 
numbers of red blood cells, skin/mucosal/retinal haemorrhage caused by the  
thrombocytopenia, and recurrent neutropenia-related infections (Killick et al., 2016). 
Likewise, AA patients do not present abnormal lymph nodes (lymphadenopathy) or 
enlarged liver and spleen (hepatosplenomegaly) in the absence of infection (Gordon-
Smith, 1991).  
1.1.4 Diagnosis and management of AA 
1.1.4.1 Diagnosis of AA 
AA diagnosis is characterised by neutrophil count fewer than 1.5x109/L, a haemoglobin 
concentration less than 100g/L and a platelet count fewer than 50x109/L according to 
established Camitta criteria (Camitta et al., 1975) and two lineages in peripheral blood 
cells must be affected. The number of lymphocytes does not appear to be affected in 
AA patients. Based on the blood counts and the degree of marrow hypocellularity, AA 
has been stratified into moderately severe, severe and very severe (Camitta et al., 
1975; Bacigalupo et al., 1988) (Table 2).   
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Degree Bone marrow cellularity Blood cell count 
Non-severe AA 
(NSAA) 
Patients not fulfilling the criteria for severe and very severe AA 
Severe AA 
(SAA) 
<25%  
Or 
25-50% with <30% residual 
haematopoietic cells 
compared to normal controls 
At least one of 
the following 
Neutrophils 
<0.5x109/L 
Platelets 
<20x109/L 
Reticulocytes 
<20x109/L 
Very Severe AA 
(VSAA) 
<25%  
Or 
25-50% with <30% residual 
haematopoietic cells 
compared to normal controls 
At least one of 
the following 
Neutrophils 
<0.2x109/L 
Platelets 
<20x109/L 
Reticulocytes 
<20x109/L 
Table 2. Degrees of severity of AA according to bone marrow cellularity and blood cell counts 
However, appropriate diagnosis and management of AA can be challenging since 
clinical features as hypocellular bone marrow and low blood cell counts can be also 
found in inherited and clonal disorders associated with aplastic anaemia (Figure 2). 
This overlap observed in AA and inherited forms of aplastic anaemia, referred as bone 
marrow failure syndromes (BMFS) thereinafter, such as DC and Schwachman-
Diamond syndrome (SDS), is likely due to shared pathogenic mechanisms (Young et 
al., 2008). Likewise, reduced stem cell compartment, which is characteristic for AA, 
can favour the evolution to clonal disorders such as myelodysplastic syndrome (MDS) 
paroxysmal nocturnal haemoglobinuria (PNH) and acute myeloid leukaemia (AML). 
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Figure 2. Clinical association of AA with inherited aplastic anaemia and clonal disorders. 
DC, dyskeratosis congenita; SDS, Schwanman-Diamond syndrome, AA, idiopathic aplastic anaemia; 
PNH, paroxysmal nocturnal haemoglobinuria; MDS, myelodysplastic syndrome; AML, acute myeloid 
leukaemia. Adapted from Young et al. 2006 (Young et al., 2006) 
AA is diagnosed by exclusion. The British Journal of Haematology published in 2009 
the AA diagnosis and management guidelines as a series of tests recommended to 
confirm the clinical manifestation of AA and exclude other causes of pancytopenia and 
bone marrow hypocellularity as well as assessment of the severity of the disorder 
(Marsh et al., 2009) (Figure 3). Likewise, in order to rule out influence of drugs or 
chemicals that might be involved in the aetiology of the AA, careful drug and 
occupational exposure history would be required during diagnosis. 
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Figure 3. Diagnosis of AA. 
DEB, diepoxybutane; MMC, mitomycin C; FA, Fanconi anaemia; DC, dyskeratosis congenital; BMFS, 
bone marrow failure syndrome; HIV, human immunodeficiency virus; MDS, myelodysplastic syndrome; 
GPI, glycerophosphatidylinositol; PNH: paroxysmal nocturnal haemoglobinuria 
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Patients with BMFS usually present physical features such as short stature, skin areas 
with hyper/hypo pigmentation and skeletal abnormalities in FA and dystrophy, oral 
leucoplakia and reticular skin pigmentation in DC (Shimamura and Alter, 2010). Clinical 
assessment for these characteristic features together with the required family history 
for potential existence of other family affected members can confirm the diagnosis of 
BMFS. However, BMFS patients present a high degree of heterogeneity in the disease 
phenotype with different genes potentially associated with the aetiology of the disorder  
(Vulliamy et al., 2006). Additionally, physical features associated with BMFS may 
present a late onset or may remain absent even in adult life making necessary the use 
of additional tests for diagnosis (Zhang et al., 2015). This makes the distinction of AA 
and BMFS rather difficult leading to misdiagnosis of BMFS cases as AA and 
inappropriate treatment. Thus, Fogarty et al. reported in 2003 that five percent of AA 
patients are undiagnosed cases of BMFS where the established abnormal phenotype 
characteristic of these patients was not apparent (Fogarty et al., 2003).  
 
Alternatively, AA may present or evolve to clonal disorders such as MDS, PNH and 
AML (Figure 2). Hypocellular MDS patients can present a profound cytopenia and 
extreme hypocellular bone marrow making it difficult to distinguish from AA in clinical 
diagnosis. However, there are features characteristic of hypocellular MDS such as 
dysplastic megakaryocytes, increased blasts in the bone marrow or blood and 
presence of reticulin fibrosis in trephine samples that are not common in AA patients 
helping in the diagnosis (Bennett and Orazi, 2009). In recent years, different studies 
have shown that around 20-25% of AA patients present acquired somatic mutations in 
genes such as ASXL1 and DNMT3A which could predispose to clonal evolution to 
MDS (Kulasekararaj et al., 2014; Yoshizato et al., 2015). Around 40-50% of AA patients 
have PNH clones resulting for the somatic PIG-A mutations in HSC (Young, 2005). 
However, the presence of these PNH clones does not necessarily imply the clinical 
manifestation of PNH since the number of these clones can reduce, remain stable or 
even disappear. In contrast, an expansion of the PNH clones in the multipotent HSC 
population can lead to the evolution of AA into the classic PNH (AA/PNH) with clinical 
manifestation of the characteristic haemolysis of PNH (Pu et al., 2012). Mechanisms 
leading to this clonal expansion and advantage of the PNH clones in the HSC 
compartment of AA patients remain unknown although it has been hypothesized that 
8 
 
the absence of GPI proteins in PNH clones provides a mechanism to escape the 
immune attack associated with AA pathogenesis (Murakami et al., 2002).  
1.1.4.2 Management of AA  
AA patients undergo supportive care such as packed red blood cell transfusions in 
order to alleviate anaemia symptoms and platelet transfusions when platelet levels are 
below 10x109/L or in case of frequent bleeding and bruising to improve symptoms 
associated with thrombocytopenia (Miano and Dufour, 2015). Prevention of infection 
is highly considered in patients with severe neutropenia as well as granulocyte 
transfusions for those affected by infections (Quillen et al., 2009) since it is the major 
cause of mortality in AA patients (Dezern and Brodsky, 2011). However, more curative 
treatments have been developed to overcome the disorder and restore permanently 
normal levels of blood cells in AA patients. The choice of treatment to apply to AA 
patients depends on several factors such as the severity of the disease, the age of the 
patient and the availability of a suitable human leukocyte antigen (HLA)-matched HSC 
donor (Marsh et al., 2009). Patients with non-severe AA are advised regular follow-ups 
if they are not transfusion dependent (Kwon et al., 2010). For patients with severe AA 
(SAA) and very severe AA (VSAA) two main options of treatment are considered 
depending on the factors mentioned above: syngeneic or allogeneic haematopoietic 
stem cell transplantation (HSCT) and immunosuppressive therapies (IST) (Marsh et 
al., 2009) (Figure 4).  
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Figure 4. Proposed algorithm for treatment of SAA patients. 
Solid lines indicate first-line treatment whereas dashed line indicates alternative treatment. SAA, severe 
idiopathic aplastic anaemia; HLA, human leukocyte antigen; HSCT, haematopoietic stem cell 
transplantation; ATG, anti-thymocyte globulin; CSA, cyclosporine. Adapted from Killick et al. 2016 (Killick 
et al., 2016) 
The first-line of treatment for SAA/VSAA patients <35 years is HSCT from HLA-
matched sibling donor if available with 70-80% survival rate reported (Gupta et al., 
2010). This approach has serious complications such as rejections and chronic graft-
versus-host disease (Young et al., 2010). IST is the treatment of choice for SAA/VSAA 
patients >50 years and second-line treatment for adult patients 35-50 years who do 
not have a HLA-matched sibling donor (Sureda et al., 2015). Combination of horse 
anti-thymocyte globulin (ATG) and cyclosporine (CSA) represents the first line of IST 
with a response of 50% in the first three months and around 75% in 6 months (Young 
et al., 2010). However, AA patients might show refractory to IST treatment and 
cytopenia-associated symptoms might persist after 3-6 months. In the cases with lack 
of IST response, HSCT from HLA-matched or alternatively unrelated donor is 
recommended if available. Likewise, if no suitable donor can be found, a second 
course of IST is advised using rabbit or horse ATG (Killick et al., 2016). Alternate 
approaches can be used for patients who failed to respond to a second round of IST 
including the use of experimental drugs such as eltrombopag (EP) and danazol.  
 
EP is a non-peptide molecule mimetic to thrombopoietin (TPO). It has an additive effect 
to TPO since it does not bind at the same domain of the TPO receptor (MPL). Activation 
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of TPO signalling leads to megakaryocyte expansion and maturation as well as platelet 
release (Erickson-Miller et al., 2009). Haematopoietic stem and progenitor cells 
(HSPCs) harbour TPO receptors (Zeigler et al., 1994) and TPO signalling has been 
shown to be critical for HSC homeostasis and expansion (Alexander et al., 1996; Qian 
et al., 2007). EP has been originally used to treat immune thrombocytopenia purpura 
(ITP), an autoimmune disorder characterized by a destruction of platelets and inhibition 
of platelet production mediated by antibodies (Zhang and Kolesar, 2011). Recently, 
Desmond et al., in a recent update of the Phase II study originally published by Olnes 
et al, confirmed the efficacy of EP in stimulating bi- and trilineage haematopoiesis by 
increasing platelet and neutrophil counts and haemoglobin levels with 40% of SAA 
patients showing response at 3-4 months (Desmond et al., 2014). Likewise, an 
increase in the bone marrow cellularity in some of the AA responders to EP was 
observed. Interestingly, patients that were withdrawn of EP showed normal stable 
blood counts and normocellular bone marrow after 24 months off drug. The authors of 
the study hypothesized that EP favours the generation of certain number of HSC that 
can sustain normal levels of blood cells once the patients are removed from treatment 
(Desmond et al., 2015). Likewise, it has been suggested that EP might increase 
regulatory T cell activity in AA patients restoring immune tolerance as demonstrated 
by the inhibition of autologous activated T cells by TPO-receptor agonists in ITP 
patients (Marsh and Mufti, 2014). However, there is a general concern regarding clonal 
evolution since around 20% of the patients treated with EP developed clonal 
cytogenetic abnormalities. Stimulation of HSPC proliferation by EP might lead to 
accelerated telomere attrition that can cause destabilization of the genome and 
emergence of clonal transformation has been proposed as a mechanism to explain 
clonal evolution of treated patients (Desmond et al., 2015).  Thus, how EP is promoting 
the generation of blood cells and impacting HSPC from AA patients remains 
undetermined. 
1.1.5 Pathophysiology of AA  
Very reduced numbers of HSPC is a consistent finding observed in the bone marrow 
of AA (Scopes et al., 1994; Maciejewski et al., 1996; Manz et al., 1996; Schrezenmeier 
et al., 1996; Rizzo et al., 2002; Matsui et al., 2006). Likewise, haematopoietic 
progenitors of AA patients have shown an impaired capacity to form haematopoietic 
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progenitor colonies when assayed in in vitro clonogenic assays (Marsh et al., 1990; 
Bacigalupo et al., 1992; Rizzo et al., 2004). Several potential mechanisms leading to 
increased apoptosis and/or reduced proliferation and differentiation capacity have 
been traditionally linked to pathogenesis of AA including immune suppression of the 
HSC in the bone marrow, underlying dysfunction of the HSPCs and defective bone 
marrow mesenchymal stem cells (MSC) (Figure 5).   
 
Figure 5. Proposed mechanisms and aetiologies associated with AA pathogenesis 
1.1.5.1 Immune destruction of HSPC in the bone marrow 
The strongest evidence supporting the immune mediated destruction of bone marrow 
in AA is the fact that around 80% of AA patients show response to IST (Young et al., 
2006). There is compelling evidence suggesting that HSCs in the bone marrow of AA 
patients suffer an autoimmune suppression by cytotoxic T lymphocytes. Elevated 
levels of interferon gamma (IFN-γ) in serum of 30% of AA patients (Nistico and Young, 
1994), the presence of tumour necrosis factor alpha (TNF-α) in the bone marrow of a 
large number of AA patients as well as detection of specific T helper lymphocytes and 
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oligoclonal T cytotoxic lymphocytes in AA patients support the autoimmune basis 
associated with AA pathogenesis (Risitano et al., 2004; Kordasti et al., 2012). Thus, 
this immune-related marrow failure in AA is based on the induction of apoptosis of 
multipotential haematopoietic progenitors by inhibitory cytokines secreted by cytotoxic 
T lymphocytes (Sloand et al., 2002). Activation of cytotoxic T lymphocytes by antigen 
recognition leads to the production of interleukin-2, (Giannakoulas et al., 2004), clonal 
polyclonal expansion of T lymphocytes (Kordasti et al., 2012) and up-regulation of T 
lymphocytes receptors (Ren et al., 2014) and Fas receptor in haematopoietic 
progenitor cells by IFN-γ and TNF-α (Kakagianni et al., 2006) (Figure 6).  
 
 
Figure 6. Immune-mediated destruction of haematopoietic progenitor cells in AA. 
IFN-γ, interferon gamma; TNF, tumour necrosis factor; IRF-1, interferon regulatory factor-1; NOS, nitric 
oxide synthase; NO, nitric oxide. Reproduced from Marsh 2005 (Marsh, 2005)  
IFN-γ secreted by cytotoxic T lymphocytes induces activation of interferon regulatory 
factor-1 (IRF-1) which inhibits the transcription of cellular genes and cell cycle 
progression and induces the production of nitric oxide synthase (NOS) and nitric oxide 
(NO) ultimately leading to cell death by apoptosis of the haematopoietic progenitor 
cells in the bone marrow (Young et al., 2006). Likewise, decreased levels of regulatory 
T lymphocytes might explain excessive presence of cytotoxic and helper T 
lymphocytes, therefore supporting an immune-related destruction of haematopoietic 
progenitor cells (Solomou et al., 2007). What triggers the activation of T lymphocytes 
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remains unclear. Young et al hypothesized that this aberrant activation of T cells in AA 
might have a genetic basis since it has been reported that the frequency of human 
leukocyte antigen (HLA) DR2 haplotype is significantly increased in AA patients and 
specific polymorphisms in TNF2, IFN-γ and IL-6 genes are associated with a high 
production of these cytokines in AA patients (Young et al., 2006). A microarray gene 
expression analysis of the CD34+ haematopoietic progenitors from AA bone marrow 
patients revealed that genes associated with apoptosis, cell death and 
defence/immune regulation were the most differentially up-regulated compared to 
CD34+ progenitors from healthy volunteers (Zeng et al., 2004). IFN-γ and TNF-α inhibit 
in vitro haematopoietic colony formation capacity of bone marrow progenitors by 
inducing apoptosis through increased expression of Fas receptor (Maciejewski et al., 
1995). Thus, the increased levels of proinflammatory cytokines present in AA patients 
would explain this significantly induced apoptosis observed in the AA haematopoietic 
progenitors indicating that it could be secondary to T cell-mediated destruction. 
Likewise, similarly to the study published in 2004, Zeng et al. used microarray 
technologies in 2006 to analyse the effect of IFN-γ on CD34+ haematopoietic 
progenitors from healthy volunteers. They observed that IFN-γ-induced CD34+ 
haematopoietic progenitor cells from healthy volunteers showed an upregulation of 
apoptotic and immune response genes in a similar fashion than the CD34+ from AA 
patients providing more evidence of the role of IFN-γ in the pathogenesis of AA (Zeng 
et al., 2006).        
1.1.5.2 HSPC defect  
No response or relapse after IST observed in a substantial number of AA patients might 
also indicate an underlying defect of the HSPC in these patients. Several intrinsic 
deficits have been observed in AA-HSPC that might be associated with the 
pathophysiology of AA, including increased apoptosis and reduced proliferation and 
differentiation capacity. Excessive telomere shortening and defective cell cycle 
checkpoints could explain this aberrant behaviour observed in AA HSPC. 
 
Telomere shortening. Telomeres are structures located at the end of the 
chromosomes that protect them from being recognized by cellular DNA damage 
response mechanisms as double-strand breaks that otherwise could lead to end-to-
end chromosome fusions and nonreciprocal translocations (Blasco, 2005). In each cell 
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division the telomere length of the daughter DNA strand is shortened about 50-100 
base pair due to what is called the end-replication problem (Huffman et al., 2000) 
(Figure 7).  
 
Figure 7. End replication problem. 
In telomerase-negative cells, telomeres shorten in the 5’ end of the lagging strand in every division due 
to incomplete replication when RNA primers (in red) are removed. Once the telomeres become critically 
short, a DNA damage signalling response is activated leading to replicative senescence. In telomerase-
positive cells, telomerase complex uses its RNA component (in orange) to elongate the 5’ end of lagging 
strand maintaining telomere length and unlimited proliferative capacity. Reproduced from Wong et al 
2014 (Wong et al., 2014)  
Telomere shortening is a mechanism developed to avoid indefinite proliferation of cells 
suppressing risk of tumorigenesis associated with aberrant replication (Hackett and 
Greider, 2002). When telomeres become critically short, cellular mechanisms that lead 
to cell proliferation arrest or apoptosis are activated protecting the cell from 
chromosomal instability that could ultimately lead to malignant transformation 
(Bernardes de Jesus and Blasco, 2013). In humans, telomeres are formed by 
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hundreds of repetitions of a specific sequence, TTAGGG in the sense strand and 
CCCTAA in the antisense strand. In order to protect the end of chromosomes from 
being recognized as double-strand breaks, telomeres are structured forming a terminal 
loop structure (T loop) (Griffith et al., 1999) together with a telomere-binding protein 
complex named shelterin (de Lange, 2005) (Figure 8A). To overcome the end 
replication problem, cells with high proliferative capacity are able to extend the 
telomere length by activating the telomerase complex (Collins and Mitchell, 2002) 
(Figure 7). Excessive telomere shortening has been linked to AA pathogenesis since 
leukocytes with significantly short telomeres have been identified in one third of AA 
patients, especially those who are refractory to IST (Ball et al., 1998; Brummendorf et 
al., 2001). To date several components have been involved in human telomere 
maintenance including telomerase complex, RNA chaperone TCAB1, CST complex, 
DNA helicase RTEL1 and the shelterin complex (Figure 8B).   
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Figure 8. Telomere protection and maintenance. 
(A) Telomere protection. The 3’ G-overhang present at the end of the leading strand in human telomeres 
invades the double-stranded TTAGGG repeats forming the telomeric loop (T-loop) with the help of the 
shelterin complex (TRF1, TRF2, TIN2, RAP1, TPP1 and POT1).  Reproduced from O’Sullivan et al. 
2010 (O'Sullivan and Karlseder, 2010). (B) Telomerase maintenance components. Telomerase complex 
consists of reverse transcriptase telomerase (TERT), an RNA template (TERC) and a protein scaffold 
complex involved in the stability and recruitment of telomerase to telomeres (dyskerin, NOP10, NHP2 
and GAR). TCAB1 is involved in the trafficking of the telomerase complex along the telomeric ends. 
CST complex is associated with telomerase activity inhibition and lagging strand synthesis. RTEL1 
unwinds the T loop needed for telomere elongation and shelterin complex is also involved in recruitment 
and regulation of the telomerase complex. Reproduced from Townsley et al. 2014 (Townsley et al., 2014) 
Mutations in any of the genes involved in telomere maintenance and protection might 
result in accelerated telomere attrition in high proliferative cells such as HSPCs leading 
to low proliferative capacity and reduced haematopoietic function (Calado and Young, 
2008). In DC patients, mutations in genes encoding for telomerase complex 
components such as TERT (Marrone et al., 2007), TERC (Vulliamy et al., 2001), DKC1 
(Mitchell et al., 1999) and NOP10 (Walne et al., 2007), genes encoding for a DNA 
helicase RTEL1 (Walne et al., 2013) and shelterin complex component TINF2 (Savage 
et al., 2008) have been described. In  AA, approximately 4% of patients present 
mutations in TERT (Yamaguchi et al., 2005) and TERC (Yamaguchi et al., 2003) genes 
and less of 1% have mutations in genes TERF1 and TERF2  encoding for shelterin 
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components (Savage et al., 2006). Interestingly, not all AA patients with mutations in 
TERT/TERC genes show DC-associated phenotypic features. This highly variable 
phenotypic expression in patients with mutations in TERC and TERC suggests that 
other factors might also be involved in bone marrow failure (Yamaguchi et al., 2005). 
Many AA patients have relatives with the same mutation in telomere-associated genes 
displaying short telomeres but normal blood counts (Fogarty et al., 2003).  In order to 
explain this, Calado et al suggested that HSPC with short telomeres and mutations in 
telomere-associated genes might be able to maintain normal haematopoiesis but are 
unable to cope with the stress induced by immune attack or environmental factors due 
to their reduced telomere length (Calado and Young, 2008). Therefore, mutations in 
telomere-associated genes should be considered risk factors of bone marrow failure 
and not genetic determinants. 
 
Nevertheless, only 10% of AA patients displaying short telomeres present mutations 
in previously characterised telomere-associated genes (Young et al., 2006). First, 
excessive telomere shortening has been suggested to be the result of increased 
proliferative stress in HSPC as compensatory mechanism to replenish the reduced 
bone marrow stem cell compartment as reported in patients following allogeneic HSCT  
(Gadalla and Savage, 2011). However, telomere attrition rate observed in patients with 
mutations in telomere-associated genes is more pronounced, more than 3kb, than the 
shortening produced due to ‘regenerative stress’ after transplantation, less than 1kb 
(Calado and Young, 2008). Excessive telomere shortening observed in AA patients 
could be also explained by the presence of mutations in telomere pathway-associated 
genes uncharacterised to date due to the complexity of the telomere maintenance, 
regulation and repair processes. Difficulties identifying these genetic defects could be 
also explained by the hypothesis that manifestation of the abnormal phenotype is not 
entirely originated by mutations in these genes but also environmental factors inducing 
bone marrow failure in genetically predisposed AA patients as suggested by Calado et 
al. (Calado and Young, 2008). 
 
As discussed in section 1.1.4 of this introduction, evolution of AA into clonal disorders 
such as MDS and PNH due to the reduced stem cell compartment in the bone marrow 
has been described in some AA patients. Presence of short telomeres in AA patients 
would provide an explanation to this increased probability to develop clonal disorders 
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and risk of relapse observed in these patients due to the chromosomal instability 
associated with critically reduced telomere length  (Scheinberg et al., 2010; Dumitriu 
et al., 2015).   
 
Cell cycle deregulation. Potential role of cell cycle deregulation in AA pathogenesis 
was recently proposed by Zeng et al. on the basis that defective proliferation capacity 
might explain insufficient generation of haematopoietic cells despite the abundance of 
haematopoietic growth factors present in AA patients (Zeng and Katsanis, 2015). As 
described by these authors in 2004, besides displaying up-regulation of genes 
associated with apoptosis, CD34+ haematopoietic progenitor from AA patients also 
showed a significant up-regulation of genes associated with inhibition of cell cycle entry 
and down-regulation of cell proliferation and cell-cycle progress-enhancing genes such 
as cyclin-dependent kinase (CDK) genes and cell division cycle (CDC) genes (Zeng et 
al., 2004). Likewise, it is also hypothesized that down-regulation observed in the same 
study of other cell cycle “checkpoint” genes such as FANCG, c-myb and c-myc might 
also explain susceptibility of AA patients to develop clonal disorders. It remains 
undetermined if these cell cycle defects observed in AA CD34+ progenitors might be 
associated with telomere dysfunction.     
1.1.5.3 Defective bone marrow MSCs  
Bone marrow stroma is formed by adipocytes, fibroblasts, osteoblasts, osteoclasts and 
endothelial cells, all derived from mesenchymal stem cells (MSC), providing a suitable 
microenvironment for haematopoiesis, protecting stem cells from damage and 
restraining them from differentiation (Muguruma et al., 2006). Likewise, MSCs play an 
important role regulating immune cells function (Uccelli et al., 2008). There are 
conflicting results in the literature regarding the role of MSC in the pathogenesis of AA. 
Some studies have shown that MSC from AA patients had low proliferation activity, 
were more prone to differentiate into adipocytes than osteoblasts and deficient in 
suppressing T cell activation/proliferation (Chao et al., 2010; Li et al., 2012). However, 
this hypothesis seems unlikely since functionality of MSC in AA patients was 
demonstrated in an elegant crossover experiment carried out by Marsh et al. showing 
that AA stromal cells support normal growth of CD34+ cells from healthy volunteers 
whereas CD34+ cells from AA patients still showed poor growth properties when 
cultured on normal stromal cells (Marsh et al., 1991). Additionally, other studies have 
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also shown normal functionality and immunosuppressive properties of the MSC of AA 
patients (Xu et al., 2009; Bueno et al., 2014). Not sufficiently large populations and 
differences in the degree of severity and the age of AA patients at diagnosis in these 
studies might explain the divergences in the results with regards to the role of bone 
marrow MSCs in AA pathogenesis. 
1.1.6 Current problems in the investigation of AA   
Several studies have reported the use of CD34+ from AA patients in in vitro clonogenic 
assays to investigate the numbers of HSPC in the bone marrow and their clonogenic 
properties. In these studies CD34+ progenitors from AA patients appeared in extremely 
low numbers in the bone marrow and also showed a reduced ability to generate 
haematopoietic progenitor colonies (see section 1.1.5). Thus, acquisition of HSPC 
from AA patients to evaluate stem cell function and properties is extremely difficult due 
to the paucity of these cells in the bone marrow of these patients. Likewise, use of 
HSPC from AA patients for disease modelling studies is also restricted by the absence 
of valid protocols to properly expand HSC in vitro (Walasek et al., 2012). As an 
example, the microarray gene expression analysis of CD34+ from AA patients reported 
by Zeng et al. needed to pool RNA from several AA patients in order to provide 
sufficient material to perform the gene expression analysis of AA CD34+ progenitors 
(Zeng et al., 2004).  Currently, there are no animal models suitable for the in vivo study 
of AA (Elbadry et al., 2017). Animal models have been generated to study the bone 
marrow failure induced by different toxic chemicals as well as to investigate the role of 
the different factors involved in immune-mediated mechanisms associated with AA 
pathogenesis (Chen, 2005; Scheinberg and Chen, 2013). This involves infusing 
haploidentical parental lymphocytes into offspring (Chen et al., 2004), administration 
of toxic drugs such as chloramphenicol (Turton et al., 2000) or busulfan, exposure to 
ionizing radiation (Meng et al., 2003) or generation of genetically modified mice (Trf-1 
and Tert-deficient) displaying short telomeres (Bar et al., 2016). However, these 
models do not recapitulate the entire spectrum of AA. Additionally, animal models have 
been also used to model BMFS such as FA, DC and Diamond-Blackfan anaemia (DBA) 
among others providing valuable insights into the pathological mechanisms of these 
syndromes. Thus, Beier et al. generated a conditional and bone marrow-specific Trf1 
mouse mutant to address the possible role of the shelterin component protein Trf1 in 
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the pathogenesis of BMFS (Beier et al., 2012). Trf1-deleted haematopoietic 
progenitors displayed increased cellular senescence resulting in telomere shortening 
of wildtype haematopoietic progenitors by hyper-proliferation and high turnover to 
compensate for constant progenitor loss. This study highlights the importance of the 
different components associated with telomere pathway and how mutations in those 
components might lead to bone marrow failure. Despite the existence of these animal 
models, important physiological differences between animal and humans can prevent 
the recapitulation of the disease phenotype in animal models (Adam et al., 2017). 
Disease causing mutations in humans might have the same mechanistic role in 
animals leading to differences in the abnormal phenotype. The need to create double 
knock-outs in the FANC genes in mice to recapitulate FA phenotype observed in 
humans or prolonged breeding of knock-out mice during several generations in order 
to erode sufficiently telomeres due to longer telomere length and shorter lifespan of 
mice are some of the problems that undermine the utility of animal models to 
investigate disease mechanisms and pathology of BMFS. Thus, there is an urgent 
need to generate a human AA disease model that can complement animal model 
studies and be used as a platform to provide insight into the underlying dysfunction of 
AA-HSPCs.  
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1.2 Induced Pluripotent Stem Cell Technology (iPSC) technology 
Pluripotent stem cells (PSCs) are capable of unlimited self-renewal capacity and have 
the potential to differentiate into tissues of all three germ layers contributing to the 
generation of all somatic cell types of the human body (De Los Angeles et al., 2015) 
(Figure 9). 
 
Figure 9. Pluripotent stem cells (PSCs).  
PSCs are commonly obtained after isolation of the inner cell mass of human blastocyst or nuclear 
reprogramming of somatic cells. PSCs can proliferate indefinitely and give rise to any foetal cell type or 
any of the 200+ cell types present in the adult body 
1.2.1 Origin of Pluripotent Stem Cells (PSCs) 
The interest in PSCs began in 1954 with the study in mouse of teratocarcinomas which 
are germ cell tumours (Stevens and Little, 1954). Subsequent studies of these tumours 
showed the presence of cells with the ability to differentiate into almost any cell type of 
the developing embryo (Stevens, 1967). Embryonic carcinoma cells (ECCs) exhibit 
similar characteristics to the cells present in the inner cell mass (ICM) of the early 
embryo (Solter, 2006). Studies with ECCs provided the basis for the process of 
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isolation of these ICM cells from mouse blastocyst and the derivation of the first 
embryonic stem cell (ESC) line. The firsts derivations of ESCs were performed in 1981 
from the ICM of a mouse embryo by Martin and Evans and Kauffman (Evans and 
Kaufman, 1981; Martin, 1981). However, it was not until 1998 when Thompson et al 
successfully derived the first human ESC line from surplus IVF-produced human 
embryos (Thomson et al., 1998). There is also a further PSC type that can be obtained 
naturally in humans; embryonic germ cells (EGCs). While human ESCs are derived 
from the cells of the ICM of the early embryos, human ECCs and EGCs have a shared 
origin in primordial germ cells (PGCs). These human PGCs are unipotent cells that are 
the founder cell population of the gametes. PGCs can be identified in humans around 
day 22 of gestation by expression of tissue non-specific alkaline phosphatase (TNAP). 
Thus, human PGCs can give rise in vivo to ECCs, whereas generation of human EGCs 
requires the in vitro culture of PGCs with a specific cocktail of growth factors (Matsui 
et al., 1992; Resnick et al., 1992; Shamblott et al., 1998; Donovan and de Miguel, 2003) 
(Figure 10).  
 
 
Figure 10. Types of PSCs existing in humans naturally. 
Reproduced from Donovan (2001). (Donovan and Gearhart, 2001) 
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ECCs are considered the malignant counterpart of ESC, as they share the same 
pluripotency markers, but ECCs are usually aneuploid and the malignancy of ECCs is 
highly dependent on their microenvironment. However, PGCs rapidly lose the ability to 
give rise to cells that form teratomae after 12.5 day post coitum in mice, suggesting 
that at this time they lose developmental potential. Despite their pluripotency, human 
PGCs show many disadvantages for their use in regenerative medicine. As well as 
their noted tumorigenic nature, they also have a reduced capacity for multi-lineage 
differentiation, so the use of ECCs is usually limited to models for investigation of cell 
differentiation in a manner pertinent to early vertebrate embryogenesis, especially in 
mouse (Martin, 1980). However, human ESCs are not identical to ICM cells in the 
human embryo, showing distinct global DNA methylation profile to the cells found in 
blastocysts (Smith et al., 2014). Human ESCs spontaneously adopt a ‘primed’ state 
similar to the ones found in cells of the late epiblasts of post-implantation. Conversely, 
mouse ESCs represent a ‘naive’ state that is considered more similar to the cells found 
in earlier stages of the development in pre-implantation embryos displaying higher 
differentiation potential than primed PSCs. Thus, mouse ‘primed’ PSCs are more 
heterogeneous and show limited in vivo differentiation potential compared to ‘naïve’ 
mouse PSCs as they show low contribution to the formation of chimeric embryos in 
post-implantation embryos (Huang et al., 2012) 
1.2.2 Features of PSCs 
Human ESCs express specific markers or characteristics similar but not identical to 
the pluripotent cells present in the ICM of an embryo. These characteristics include 
stage specific embryonic antigens (SSEA), enzymatic activities such as alkaline 
phosphatase (AP), telomerase activity and expression of “stemness” genes that are 
rapidly down-regulated upon differentiation, which include POU5F1 (OCT4) and 
NANOG among others (De Los Angeles et al., 2015). Under specific conditions, human 
ESCs can proliferate indefinitely maintaining an undifferentiated phenotype with self-
renewing properties due to a high telomerase activity (Thomson et al., 1998). 
Furthermore, ESCs retain their ability to differentiate into any cell-type present in the 
adult body as shown when ESCs are injected in severe combined immunodeficiency 
disease (SCID) mice resulting in the formation of tumours (teratomae) which contain 
cells from the three major germ layers: endoderm, mesoderm and ectoderm (Mitalipov 
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and Wolf, 2009). This huge potential for differentiation and their potential therapeutic 
effect has been reported in animal models of spinal cord injury, retinal dystrophies and 
Parkinson´s disease (Keirstead et al., 2005; Yang et al., 2008; Lamba et al., 2009). 
Currently, there are several clinical trials involving human ESC-derived differentiated 
cells approved by the U.S. Food and Drug Administration (FDA) to treat disorders such 
as spinal cord injury, Stargardt´s Macular Dystrophy and type 1 diabetes (Alper, 2009; 
Liras; Takahashi and Yamanaka, 2016). The primary objective of these Phase I/II 
studies is to assess the safety and tolerability of these human ESC-derived cells in 
patients. 
 
However, there are concerns with the use of human ESCs as a therapeutic. The 
immune response initiated by transplantation of human ESC into genetically unrelated 
patients that may result in rejection and the ethical issues associated to the use of 
human embryos are issues that need to be considered when using human ESC  
(Dawson et al., 2003; Fischbach and Fischbach, 2004).  
1.2.3 Inducing Pluripotency in somatic cells 
Nuclear reprogramming of somatic cells allows the generation of pluripotent cells 
resembling ESCs. Nuclear reprogramming has been defined as the reversal of the 
differentiation state of a mature cell to one that is characteristic of the undifferentiated 
embryonic state (Gurdon, 2006; Hochedlinger and Jaenisch, 2006). Traditionally, 
normal embryonic development has been considered an irreversible state, a one way-
street where the process of cellular differentiation of an undifferentiated cell was 
pictured by Conrad Waddington on the mid-20th century as a ball rolling downhill 
reaching the physiologically mature state at the bottom of the hill (Figure 11). 
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Figure 11. Conrad Waddington’s epigenetic landscape. 
In this model, the ball on the top of the hill represents a PSC that remains in an undifferentiated state. 
As the ball (PSC) rolls down the hill the ball can take different paths, representing the different lineages 
that a PSC can take upon differentiation. The ball reaching the bottom of the hill represents the 
acquisition of the mature state of the differentiated cell, such as a blood cell or a neuron.  Differentiated 
cells can be differentiated to another cell type (trans-differentiation) pictured as moving the ball from one 
hill to other hill. Likewise, the re-acquisition of the undifferentiated state of a differentiated cell 
(reprogramming/rejuvenation) is represented as taking the ball back to the top of the hill. Modified from 
Ohnuki et al 2015 (Ohnuki and Takahashi, 2015).  
However, Sir John Gurdon demonstrated in 1962 that differentiated intestinal cells of 
frogs were capable of developing into adult frogs following somatic cell nuclear transfer 
(SCNT) of the nucleus of the intestinal cell into the ooplasm of the frog oocyte, although 
at low efficiency (approximately 1%) (Gurdon, 1962). These experiments were the 
basis for the later mammalian cloning experiments that gave rise to the first cloned 
sheep, “Dolly”, by Wilmut and colleagues (Wilmut et al., 1997) and recently the 
derivation of the first human ESCs lines from  human cloned embryos via nuclear 
transfer (Tachibana et al.) (Figure 12). Fusion of somatic cells with ESCs to form 
tetraploid hybrids or exposing them to ECC extracts can also generate cells with 
pluripotent phenotype (Cowan et al., 2005) (Figure 12).  
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Additionally, studies with somatic cells have demonstrated that cell fate can be 
modified by forcing the expression of a single lineage-specific transcription factor, 
leading to the trans-differentiation or dedifferentiation of the somatic cell (Figure 12). 
Early research in this field by Weintraub et al. showed that fibroblasts can be converted 
into muscle cells by the overexpression of the muscle specific transcription factor MyoD 
while recent research has shown that mature B-cells can be reprogrammed into 
macrophages by the overexpression of C/EBPα or C/EBPβ (Davis et al., 1987; Xie et 
al., 2004). These studies led to the publication of the ground breaking work by 
Takahashi and Yamanaka first in 2006 and later in 2007 that demonstrated that forced 
expression by retroviral transduction of four known ESC factors (OCT4, SOX2, KLF4 
and c-MYC) in murine fibroblasts can reprogram them to a pluripotent state (Takahashi 
and Yamanaka, 2006; Okita et al., 2007). These reprogrammed cells were named 
induced pluripotent stem cells (iPSC) and, within months, the same group succeed in 
generating human iPSC by introducing the human orthologues of the four transcription 
factors into human fibroblast (Takahashi et al., 2007). Concurrently, Yu et al. achieved 
a similar reprogramming of human somatic cells using slightly different combinations 
of genes (OCT4, SOX2, NANOG and LIN28) (Yu et al., 2009). The generated iPSCs, 
both human and mouse, were similar to corresponding ESCs in morphology, growth 
characteristics and expression of phenotypic markers. These cells maintained a 
normal karyotype and a pluripotential developmental capacity for extended periods and 
mouse iPSC appear to be competent for germline transmission in mice (Okita et al., 
2007). Moreover, mouse iPSC have also succeeded the most stringent test of 
pluripotency, tetraploid complementation, showing their ability to contribute to the 
generation of an entire living mouse (Kang et al., 2009).  
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Figure 12. Strategies to induce pluripotency by nuclear reprogramming. 
Reproduced from Yamanaka et al 2010 (Yamanaka and Blau, 2010) 
1.2.4 Advantages of using iPSC technology 
Human iPSC have the same features/properties as human ESC including expression 
of human pluripotent factors, self-renewal capacity and potential to differentiate into 
three germ layers. However, iPSC present additional features that make them more 
appealing for basic and clinical studies:     
1.2.4.1 Patient specific 
Cells from patients carrying genetic mutations can be reprogrammed into iPSC, 
opening a new window of opportunity for applications of iPSC technology in disease 
modelling, drug screening and cell-based therapy (Figure 13). 
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Figure 13. Short-term and long-term applications of iPSC technology. 
Patient specific iPSC and iPSC-derived differentiated cells generated from blood cells can be used for 
disease modelling and drug screening. Genetic correction of patient specific iPSC allows the generation 
of corrected differentiated cells that could be potentially used in cell therapy. RBC,red blood cells. 
Reproduced from Sayed et al 2016 (Sayed et al., 2016) 
Disease modelling. Differentiation of patient-specific iPSC into the disease-relevant 
cell type makes possible to recapitulate specific disease phenotypes and pathologies 
in a dish. This disease-in-a-dish model would allow the identification of pathological 
mechanisms associated to those disorders and reveal disease aetiology (Figure 13).  
To date, numerous studies have reported the generation of disease-specific iPSC lines 
recapitulating the phenotype observed in patients including BMFS (Adam et al., 2017). 
Additionally, iPSC technology in combination with gene editing technologies has 
proved to be a powerful tool to confirm the pathogenic nature of the identified genetic 
defects by the correction of disease-causing mutations in patient iPSC as wells as 
introduction of specific mutations into control-iPSC (Hotta and Yamanaka, 2015). This 
is especially relevant for disorders caused by a single mutation and an early onset 
(Ebert et al., 2009; Lee et al., 2009). For disorders classified as idiopathic, where the 
aetiology is unknown and genetic risk variants and environmental factors may 
contribute to the pathogenesis of the disease, is important to minimize the genetic 
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background variations present in order to confidently identify the disease-associated 
phenotype in the patient iPSC when comparing to unaffected controls (Shi et al., 2017). 
Thus, by using iPSC technology, specific gene mutations were identified in several 
idiopathic cases of Alzheimer disease exhibiting the same phenotype leading to 
improved diagnosis and re-classification of this condition (Kondo et al., 2013). 
 
Drug screening. Generation of specific disease-relevant cell types from patient iPSC 
at high scale in an in vitro setting is one of the main advantages that iPSC technology 
offers in drug screening to identify and test the efficacy of drug candidates (Figure 13). 
Thus, drug screening in iPSC-based cells have been used to identify candidate drugs 
in disorders including spinal muscular atrophy, amyotrophic lateral sclerosis and 
progressive supranuclear palsy that are currently being tested in clinical trials by 
pharmaceutical companies such as Roche and GlaxoSmihKline (Shi et al., 2017). 
 
Cell-based therapy. Although it is considered by experts as a long term goal, the most 
promising application of iPSC technology is the possibility of creating personalized 
therapies to treat patients with their own cells avoiding immunological rejections 
associated to allogeneic therapies and reducing costs and secondary effects 
associated to IST. Combination of gene editing and iPSC technologies may allow the 
correction of the disease-causing genetic defect in patient-specific iPSC, differentiation 
into the cell type of interest and transplantation of autologous healthy cells to treat the 
patient (Figure 13).   As a proof-of-concept of the therapeutic use of iPSC, a study 
using a mouse model of sickle-cell anaemia reported in 2007 the correction of the 
mutation in the β-globin gene in mutant iPSC using gene editing approach (Hanna et 
al., 2007). The mutation-free mouse iPSCs were differentiated into haematopoietic 
progenitors and transplanted to the affected mouse allowing for the disease to be cured. 
In 2014, the first clinical trial using human iPSC was launched by Masayo Takahashi 
to treat patients with age-related acute macular degeneration (AMD) (Ohnuki and 
Takahashi, 2015). The therapy consisted in autologous transplantation of iPSC-
derived retinal pigment epithelium (RPE) cells resulting in promising results since the 
patients had a reduction of macular degeneration and improvement of vision. 
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1.2.4.2 Telomere rejuvenation  
iPSC have self-renewal capacity due to the activation of the telomerase activity during 
reprogramming that leads to the elongation of the telomeres and maintenance of those 
telomeres during long-term culture (Marion et al., 2009; Rivera et al., 2017). Firstly, 
this ability to self-renew makes iPSC technology a very attractive tool to be used as 
unlimited source of disease-relevant cells, overcoming difficulties of using primary cells 
from patients which can be difficult to expand, hard-to-access or difficult to obtain due 
to low numbers as in the case of AA. Secondly, ability to elongate telomeres during the 
reprogramming process gives iPSC the potential to be used as a disease model to 
investigate the pathological mechanisms involved in telomeropathies or uncover 
uncharacterised genetic defects associated to telomere maintenance. Thus, different 
studies have reported the use of iPSC technology to model telomeropathies associated 
to mutations in genes such as TERT, TERC and DKC showing that defective iPSC 
failed to elongate telomeres and showed a reduced haematopoietic differentiation 
capacity (Batista et al., 2011; Winkler et al., 2013; Gu et al., 2015) 
1.2.4.3 Avoidance of ethical issues  
iPSC do not have the ethical problems associated to human ESCs and SCNT since 
they can be generated from differentiated cells without the need for human embryos 
or oocytes. 
1.2.4.4 Accessibility of cell source for reprogramming  
Generation of iPSC lines from easily accessible cell types such as skin fibroblasts and 
peripheral blood cells have been widely reported (Takahashi et al., 2007; Yu et al., 
2007; Loh et al., 2009; Staerk et al., 2010). Thus, a simple blood sample or skin biopsy 
from a donor can usually provide with enough material to establish different donor-
specific iPSC lines. This availability and accessibility in the source of cell for 
reprogramming confers iPSC technology a huge advantage compared to disease 
modelling approaches using primary cells that are difficult to isolate or access in the 
human body such as brain or heart cells or the use of oocytes to induce reprogramming 
such as in SCNT approaches. 
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1.2.5 Challenges in iPSC technology 
Although a very promising future lies ahead for the iPSC field, several challenges need 
to be addressed in order to get the full potential from this technology. ESC are 
considered the gold standard of pluripotency (De Los Angeles et al., 2015). Currently, 
the degree of similarity between ESC and iPSC is still a matter of debate. Several 
studies have reported transcriptional and epigenetic differences between ESC and 
iPSC, which can lead to a reduced iPSC differentiation potential, attributable to a an 
inefficient reprogramming to pluripotency (Chin et al., 2009; Deng et al., 2009; Ghosh 
et al., 2010). However, more recent studies using high-throughput sequencing analysis 
indicate that ESC and iPSC are indistinguishable and that the differences observed in 
ESC and iPSC are most likely due to genetic background differences rather than 
reprogramming artefacts present in iPSC (Newman and Cooper, 2010; Bock et al., 
2011; Choi et al., 2015). Moreover, by comparing 4 ESC and 14 iPSC lines 
reprogrammed using Sendai virus-based vector, Feraud et al. reported that ESC and 
iPSC showed similar haematopoietic differentiation potential, and that differences in 
the differentiation potential were attributable to donor cell of origin (Feraud et al., 2016).  
To date, these are the challenges described in the use of iPSC technology: 
1.2.5.1 Viral integration 
Integration of provirus transgenes into the host genome and silencing of the provirus 
transgenes in the reprogrammed cells are problems associated with the use of 
integrative vectors in reprogramming such as retroviral and lentiviral vectors. The use 
of retroviruses and lentiviruses to generate iPSC leads to the random integration of 
viral transgenes into the host genome (up to 40 viral integration sites in their genomes). 
This transgene integration could lead to mutation within the host genome or could alter 
expression of neighbouring host genes in a similar manner than gene therapy induced 
oncogenesis in children with SCID following transplantation of retroviral gene-modified 
HSCs (Hacein-Bey-Abina et al., 2003). Likewise, although integrated proviruses are 
usually silenced during iPSC generation,   risk of reactivation of these viral transgenes, 
including potent oncogenes, could result in formation of tumours. Additionally, if the 
viral transgenes are not silenced properly, leaky expression may inhibit proper iPSC 
differentiation and maturation, leading to a greater risk of immature teratoma formation 
(Chan et al., 2009; Ramos-Mejia et al., 2012). These problems are especially relevant 
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for the first generation of iPSC since they were generated via integrative viral vectors. 
However, many methods have been developed during the last years to overcome 
these problems. Thus, in order to promote reprogramming without transgene 
integration, different strategies have been designed including use of adenoviral vectors 
based on a transient expression of exogenous factors without integration (Stadtfeld et 
al., 2008), Cre/LoxP recombination system to excise integrated transgenes after 
transfection of target cells (Kaji et al., 2009), use of DNA-based vectors (Yu et al., 
2009), reprogramming factors in the form of proteins instead of DNA (Kim et al., 2009), 
synthetically modified messenger RNA (mRNA) (Warren et al., 2010), ectopic 
introduction of microRNA (miRNA) (Judson et al., 2009; Miyoshi et al., 2011) and use 
of RNA viruses such as Sendai virus (SeV) (Fusaki et al., 2009). All these new 
strategies are on the right track to avoid problems associated to transgene integration, 
with episomal DNAs, synthetic mRNA and SeV being the most commonly applied due 
to their high reprogramming efficiency. SeV stands out by both its relative simplicity of 
use and its high efficiency of reprogramming compared to other integration-free 
approaches. This type of virus is a RNA virus that replicates its genome in the 
cytoplasm of the host cell and can stably express reprogramming factors with a high 
reprogramming efficiency with no need of multiple transductions (Fusaki et al., 2009). 
However, Sendai-based iPSC tend to carry the virus genome even after long-term 
culture. Therefore, it is necessary, in some cases, to subclone part of the iPSC culture 
or use a temperature-sensitive mutant in order to eliminate remaining SeV particles 
that could be present in the culture. Nonetheless, the high reprogramming efficiency 
together with the lack of genomic integration and the easy-to-use performance showed 
by SeV appears as one of the best methods to reprogram somatic cells to pluripotency 
developed to date. 
1.2.5.2 Incomplete reprogramming  
Reprogramming to pluripotency is a complex process where many stages have to be 
completed in order to obtain fully-reprogrammed cells. In the first stages of 
reprogramming, there is an induction of proliferation and down-regulation of cell-of-
origin specific genes. In the following stages of reprogramming acquisition of epithelial 
characteristics and induction of pluripotency network by up-regulation of pluripotency-
related genes are crucial (Plath and Lowry, 2011). Thus, absence/defective 
transcriptional and epigenetic changes during these stages can lead to an incomplete 
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reprogramming of the cell and the appearance of partially-reprogrammed clones with 
different degrees of reprogramming status within the same iPSC line, leading to clonal 
heterogeneity. Although these partially-reprogrammed clones may present similar 
characteristics to fully-reprogrammed iPSC clones such as morphology, pluripotency 
gene expression and even ability to form teratomae in SCID mice, they exhibit impaired 
differentiation potential (Chan et al., 2009; Koyanagi-Aoi et al., 2013). Thus, it is 
necessary to identify these partially-reprogrammed clones in order to avoid confusion 
and enable the identification of true biological phenotypes when analysing the 
differentiation potential of patient-specific iPSC lines. Better understanding of the 
reprogramming process may help to thoroughly characterize and select fully-
reprogrammed iPSC. Thus, Nishizawa et al., carried out a comprehensive study using 
35 human iPSC lines generated by different methods and reported the identification of 
genes (IGF2 and TRIM58) as indicators of the haematopoietic differentiation potential 
of human iPSC (Nishizawa et al., 2016). Differences in the expression of these genes 
in iPSC due to aberrant DNA methylation patterns acquired during reprogramming can 
lead to impaired differentiation potential within clones from the same iPSC line 
providing with a method to faithfully select the best iPSC lines for downstream 
applications.  
1.2.5.3 Epigenetic memory  
Currently, the existence of somatic memory in iPSC is a matter of debate. The fact that 
iPSC originated from peripheral blood cells have a higher differentiation capacity to 
generate haematopoietic cells than neuronal cells might suggest that iPSC retain some 
memory from the cell of origin (Kim et al., 2010). Several studies reported  incomplete 
erasure of histone modifications and existing epigenetic marks in DNA of tissue of 
origin that might lead to changes at transcriptional and proteomic levels in different 
iPSC lines ultimately resulting in impaired differentiation potential and clonal 
heterogeneity (Bar-Nur et al., 2011; Kim et al., 2011; Ohi et al., 2011; Nishizawa et al., 
2016). Interestingly, Polo et al. reported that prolonged passaging of iPSC seems to 
contribute to the erasure of the epigenetic memory associated to the cell of origin, 
indicating that reprogramming process is prolonged over time (Polo et al., 2010). 
However, high-throughput sequencing studies showed recently that iPSC lines 
generated from different tissues are transcriptionally similar suggesting no retention of 
memory associated to cell type of origin (Rouhani et al., 2014; Kyttala et al., 2016; 
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Carcamo-Orive et al., 2017). Likewise, accumulation of repressive marks such as DNA 
methylation has been reported in both ESC and iPSC (Bock et al., 2011) suggesting 
that the reprogramming process has no influence in the presence of epigenetic marks 
in iPSC. In fact, this global increased in DNA methylation has been associated to the 
primed state characteristic of human PSC described in section 1.2.1. Acquisition of 
naïve pluripotency is associated with the removal of epigenetic repressive marks that 
would explain the greater differentiation potential of naïve PSCs over primed PSCs 
(Gafni et al., 2013). Conversion of human PSC from primed to naïve state has been 
achieved by a combination of transgenes, inhibitors and growth factors (Takashima et 
al., 2014; Theunissen et al., 2014) or use of inhibitors and growth factors only (Gafni 
et al., 2013; Theunissen et al., 2014; Theunissen et al., 2016). Conversion to naive 
state would provide a means to improve quality of iPSC by facilitating the removal of 
residual epigenetic memory and minimize clone heterogeneity (Weinberger et al., 
2016). Use of epigenetic modifiers have been suggested by different authors to 
increase reprogramming efficiency and erasure potential epigenetic memory of the 
tissue of origin (Nashun et al., 2015). Interestingly, Hou et al. reported in 2013 the 
generation of iPSC through the use of epigenetic modifiers and manipulation of 
signalling pathways using solely small-compounds, highlighting the importance of 
chromatin manipulation for establishment of reprogramming  (Hou et al., 2013).  
1.2.5.4 Genomic instability  
Presence of genetic variations in iPSC, potentially attributed to the reprogramming-
induced stress or long-term in vitro culture, might alter the differentiation capacity of 
the ESC/iPSC and increase risk of tumorigenicity (Ben-David and Benvenisty, 2011).  
Thus, genetic mutations were identified in the iPSC used in one of the patients in the 
first clinical trial evaluating human iPSC-derived RPE cells started in 2014, although 
there was no clear evidence that these mutations could lead to adverse effects (Shi et 
al., 2017). Genetic variations found in iPSC can be present in parental somatic cells, 
induced by reprogramming or by prolonged passaging and include chromosomal 
aberrations such as aneuploidy, copy number variations (CNV),   and single nucleotide 
variations (SNV) (Liang and Zhang, 2013). Trisomy 12 is the chromosomal abnormality 
most commonly found in both ESC and iPSC and it has been suggested to provide a 
selective advantage by increasing proliferation and reprogramming due to the 
presence of cell-cycle related genes and pluripotency gene NANOG (Taapken et al., 
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2011). Early studies using comparative genomic hybridization (CGH) and single 
nucleotide polymorphism (SNP) array analysis reported the presence of CNV in iPSC 
that were not detected in parental cell of origin, leading to the hypothesis that the 
reprogramming process generates de novo genetic variations  (Elliott et al., 2010; 
Hussein et al., 2011; Martins-Taylor et al., 2011). However, with the use of most recent 
technologies such next-generation sequencing (NGS) technologies, deeper genetic 
analysis revealed that most of the CNV detected in iPSC were present in low frequency 
in the parental cell population (Abyzov et al., 2012; Kwon et al., 2017) indicating that 
the iPSC reprogramming process does not induce variations in the number of copies. 
Such discrepancy in the conclusions has been attributed to the limited dynamic range 
to detect low-frequency SNP by array-based analysis compared to the higher 
resolution offered by the NGS technologies (Liang and Zhang, 2013). Likewise, by 
using NGS, different studies have identified no more than a dozen SNV in protein-
coding genes in iPSC with half of them already present in the subpopulation of the 
parental population and hundreds of mutations considered as benign distributed 
throughout the genome (Young et al., 2012; Bhutani et al., 2016), suggesting that the 
reprogramming process is not mutagenic. Nonetheless, extensive screening for 
meaningful genetic alterations is necessary in order to ensure the safety, quality and 
purity of the iPSC cultures for downstream applications, especially for clinical 
application of iPSC-derived cells (Yoshihara et al., 2017). 
1.2.5.5 Use of proto-oncogenes.  
Use of proto-oncogenes such as cMyc in the reprogramming cocktail of factors have 
raised concern regarding the potential therapeutic use of iPSC due to the potential 
tumorigenic transformation of the reprogrammed cells (Nakagawa et al., 2008). 
Although not essential to generate iPSC, cMyc seems to increase the reprogramming 
efficiency significantly by regulating cellular proliferation (Nakagawa et al., 2008; 
Sridharan et al., 2009). Interestingly, it has been found that the use of a transformation-
deficient variant of the Myc family, L-myc, resulted in the generation of mouse iPSC 
even with a higher efficiency than with cMyc and a much lower rate of tumour formation 
(Nakagawa et al., 2010).  
 
The iPSC field is progressing rapidly and increased knowledge of the reprogramming 
process and development of improved reprogramming strategies is helping to 
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overcome these challenges, ultimately leading to the generation of bona fide patient-
specific PSCs for disease modelling studies and therapeutic applications. 
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1.3 Differentiation of human PSCs into haematopoietic cells 
Human PSCs provide a useful means to study human blood development due to their 
ability to differentiate into cell lineages of all three germ layers. Several studies have 
shown that in vitro haematopoietic differentiation of PSCs similarly mirrors in vivo 
haematopoiesis making them very useful for the study of haematopoiesis during 
embryonic development (Lensch and Daley, 2006).Likewise, numerous studies have 
demonstrated the ability of PSCs to generate specifically all mature blood cell types 
under suitable conditions, from haematopoietic progenitors to mature blood cells 
(Vodyanik et al., 2006; Kennedy et al., 2007; Woll et al., 2008; Galic et al., 2009; Saeki 
et al., 2009; Tseng et al., 2009; Carpenter et al., 2011; Dias et al., 2011; Mills et al., 
2013) . Thus, PSCs can be an excellent source for large-scale production of blood cells 
components because of their ability of being expanded indefinitely without losing 
pluripotency (Olivier et al., 2006).  
1.3.1 Haematopoietic ontogeny in the human embryo 
Understanding the process of in vivo haematopoiesis will help to design in vitro 
strategies to generate functional transplantable haematopoietic cells.  Haematopoietic 
cells have been detected in the human yolk sac (YS) between days 16 and 19 of 
embryonic development, and in the placenta, aorta-gonad-mesonephros (AGM) and 
liver from days 24 and 28 (Luckett, 1978; Tavian et al., 1999; Robin et al., 2009). These 
cells subsequently enter the circulation and colonize the foetal liver, where they mature 
from week 6 to 16 and migrate to the bone marrow, the major haematopoietic organ 
from the second half of the gestation (Lensch and Daley, 2004).  In vitro culture of cells 
from both YS and AGM generate haematopoietic derivatives, indicating the 
independent origin of haematopoietic cells in different sites. However, only cells from 
AGM give rise to B- and T-cells and HSC (referred to as definitive haematopoiesis), 
whereas YS predominantly generates nucleated erythroid cells, macrophages and 
monocytes (referred to as primitive haematopoiesis) (Tavian et al., 2001) (Figure 14).  
 
38 
 
 
Figure 14. Human embryonic haematopoiesis 
Primitive erythrocytes and monocytes (primitive haematopoiesis) are generated in the yolk sac. With 
onset of circulation, yolk-sac derived blood cells enter embryonic tissues. Definitive erythrocytes, 
myeloid and lymphoid progenitors and HSC emerge on the floor of the AGM region and migrate to foetal 
liver where they undergo expansion before colonizing the bone marrow where they will reside throughout 
adult life. AGM, aorta-gonad-mesonephros. Reproduced from Dravid and Crooks, 2011. (Dravid and 
Crooks, 2011)   
Medvinsky and Dzierzak reported that definitive haematopoiesis in the mouse emerges 
in the AGM region prior colonization of foetal liver of haematopoietic stem cells 
(Medvinsky and Dzierzak, 1996). This common origin between haematopoietic and 
endothelial cells could reflect two intrinsic processes to produce haematopoietic cells, 
i.e., either via a cell without evidence endothelial or haematopoietic differentiation 
(haemangioblast) or a cell that already displays endothelial features but able to 
produce haematopoietic cells (haemogenic endothelium). Studies based on the in vivo 
haematopoiesis in the mouse show that haemangioblast cells migrate to the YS and 
39 
 
could be responsible for the generation of primitive haematopoietic cells, whereas the 
vascular endothelial cells, located in the dorsal aorta in the AGM region, forming the 
haemogenic endothelium, may be responsible for the generation of the adult-definitive 
haematopoietic cells (Dzierzak and Speck, 2008). The existence of the 
haemangioblast has been identified in the mouse, but not yet in human due to the 
inaccessibility to human embryonic tissue. Keller and his colleagues demonstrated that 
a comparable haemangioblast population exists by generating blast cells from mouse 
with both haematopoietic and vascular potential (Choi et al., 1998). On the other hand, 
studies based on lineage tracing and live imaging in the mouse and zebra fish proved 
that endothelial cells can transform into haematopoietic cells that will form the HSCs 
in the adult animal (Zovein et al., 2008; Eilken et al., 2009; Boisset et al., 2010; Kissa 
and Herbomel, 2010)  Thus, the concept of haemangioblast is still controversial since 
most of the data published so far can be explained by the concept of haemogenic 
endothelium (Bautch, 2011).   
1.3.2 In vitro differentiation of PSC to haematopoietic cells 
Haematopoiesis is an intricate process resulting from a cascade of specific events 
determined by the expression of a specific group of genes that encode surface 
antigens. The expression of these antigens can change as the cells get further through 
the differentiation process. Understanding of the in vivo process is extremely important 
to establish the culture conditions to in vitro differentiate PSC into haematopoietic cells, 
identify the stage-specific phenotypes of the cell through the differentiation process 
and establish methods to distinguish the cells as they are specified.  
1.3.2.1 Molecular mechanisms and factors promoting haematopoiesis 
Different signalling cascades are activated during the in vitro generation of HSPCs 
trying to mimic the molecular events occurring in the haematopoietic development in 
vivo.  Similarly to early embryonic development, activation of signalling pathways by 
bone morphogenetic protein 4 (BMP4), WNT, fibroblast growth factor-2 (FGF2) and 
vascular endothelial growth factor (VEGF) is required in the haematopoietic 
specification of PSCs (Chadwick et al., 2003; Kennedy et al., 2007; Pick et al., 2007). 
Formation of primitive streak (PS) is characterized by up-regulation of transcription 
factors such as Brachyury (T) and MIXL1 induced by BMP4, Activin A and FGF2 during 
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the early phases of PSCs differentiation (Davis et al., 2008). Formation of 
posterior/anterior mesendoderm requires the activation of WNT signalling, whereas 
specification to posterior PS (mesoderm) or anterior PS (endoderm) is regulated by 
the balance between BMP4 and Activin signalling pathways (Sumi et al., 2008) (Figure 
15).   
 
Figure 15. Early differentiation of PSCs into primitive streak (PS).  
Wnt/β-catenin signalling pathway is essential to establish the generation of PS-mesendoderm 
progenitors from PSCs. Balance of Activin/BMP signalling pathways dictates specification into 
endoderm and mesoderm. ES, embryonic stem cells; T, Brachyury; PS, primitive streak. Reproduced 
from Sumi et al. 2008 (Sumi et al., 2008) 
Primitive posterior mesodermal cells can be identified by the expression of markers 
such as apelin receptor (APLN), platelet-derived growth factor receptor 
(PDGFR)α/CD140a and KDR (Vodyanik et al., 2010) (Figure 16).  Likewise, WNT 
signalling induces the formation of haematovascular mesodermal progenitors (HMVP) 
from the posterior PS population inducing up-regulation of angiohaematopoietic genes 
such as T cell acute lymphocytic leukaemia 1 (TAL1), HHEX, LMO2, GATA protein 2 
(GATA2) and ETS variant 2 (ETV2) and high expression of KDR and low expression 
of PDGFR markers (Choi et al., 2012) (Figure 16). Likewise, it has been described the 
existence of intermediate progenitors at the mesodermal stage, referred as 
haemangioblasts, that, unlike HMVP, have potential to generate haematopoietic 
colonies through endothelial intermediates in the presence of FGF2 (Kennedy et al., 
2007) (Figure 16). These progenitors define the onset of haematopoiesis since they 
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consist of vascular and haematopoietic progenitors; however, their potential is 
restricted to primitive haematopoietic cells similarly to their in vivo counterparts found 
in the posterior PS (Huber et al., 2004). 
 
Following in vitro differentiation, the first population of endothelial cells, characterized 
by the expression of VE-cadherin, CD31 and CD34 markers, emerge from the HMVP 
population (Figure 16). Within this population of endothelial cells, Choi et al. identified 
two distinct subpopulations of cells based on the expression of CD73, leukosialin 
(CD43) and CD235a markers: haemogenic endothelium (HE) (CD73-/CD43-) and non-
HE (CD73+/CD43-) (Choi et al., 2012). Both HE and non-HE display endothelial 
features and lack of haematopoietic colony-forming potential when cultured in 
methylcellulose-based media supplemented with haematopoietic cytokines However, 
HE cells have the ability to generate both endothelial cells and definitive 
haematopoietic progenitors upon cultivation on OP9 mouse stromal cells (Choi et al., 
2012). Interestingly, Kennedy et al. reported that HE cells display T lymphoid potential 
when cultured on OP9 cells (Kennedy et al., 2012). Various subpopulations of HE cells 
can be defined by runt-related transcription factor 1 (RUNX1) expression (Ran et al., 
2013). Runx1 is required for definitive haematopoiesis but not for primitive and 
endothelial cells from HE for it has been shown to be critical in the endothelial to 
haematopoietic transition (EHT) during mouse embryonic development (Chen et al., 
2009). SRY-box 17 (SOX17) is another transcription factor that has been involved HE 
regulation and EHT in human PSCs (Clarke et al., 2013; Nakajima-Takagi et al., 2013).  
 
First haematopoietic progenitors arising from HE population can be detected by 
surface expression of CD43 (Vodyanik et al., 2006; Kennedy et al., 2012) (Figure 16). 
This is important because use of this marker allows the separation of haematopoietic 
progenitor cells, characterized by colony-forming potential in semi-solid medium 
supplemented with haematopoietic cytokines, from non-haematopoietic cells such as 
endothelial and mesenchymal cells. Emerging from this CD34+CD43+ haematopoietic 
progenitor population, different subpopulations of progenitors can be found. The first 
to emerge are CD235a+ and CD41a+ cells within the CD43+ cells with potential to 
generate erythroid (EryP) and megakaryocytic progenitors (MkP) in colony-forming 
assays (Vodyanik et al., 2006; Klimchenko et al., 2009) (Figure 16). These progenitors 
display features of primitive haematopoiesis since they mainly express embryonic 
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haemoglobins and contain large nucleated cells. Finally, CD43+ haematopoietic 
progenitors with potential to generate myeloid lineage colonies appear shortly after 
emergence of erythroid/megakaryocytic progenitors (Ery/MkP) and are characterized 
by CD41a-CD235a- phenotype (Vodyanik et al., 2006) (Figure 16). These 
CD34+CD43+CD41a-CD235a- myeloid progenitors (MyeP) have been associated 
with initial stages of definitive haematopoiesis since show expression of 
haematopoietic-regulator genes GATA-2, GATA-3, RUNX1 and c-MYB (Rodrigues et 
al., 2012; Frelin et al., 2013; Ran et al., 2013; Sankaran and Orkin, 2013) and display 
potential to generate cells of lymphoid lineage such as natural killer cells and cells from 
B-lymphoid lineage (Carpenter et al., 2011; Knorr et al., 2013). Expression of the pan-
haematopoietic marker CD45 is acquired in later stages and it has been associated to 
commitment to more mature myeloid progenitors (Vodyanik et al., 2006). 
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Figure 16. Haematopoietic differentiation from PSCs. 
Generation of mesoderm from PSCs is defined by expression of mesodermal markers APLNR and KDR. 
Most primitive mesodermal precursors with haematopoietic potential emerge from the primitive posterior 
mesoderm cells and are able to generate primitive haematopoietic cells (CD41a+/-CD235a+/-) in 
clonogenic medium. Endothelial commitment of mesodermal precursors is characterized by up-
regulation of KDR in haematovascular mesodermal precursors (HVMP). HVMP give rise to endothelial 
progenitors identified by expression of VE-cadherin, CD31 and CD34 endothelial markers. Within this 
endothelial, haemogenic endothelium (HE) cells display endothelial features but are capable of forming 
haematopoietic cells when cultured under specific conditions. Up-regulation of CD43 expression defines 
the emergence of the haematopoietic progenitor cells including erythroid-megakaryocytic 
(CD41a+CD235a+) and multipotent myelolymphoid progenitors (CD34+CD43+CD45+/-lin-). Lin: 
CD41aCD235a. Modified from Slukvin, 2013. (Slukvin, 2013)  
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1.3.2.2 Methods to generate haematopoietic cells from PSC 
Directed differentiation. Two distinct differentiation approaches have been most 
commonly used for the differentiation of PSCs into haematopoietic progenitors: co-
cultivation of PSC on feeder cells mimicking the HSC niche or timed addition of key 
cytokines and morphogens to induce activation of specific signalling pathways. 
 
Several cell lines have been reported as stromal feeder cells such as OP9, S17 and 
MS5 from murine bone marrow, mFLSC from murine foetal liver derived stromal line, 
FH-B-hTERT from immortalized human foetal liver hepatocyte line and primary human 
stromal cell lines derived from AGM, foetal liver and foetal bone marrow (Vodyanik et 
al., 2005; Moore et al., 2006; Ledran et al., 2008). Stromal cells create an in vitro 
microenvironment, similar to that in vivo, that seems to help survival, proliferation and 
haematopoietic differentiation of PSC. Likewise, stromal cell lines can be modified to 
produce specific factors that can help to reproduce specific environment for the 
generation of specific haematopoietic lineages such as T and B cells by using OP9 
stromal cells constantly overexpressing the Notch ligand Delta-like 1 or 4 
(Timmermans et al., 2009; Roundy et al., 2010; Kennedy et al., 2012). However, the 
need for serum-containing media to grow these stromal cell lines distances this method 
from a future clinical application.  
 
Use of cytokines and morphogens for the derivation of in vitro HSPCs is an alternative 
method that enables the differentiation of PSC in a serum-free and defined media. 
Early differentiation of PSCs into mesodermal and endothelial lineages relies on the 
addition BMP4, VEGF, WNT and stem cell factor (SCF) (Pick et al., 2007; Sumi et al., 
2008; Niwa et al., 2011; Sturgeon et al., 2014). Likewise, use of cytokines such as SCF, 
TPO, fibroblast-growth factor (FGF), Fms-related tyrosine kinase 3 ligand (FLT3-L), 
granulocyte colony-stimulating factor (G-CSF), interleukin-6 (IL-6) and interleukin-3 
(IL-3) at specific time points promote the haematopoietic differentiation and expansion 
from PSCs in vitro (Chadwick et al., 2003; Zambidis et al., 2005; Uenishi et al., 2014). 
These methods are usually combined with the formation of 3 dimensional spheres, 
embryoid bodies (EB), by plating the PSCs on ultra-low attachment surface. The lack 
of adhesion will promote the formation of these structures and the differentiation of the 
PSCs into all three germ layers. The use of serum-free defined media helps to the 
study of the roles of specific morphogens and cytokines in the haematopoietic 
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differentiation of PSC as well may make it the method of choice for a possible clinical 
use of the cells. Likewise, differentiation recipes can include erythropoietin (EPO) to 
further differentiation of PSCs to red blood cells (Chang et al., 2006) or combined with 
stromal cells for driving differentiation to B and T cells (Kennedy et al., 2012; Sturgeon 
et al., 2014).     
 
However, these approaches used to differentiate in vitro PSCs into haematopoietic 
progenitors have several limitations.  Studies using these strategies have reported the 
generation of in vitro-derived haematopoietic progenitor populations but lacking robust 
engraftment and lymphoid potential (Ackermann et al., 2015). Additionally, the 
haematopoietic progenitors resemble those generated in the yolk sac during in vivo 
primitive wave of haematopoiesis producing erythrocytes mostly nucleated and 
containing embryonic and foetal globins (Wahlster and Daley, 2016).  
 
Directed conversion. Overexpression of critical transcription factors in PSCs is an 
alternative strategy developed to directly convert PSCs into angiohaematopoietic 
progenitors or HSPCs. First attempts inducing haematopoietic differentiation of human 
ESCs using transcription factors involved the overexpression of the homeobox B4 
(HOBX4) gene, with multiple roles in haematopoietic development (Alharbi et al., 2013). 
Different studies using ectopic expression of HOXB4 are characterized by variability 
and lack of consistency in their findings (Forrester and Jackson, 2012), with one study 
reporting that HOXB4 is dispensable for haematopoietic differentiation in human cells 
(Wang et al., 2005), leading to researchers to focus on other transcription factors. 
 
Cells with endothelial features displaying haematopoietic potential, HE cells, have 
been generated from human iPSCs using two combinations of transcriptions factors 
ETV)/GATA2 and TAL1/GATA2 (Elcheva et al., 2014) (Figure 17). Haematopoietic 
progenitors generated from each population of HE cells displayed different potential 
depending on the combination of transcription factors used, with ETV2/GATA2 
resulting in progenitors with myeloid potential and TAL1/GATA2 in progenitors with 
erythro/megakaryocytic potential, highlighting the complexity of haematopoietic 
specification, starting at the HE stage (Easterbrook et al., 2016).  
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Screening of genes differentially expressed in umbilical cord blood HSC and 
haematopoietic myeloid progenitors enabled the identification of up-regulated genes 
in cord blood haematopoietic progenitors such as homeobox A9 (HOXA9), ETS 
transcription factor (ERG) and RAR-related orphan receptor A (RORA) (Doulatov et al., 
2013). Ectopic expression of all these genes combined conferred self-renewal and 
multipotential differentiation capacity to myeloid-committed haematopoietic 
progenitors. Likewise, addition of transcription factors SRY-Box 4 (SOX4) and MYB 
proto-oncogene (MYB) enabled engraftment of these progenitors in vivo, highlighting 
the relevance of these regulatory networks in haematopoietic development (Figure 17). 
However, engraftment of these converted haematopoietic progenitors was not 
maintained in time and no lymphoid cells were generated in vivo (Easterbrook et al., 
2016). Similar approach was very recently developed by Daley’s group that reported 
the generation of HSPCs with multi-lineage haematopoietic engraftment potential in 
immunodeficient mouse by forcing expression of ERG, HOXA5, HOXA9, HOXA10, 
ligand dependent nuclear receptor corepressor (LCOR), RUNX1 and Spi-1 proto-
oncogene (SPI1) genes previously identified to facilitate in vivo haematopoietic 
engraftment (Sugimura et al., 2017). Interestingly, PSCs were differentiated into HE 
cells via directed differentiation using cytokines and morphogens. PSCs-derived HE 
cells were transduced with the combination of transcription factors giving rise to HSPCs 
with multi-lineage differentiation potential and engraftment potential although not in a 
robust fashion.  
    
Crucial genes for generation of HE and definitive haematopoiesis such as RUNX1, 
SOX17 and TAL1 have been used separately to induce the generation of 
haematopoietic progenitor cell generation from human PSCs. Upon RUNX1A isoform 
overexpression, haematopoietic progenitor cells with definitive features, such as ability 
to generate erythrocytes containing adult haemoglobin and in vivo multilineage 
engraftment, were generated (Ran et al., 2013) (Figure 17). However, a high 
percentage of the engrafted cells retain a  phenotype characteristic of undifferentiated 
progenitors questioning the ability of these progenitors to efficiently differentiate into 
mature haematopoietic cells (Easterbrook et al., 2016). Likewise, SOX17 
overexpression led to the successful formation and expansion of HE cells from human 
PSCs, although it is necessary the release of HE cells from SOX17 overexpression to 
enable the generation of haematopoietic progenitor cells (Nakajima-Takagi et al., 
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2013).  Forced expression of TAL1 led to the formation of haematopoietic progenitors 
with megakaryocytic and erythroid potential from human ESCs although lacking of in 
vivo engraftment capacity (Real et al., 2012).  These studies using single transcription 
factors to induce formation of HSPCs from PSCs are characterized by the inability to 
produce fully in vivo multilineage engraftment, highlighting the complexity of the 
haematopoietic regulatory networks (Daniel et al., 2016).      
   
Likewise, transdifferentiation approaches involving the ectopic expression of OCT4 
and SOX2 in human fibroblasts (Pulecio et al., 2014) and FOSB, GFI1, RUNX1 and 
SPI1 in human endothelial cells (Sandler et al., 2014) have resulted in the generation 
of haematopoietic progenitors with in vivo engraftment capacity, albeit with a reduced 
differentiation potential  (Ackermann et al., 2015) (Figure 17). 
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Figure 17. Strategies to generate HSPCs by in vitro direct conversion of PSCs or differentiated 
cells. 
Boxes list combination of multiple transcription factors or single transcription factors used for direct 
conversion of PSCs or differentiated cells (endothelial or fibroblast cells) into HSPCs. 
Isolation from teratoma. Recently, two different studies have reported the successful 
isolation of CD34+CD45+ cells from teratomae induced in immune-deficient mice by 
mouse and  human iPSCs (Amabile et al., 2013; Suzuki et al., 2013). iPSC-derived 
haematopoietic progenitor cells isolated from teratomae were used in serial 
transplantation experiments showing engraftment and capacity for multi-lineage 
reconstitution in SCID mice. Although these studies are still displaying low induction 
efficiency and engraftment levels, they highlight the importance of the generation of a 
suitable microenviroment for HSPC generation provided in these in vivo studies by 
extracellular matrix or blood (Ackermann et al., 2015). 
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1.3.3 Challenges in haematopoietic differentiation from PSC 
Outstanding progress has been made regarding haematopoietic differentiation of PSC 
so far. However, there are several hurdles to overcome in regards to a future clinical 
use of the PSC-derived HSC.    
1.3.3.1 Engraftment potential of PSC-derived HSC 
The most stringent assay to evaluate the long-term reconstitution ability and lympho-
myeloid capacity of the in vitro PSC-derived HSC is the use of in vivo transplantation. 
Several studies have shown the engraftment potential of human PSC-derived 
haematopoietic cells (Wang et al., 2005; Narayan et al., 2006; Tian et al., 2006; Ledran 
et al., 2008; Risueno et al., 2012; Amabile et al., 2013; Suzuki et al., 2013; Sugimura 
et al., 2017). However, these studies have shown a poor engraftment ability of the 
PSC-derived haematopoietic cells generated with bone marrow engraftment levels 
going from 0.1%-2% with predominant myeloid engraftment (Slukvin, 2013). The poor 
engraftment levels observed in these studies have been associated to the limited 
proliferative and colony-forming capacity of the PSC-derived haematopoietic cells 
mainly caused by an impaired haematopoietic differentiation (Tian et al., 2009). These 
limitations are most likely due to the inability of these approaches to mimic the 
complexity of the in vivo HSC specification and expansion (Ackermann et al., 2015). 
Therefore, it is necessary to develop better in vitro protocols in order to mimic the in 
vivo microenvironment needed to generate bona fide HSCs with robust long-term 
engraftment potential. Additionally, possible rejection of the host immune system, the 
mouse strain selected to test the cells or even the host age should be considered as 
factors that might improve the engraftment levels (Brehm et al.). 
1.3.3.2 Primitive vs Definitive 
As stated in section 1.3.1, primitive haematopoiesis is defined as the initial wave of 
haematopoiesis originated in the YS given rise to primitive erythrocytes, monocytes 
and megakaryocytes. Subsequent waves of haematopoiesis originated in the embryo, 
including HSCs produced in the AGM, are considered definitive haematopoiesis. 
Primitive and definitive waves are temporally and spatially separated in the embryo 
(section 1.3.1). However, both developmental processes co-exist during in vitro 
differentiation of PSCs towards haematopoietic lineages and their identification is 
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challenging, being recognizable only by functional criteria due to the lack of specific 
markers (Figure 18). Only primitive erythroid progenitors can be properly identified 
since they generate larger erythrocytes that express embryonic haemoglobin (Palis, 
2014).  
 
Figure 18. Schematic representation of in mouse and human in vitro haematopoietic 
development. 
Timeline displaying the generation of the different types of haematopoietic precursors and emergence 
of the different waves of haematopoietic progenitors (primitive and definitive) in mouse embryos (in vivo) 
and from mouse and human PSCs (in vitro). CFCs, colony-forming cells; CFU-S, colony-forming spleen; 
HSCs, haematopoietic stem cells. Modified from Kardel and Eaves, 2012 (Kardel and Eaves, 2012)   
Limitation in the identification and generation of HSPCs capable of long-term 
engraftment has been associated to the lack of protocols recapitulating exclusively the 
definitive wave of haematopoiesis in which bona fide HSC emerge. This is most likely 
due to the difficulty in mimicking the complexity of haematopoiesis ontogeny in an in 
vitro setting (Wahlster and Daley, 2016). Several studies have reported the importance 
of blocking the Activin/Nodal signalling pathway to induce definitive haematopoiesis 
(Kennedy et al., 2012). Likewise, Sturgeon et al. reported the identification of a 
mesodermal population, characterized by the phenotype KDR+/CD235a-, as 
precursors of the definitive haematopoietic progenitor cells (Sturgeon et al., 2014). 
These studies used T lymphocyte potential to distinguish definitive from primitive 
haematopoiesis since T cells clearly represent a definitive lineage that is not generated 
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during primitive haematopoiesis, unlike erythrocytes, macrophages and 
megakaryocytes.  However, this has been recently challenged since it has been 
reported that T-cell progenitors are generated before emergence of the first HSCs, 
indicating that progenitors with T-lymphoid potential do not necessarily represent true 
HSCs (Boiers et al., 2013). 
1.3.4 iPSCs as source of haematopoietic cells 
IPSCs stand out as an ideal source patient-specific haematopoietic cells when 
differentiated under specific conditions due to their pluripotency and unlimited self-
renewal capacity (Chapter 1, section 1.2.4). Human iPSC, as human ESC, can give 
rise to cells of endodermal, mesodermal and ectodermal origin as described previously. 
The major advantage over human ESC, besides ethical dilemmas, is tailored therapy, 
since patients’ own cells can be reprogram into iPSC that can generate 
histocompatible cells for transplantation as well as unparalleled short-term applications 
as unlimited source of haematopoietic cells for disease modelling and drug discovery 
(Figure 19) (Paes et al., 2017). 
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Figure 19. Application of human iPSC technology for haematopoietic diseases. 
Patient-specific iPSCs can be potentially used as source of haematopoietic stem cells (HSCs) that can 
be subsequently differentiated into haematopoietic cells for disease modelling studies and drug 
screening. Alternatively, patient-specific iPSC of patients with monogenic genetic blood diseases can 
be gene corrected and disease-free iPSC-derived HSCs can be either transplanted into patients or used 
as source of patient-specific haematopoietic cells in cell therapy studies. Reproduced from Daniel et al. 
2016. (Daniel et al., 2016).  
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1.3.4.1 Haematopoietic cell differentiation of iPSC 
Several studies have evaluated the haematopoietic differentiation potential of iPSC 
with some variation in the results. Choi et al. compared the haematopoietic 
differentiation potential between seven different human iPSC lines and five human 
ESC lines (Choi et al., 2009b). The results shown some variation between both groups 
of cell lines, although the overall haematopoietic potential, based on the 
immunophenotypic expression of the haematopoietic markers as well as the 
production of colony-forming cells, was similar in both human iPSC and human ESC 
lines. However, Feng et al. showed  that the haemangioblastic derivatives generated 
from human iPSC-derived haemangioblasts show decreased proliferation potential as 
well as apoptotic phenotype and early senescence compared to those from human 
ESC-derived haemangioblasts (Feng et al., 2010). Variations between these studies 
may be related to a low transgene expression level resulting from the use of integrating 
vectors or variations in the degree of reprogramming of the target cells or even 
between clones of the same cell line. This highlights the need of generating transgene-
free iPSC in order to exclude variability generated by the reprogramming process. 
Many studies have reported the generation of haematopoietic cells from human iPSC 
proving the ability of these cells to be used as source of haematopoietic cells disease 
model to study haematopoietic diseases (Table 3). Thus, production of human iPSC-
derived blood cells, such as red blood cells, platelets and white blood cells, can help 
alleviate the high demand for blood products existing in transfusion medicine (Togarrati 
and Suknuntha, 2012).   
 
Different studies have reported the production of erythrocytes from human iPSCs using 
combination of co-culture and cytokines or cytokines only (Lapillonne et al., 2010; Dias 
et al., 2011; Olivier et al., 2016). However, low efficiency in the generation of 
enucleated erythrocytes expressing adult haemoglobin and use of mouse feeder layer 
are hampering the clinical application of these protocols (Dorn et al., 2015). Similarly, 
Feng et al. reported the generation of mature megakaryocyte and platelet population 
from human iPSC, although with an efficiency still insufficient for clinical use (Feng et 
al., 2014).  Large numbers of neutrophils and eosinophils have been generated from 
human iPSC-derived myeloid progenitors (Choi et al., 2009a; Lachmann et al., 2015). 
These human iPSC-derived granulocytes displayed similar chemotactic, phagocytic 
functions and potential to generate reactive oxygen species similar to their in vivo 
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counterparts. Likewise, in vitro derived macrophages show functional and 
morphological properties than those found in vivo (Choi et al., 2009a; Lachmann et al., 
2015). However, functionality in an in vivo setting of both human iPSC-derived 
granulocytes and macrophages remains to be evaluated (Ackermann et al., 2015). In 
vitro differentiation of cells from lymphoid lineage from PSCs relies on the use of feeder 
cells such as OP9 or MS-5. Activation of Notch signalling pathway has been shown to 
be essential leading to the use of modified OP9 cells constitutively expressing Notch 
ligand Delt-1 and 4 (OP9-DL1, OP9-DL4). However, efficiency to generate natural killer 
cells, T and B cells from human iPSC has been shown even lower than for generation 
of myeloid and erythroid cells (Sturgeon et al., 2014; Uenishi et al., 2014; Ferrell et al., 
2015; French et al., 2015). Thus, despite the feasibility showed by the iPSC model to 
generate all the different types of blood cells in an in vitro setting, there are some 
challenges to overcome such as large-scale production and in vivo functionality of the 
human iPSC-derived blood cells for its use as disease model and in transfusion 
therapies.    
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Cell type 
Reprogramming 
strategy 
Differentiation approach 
Reference Co-culture 
Cytokines 
Erythrocytes 
Lentivirus 
No (Lapillonne 
et al., 
2010) 
BMP4, VEGF, SCF, TPO, Flt3-L, 
IL-3, IL-6, EPO 
Episomal vectors  
OP9, MS5 
(Dias et 
al., 2011) 
TPO, IL-3, IL-6, Flt3-L, G-CSF, 
EPO 
Retrovirus 
No 
(Olivier et 
al., 2016) 
BMP4, VEGF, Activin A, WNT3a, 
Inhibitor VII, FGFα, SCF, Flt3-L, 
TPO, IL-3, IL-11, IGF1, EPO 
Megakaryocytes mRNA 
No 
(Feng et 
al., 2014) 
BMP4, VEGF, bFGF, TPO, SCF, 
Flt3-L, IL-3, IL-6, IL-9 
Granulocytes 
Lentivirus 
No (Lachman
n et al., 
2015) 
IL-3, G-CSF, GM-CSF 
Lentivirus 
OP9 (Choi et 
al., 2009a) IL-3, IL-5, G-CSF, GM-CSF 
Macrophages 
Lentivirus 
No (Lachman
n et al., 
2015) 
IL-3, M-CSF, GM-CSF 
Lentivirus 
OP9 (Choi et 
al., 2009a) IL-1-b, M-CSF, GM-CSF 
Dendritic cells 
Lentivirus 
OP9 (Senju et 
al., 2011) M-CSF, GM-CSF IL-4, TNF-α 
Lentivirus 
OP9 (Choi et 
al., 2009a) GM-CSF, IL-4, TNF-α 
NK cells Retrovirus 
OP9-DL4 
(Sturgeon 
et al., 
2014) 
BMP4, bFGF, Activin A, VEGF, 
IGF-1, IL-3, IL-6, IL-11, IL-13, IL-
15, SCF, EPO, TPO, Flt3-L   
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Retrovirus 
OP9-DL1 
(Ferrell et 
al., 2015) 
BMP4, VEGF,  SCF, IL-3, IL-6, IL-
7, IL-15, SCF, EPO, TPO, Flt3-L   
T cells 
Retrovirus 
OP9-DL4 
(Sturgeon 
et al., 
2014) 
BMP4, bFGF, Activin A, VEGF, 
IGF-1, IL-3, IL-6, IL-7, IL-11, SCF, 
EPO, TPO, Flt3-L   
Episomal vectors 
OP9-DL1 OP9-DL4 
(Uenishi et 
al., 2014) 
BMP-4, bFGF, VEGF, TPO, SCF, 
IL-3, IL-6, IL-7, Flt3-L 
B cells Lentivirus 
OP9, MS5 (French et 
al., 2015) SCF, IL-3, IL-7, Flt3-L  
 
Table 3. Studies reporting generation of mature haematopoietic cells from human iPSC. 
bFGF: basic fibroblast growth factor; BMP4: bone morphogenetic protein-4; DL: delta-like ligand; EPO: 
human erythropoietin; Flt3-L: human Fms-like tyrosine kinase 3 ligand; G-CSF: granulocyte colony-
stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating factor IGF: human insulin-like 
growth factor; IL: interleukin; M-CSF: macrophage colony-stimulating factor; SCF: human stem cell 
factor; TPO: human thrombopoietin; VEGF: human vascular endothelial growth factor. 
1.3.4.2 iPSC as a disease model for inherited BMFS 
Inherited BMFS are characterized by peripheral cytopenia and/or hypoplastic bone 
marrow (Shimamura and Alter, 2010). Use of HSPCs from BMFS patients in disease 
models is extremely challenging due to the low numbers of these progenitors in the 
patient’s bone marrow. Thus, unlimited self-renewal capacity of iPSC makes them 
especially valuable as disease model providing extensive number of cells for the study 
of the complex pathophysiology underlying BMFS. Several studies have reported the 
generation of human iPSC from patients with BMFS (Table 4). Activation of DNA repair 
pathways during reprogramming to ensure genomic integrity have hindered the 
generation of human iPSC from FA patients. This role of FA pathway during 
reprogramming to pluripotency provides an excellent opportunity for the study of this 
defective pathway in FA patient cells. Generation of FA-iPSC has been achieved by 
correction of the defect in the affected FANC genes in patient fibroblasts prior to 
reprogramming (Raya et al., 2009) or when reprogramming has been performed under 
hypoxic conditions (Muller et al., 2012). Normoxic conditions have been also used to 
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generate FA-iPSC although at much lower efficiency (Yung et al., 2013). Interestingly, 
Rio et al. reported the generation of disease-free FA-iPSC upon correction of FANCA 
defective fibroblasts that displayed resistance to exposure to DNA interstrand cross-
link drugs and normal haematopoietic colony-forming potential (Rio et al., 2014). As 
discussed in section 1.2.4.2, process of somatic cell-induced reprogramming is 
characterized by the rejuvenation of telomeres in iPSC cells due to up-regulation of 
telomerase activity (Marion et al., 2009). This characteristic hallmark of reprogramming 
is appealing for the study of DC characterized by defects in telomere maintenance 
process. Human iPSC have been derived from DC patients with mutations in DKC1, 
TERT, TERC and TCAB1 genes (Table 4).  Despite initial conflicting results regarding 
the ability of DC-iPSC to elongate telomeres, several studies have reported the 
generation of human iPSC lines with mutations in TERT, TERC, TCAB1 and DKC1 
displaying shortened telomeres, ultimately affecting self-renewal capacity, with severity 
of telomerase dysfunction depending upon the precise nature of the mutation (Batista 
et al., 2011; Gu et al., 2015; Woo et al., 2016). DBA-iPSCs have been generated from 
patients with mutations in ribosomal-associated genes RPS19 and RPL5 (Table 4). 
This DBA-iPSC model successfully recapitulated the phenotype observed in patients 
showing an impaired generation of haematopoietic progenitors mainly affecting 
erythroid lineages (Garcon et al., 2013). Likewise, DBA-iPSC displayed dysregulation 
of non-canonical TGFβ signalling pathway that may be associated to the defective 
phenotype observed in in DBA patients proving the usefulness of iPSC disease models 
to provide insights into disease pathogenesis (Ge et al., 2015). IPSC generated from 
SDS patients showed increased levels of proteases in culture supernatant and reduced 
haematopoietic colony-forming potential when differentiated towards haematopoietic 
lineages. Use of protease inhibitors in the culture media rescued the defective 
phenotype providing an example of drug-reversible phenotype using human iPSC 
model (Tulpule et al., 2013). Severe congenital neutropenia (SCN)-iPSC model was 
used by Nayak et al. to identify the mislocalization of the neutrophil elastase (NE) 
protein as the underlying cause of the dysfunctional myeloid differentiation and 
increased apoptosis observed in SCN-iPSC-derived neutrophils, successfully 
corrected by the addition of NE inhibitor sivelestat (Nayak et al., 2015).  
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Thus, these studies highlight the utility of iPSC technology to model inherited bone 
marrow syndromes leading to think that iPSCs could be in a similar fashion to 
investigate a potential underlying HSPC dysfunction in SAA patients in order to shed 
light into the complex pathophysiology of this disorder. 
 
Bone marrow 
failure 
syndrome 
Reprogramming 
strategy 
Defective 
genes 
Genetic correction 
(system  used) 
Reference 
Fanconi 
anaemia 
Retrovirus 
FANC-A,   
FANC-D2 
Yes               
(lentiviral vectors) 
(Raya et al., 
2009) 
Retrovirus, 
Lentivirus 
FANC-A,   
FANC-C,  
 FANC-D2 , 
FANC-G  
No 
(Muller et al., 
2012) 
Lentivirus 
FANC-A,   
FANC-C,   
FANC-D2,  
FANC-G 
No 
(Yung et al., 
2013) 
Lentivirus FANC-A 
Yes                          
(zinc-finger 
nucleases) 
(Rio et al., 
2014) 
Dyskeratosis 
congenita 
Lentivirus 
DKC1 
(Q31E, 
ΔL37, 
A353V) 
Yes                   
(zinc-finger 
nucleases) 
(Gu et al., 
2015) 
Lentivirus 
TERT,  
TCAB1,  
DKC1 
No 
(Batista et 
al., 2011) 
Retrovirus 
DKC1,  
TERC 
No 
(Agarwal et 
al., 2010) 
Lentivirus DKC1 
Yes   
(CRISPR/Cas9) 
(Woo et al., 
2016) 
Diamond-
Blackfan 
anaemia 
Lentivirus 
Sendai virus 
RPS19,  
RPL5 
Yes                    
(zinc-finger 
nucleases) 
(Ge et al., 
2015) 
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Shachman-
Bodian-
Diamond 
Retrovirus SBDS 
Yes                      
(lentiviral vectors) 
(Tulpule et 
al., 2013) 
Severe 
Congenital 
Neutropenia 
Retrovirus ELANE No 
(Hiramoto et 
al., 2013) 
Lentivirus ELANE 
Yes       
 (CRISPR/Cas9) 
(Nayak et al., 
2015) 
Retrovirus HAX1 
Yes                       
(lentiviral vectors) 
(Morishima et 
al., 2014) 
Table 4. Disease modelling studies of BMFS using iPSC technology. 
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1.4 Aims 
The aims of this thesis were: 
 
1. To generate and characterize iPSC from SAA patients’ cells. 
 
2. To assess the capacity of the SAA-iPSC to differentiate into haematopoietic 
progenitor cells, including megakaryocytic, erythroid and myeloid subpopulations 
and its haematopoietic colony-forming potential. 
 
3. To study the telomere dynamics of SAA cells lines during reprogramming to 
pluripotency and subsequent differentiation into haematopoietic progenitors. 
 
4. To assess the proliferation, apoptosis and DNA repair capacity of SAA-iPSC 
derived haematopoietic progenitors under normal and replicative stress conditions. 
 
5. To assess the effect of EP on colony-forming potential, proliferation, apoptosis and 
DNA repair capacity of SAA-iPSC-derived haematopoietic progenitor cells. 
  
61 
 
2 Chapter 2. Material and Methods 
2.1 Human dermal fibroblast (HDF) cell culture 
Neonatal and adult human dermal fibroblast (HDF) cells were used to generate control-
iPSC lines (Lonza, CC-2509, CC-2511). Skin biopsies from paediatric and young adult 
SAA patients were taken with informed consent by Dr Sujith Samarasinghe, Consultant 
Paediatric Haematologist at the Royal Victoria Infirmary, Newcastle upon Tyne. 
Fibroblasts from these biopsies were isolated and analysed by the Cytogenetics 
department of the Institute of Genetic Medicine (IGM) of Newcastle University. Human 
fibroblast cultures were maintained in T25/T75 culture flasks in HDF media comprised 
of Advanced Dulbecco’s Modified Eagle Medium (Thermo-Fisher, Waltham, MA, USA) 
containing 10% foetal bovine serum (FBS) (Thermo Fisher Scientific), 1% Glutamax™ 
(Thermo Fisher Scientific) and 1% penicillin/streptomycin (Thermo Fisher Scientific) at 
37°C and 5% CO2 in a humidified incubator. Fibroblasts were passaged using a 0.05% 
trypsin/EDTA solution (Thermo Fisher Scientific) at 37°C + 5% CO2. All fibroblast 
culture was performed in a Class II biosafety cabinet laminar air flow tissue culture 
hood. For long-term storage, human fibroblasts were cryopreserved in freezing media 
comprised of 90% FBS+ 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MI, 
USA) and stored in specialised cryovials. These were transferred to a pre-cooled 
isopropanol-containing freezing container which was stored in an 80°C freezer for 24 
hours prior transferring to liquid nitrogen for long-term storage.  
2.2 Mouse embryonic fibroblasts culture and feeder cell layer preparation 
Mouse embryonic fibroblasts (MEFs) were isolated from 12.5-13.5 day old embryos 
via their dissection and mechanical digestion from Swiss MF1 Pregnant mice. 
Following isolation and MEFs were cultured and passaged as described for human 
dermal fibroblast culture. The MEFs were subjected to irradiation using the cabinet X-
ray cell irradiator CP-160 (Faxitron, Tucson, AR, USA) at a dose of 120kV, 4.0mA for 
7 minutes. The irradiated MEFs were then plated onto gelatine-coated 4/6-well tissue 
culture plates (20.000 cells/cm2). The MEF-coated plates were then ready for iPSC 
seeding after a 24-hour incubation period at 37°C + 5% CO2. For conditioned media 
preparation, MEFs (seeded at a density of 5.5 x 104 cells/cm2) were irradiated as 
described above. The inactivated MEF culture was then submerged in iPSC media 
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comprised of Knock-Out Dulbecco’s Modified Eagle’s Medium (Thermo Fisher 
Scientific), 20% Knock-Out Serum Replacement (Thermo Fisher Scientific), 1% Non-
Essential Amino acids (Thermo Fisher Scientific), 1% Glutamax™ (Thermo Fisher 
Scientific), 1% penicillin-streptomycin Solution (Thermo Fisher Scientific) and 8ng/ml 
basic Fibroblast Growth Factor (bFGF) (Thermo Fisher Scientific)  and this was left to 
condition for 24 hours at 37°C + 5% CO2 in a humidified incubator before collection. 
This was repeated for 7-9 days before exhaustion of the MEFs. Following collection, 
the MEF-conditioned iPSC (CM-iPSC) media was then supplemented with 1% insulin 
transferrin selenium-A (Thermo Fisher Scientific) and 8 ng/ml bFGF and filtered with a 
0.20 µM filter before use for iPSC generation. 
2.3 iPSC generation from SAA patients and healthy volunteers 
Human dermal fibroblasts were transduced using the CytotuneTM-iPS Reprogramming 
Kit (Thermo Fisher Scientific, A13780-01) according to manufacturer’s instructions. 
Briefly, once fibroblast cultures reached 80% confluency SeV including the 
reprogramming transgenes separately were added. Transduced HDF were plated on 
mitotically-inactivated MEF feeder cells on day 9 (26.000 cells/cm2). HDF media was 
replaced by iPSC media to enhance reprogramming. First iPSCs showing 
characteristic human ESC-like morphology emerged around day 20 and were manually 
picked on day 24 and transferred to fresh mitotically-inactivated MEF feeder cell wells. 
Due to feeder cell exhaustion, culture media was replaced by CM-iPSC media from 
day 20.  
2.4 iPSC culture 
iPSC colonies were established on inactivated primary mouse embryonic fibroblasts 
feeder layer and then adapted to a feeder-free system, cultured on recombinant 
Vitronectin (Thermo Fisher Scientific) and in StemPro human ESC SFM® media 
(Thermo Fisher Scientific) supplemented with 8ng/ml basic Fibroblast Growth Factor 
(Thermo Fisher Scientific), 1% penicillin/streptomycin and 0.1mM 2-Mercaptoethanol 
(Thermo Fisher Scientific). iPSCs cultures were maintained for approximately 4/5 days 
before passage or induction of differentiation. The white, thicker, heterogeneous 
differentiated areas of iPSCs colonies were removed daily and prior to passage using 
a 200μl micropipette tip. Passaging was carried out mechanically using the 
STEMPRO® EZpassage™ tool (Thermo Fisher Scientific). For long-term storage, 
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iPSCs were cryopreserved in freezing media comprised of 90% FBS+ 10% Dimethyl 
Sulfoxide (DMSO) (Sigma-Aldrich) and stored in specialised cryovials. These were 
transferred to a pre-cooled isopropanol-containing freezing container which was stored 
in an 80°C freezer for 24 hours prior transferring to liquid nitrogen for long-term storage. 
2.5 Immunocytochemistry analysis of pluripotency markers 
For immunocytochemistry analysis, iPSC colonies were fixed in 4% Formaldehyde 
(Sigma-Aldrich) and permeabilized with 0.25% Triton-X-100 (Sigma-Aldrich). 
Following treatment, cells were stained with mouse anti-human SSEA4-Alexa Fluor® 
555 (Beckton Dickinson, BD; Franklin Lakes, NJ, USA) at 1:60 dilution, mouse anti-
human TRA-1-60-FITC (Merck Millipore, Billerica, MA, USA) at 1:60 dilution, mouse 
anti-NANOG-AF647 (Cell Signalling Technologies, Danvers, MA, USA) at 1:150 
dilution and goat anti-human OCT4 primary antibody (R&D, Minneapolis, MN, USA) at 
1:60 dilution. Secondary staining was performed using anti-goat IgG FITC (Sigma-
Aldrich) at 1:200 dilution. Following treatment with the DNA nuclear stain 4’, 6-diamino-
2-phenylindole (DAPI) (Partec, Munster, Germany), stained iPSC colonies were 
photographed using a Bioscience Axiovert microscope (Axiocam, CarlZeiss) in 
combination with the associated CarlZeiss software- AxioVision.  
2.6 Flow cytometric analysis of pluripotency markers 
To assess the percentage of cells expressing the pluripotent markers TRA-1-60 and 
SSEA-4, flow cytometric analysis was performed, iPSC colonies were dissociated 
using TrypLE™ Express (Thermo Fisher Scientific) for 5 minutes at 37°C. Dissociated 
cells were stained with the following antibodies: anti-human TRA-1-60-FITC (Millipore) 
at 1:60 dilution and mouse anti-human SSEA-4-PerCPCy™5.5 (BD) at 1:20. Cell 
population was identified based on cell size and cell granularity. Single cells were 
discriminated using Forward Scatter area (FSC-A) and Forward Scatter Height (FSC-
H) and live cells were gated from single cell population using DAPI nuclear staining 
(Partec). The cells were acquired using the BD LSRII flow cytometer (BD) and data 
analysed using FlowJo software (Tree Star, Ashland, OR, USA). At least 10.000 events 
were collected for each analysis. Gating strategies for identification of positive cell 
population are shown in Appendix A. 
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2.7 In vivo test of pluripotency 
For in vivo analysis of pluripotency via teratoma formation, 0.5x106 iPSCs were 
resuspended in 50% MatrigelTM (Becton-Dickinson, Franklin Lakes, NJ, USA) in a total 
volume of 200 µl and injected subcutaneously into both flanks of adult severe 
combined immunodeficiency (SCID) male mice (Mus musculus, ICRF-Foxn1nu). Two 
animals were injected in each group.  Following a period of 10 weeks, the mice were 
euthanized and the teratomae were excised, fixed in 4% paraformaldehyde (PFA) for 
12 hours. Fixed teratomae were processed and sectioned according to standard 
procedures and stained for Weigert’s haematoxylin, Masson’s trichrome and Mayer’s 
haematoxylin and Eosin histological analysis. Sections (5-8 µm) were examined using 
bright field microscopy and stained tissue photographed as appropriate.   
2.8 Genomic DNA extraction 
Genomic DNA was extracted from the pelleted cultures of iPSC lines and 
corresponding parental fibroblast cell lines using the QIAamp DNA Mini Kit (Qiagen, 
Germantown, MD, USA) according to standard protocols of the manufacturer. 
2.9 Karyotyping and Fingerprinting Analysis 
Genomic DNA from iPSC and parental fibroblasts was analysed using Illumina 
CytoSNP analysis and the BlueFuse Multi 4.3 software (Illumina, San Diego, United 
States) according to standard protocols of the manufacturer. 
2.10 iPSC differentiation into haematopoietic progenitors cells  
iPSCs maintained on Vitronectin™ in StemPro™ media were cut in homogeneous 
pieces using a STEMPRO® EZpassage™ tool (Thermo Fisher Scientific). Aggregates 
were resuspended in Stemline® II (Sigma-Aldrich) differentiation media supplemented 
with 1% penicillin/streptomycin and cultured in ultra-low attachment culture plates at 
37°C and 5% CO2 in a humidified incubator for 3 days to allow the formation of EBs. 
On day 3, EBs were dissociated using TrypLE™ Express (Thermo Fisher Scientific) 
for 10 minutes at 37°C and transferred to tissue-culture treated wells at a density of 
25.000 cells/cm2 to allow culture under monolayer conditions at 37°C and 5% CO2 in 
a humidified incubator. Recombinant human BMP4 (day 0-2 10ng/ml, day 2-16 
20ng/ml), VEGF (day 0-2 10ng/ml, day 2-16 30ng/ml), Wnt3A (10ng/ml), GSK-3β 
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Inhibitor VII (2µM), Activin A (5ng/ml), FGFα (10ng/ml), SCF (20ng/ml), IGF-2 
(10ng/ml), TPO (10ng/ml), β-estradiol (0.4ng/ml), Heparin (5µg/ml) and 3-isobutyl-1-
methylxanthine (IBMX) (50µM) were added to the differentiation media as previously 
described (Olivier et al., 2016). All cytokines and compounds were purchased from 
Peprotech (Rocky Hill, NJ, USA) except BMP4 and Wnt3A (R&D, Minneapolis, MN, 
USA), GSK-3β Inhibitor VII (Calbiochem, San Diego, CA, USA) and β-estradiol, 
Heparin and IBMX (Sigma-Aldrich). 
2.11 Flow cytometric analysis of mesodermal, endothelial and haematopoietic 
markers 
iPSC-derived differentiated cells were treated with 1X TrypLE™ Express for 5 minutes 
at 37ºC to obtain a single a cell suspension. Cell pellets were resuspended in FACS 
buffer and cells counted with a haemocytometer. A final amount of 1x105 cells 
resuspended in 100µl of FACS buffer a dilution of 1:20 antibody was used for each 
analysis. The following cell surface antigens were analysed for this study: KDR-PE, 
CD34-APC, CD43-FITC, CD41a-APCH7 and CD235a-BV421. All antibodies were 
purchased from Becton-Dickinson except for CD43-FITC (Thermo Fisher Scientific). 
Cells were washed using the FACS Lyse/Wash assistant (Becton-Dickinson) and 
analysed using LSRII flow cytometer (Becton-Dickinson). Size and cell complexity 
were used to identify cell populations in a scatter graph representation. Single cells 
were discriminated using FSC-A and FSC-H and live cells were gated from single cell 
population using DAPI nuclear staining. Analysis of data was performed using FlowJo 
software (Tree Star Inc., Ashland, OR, USA). At least 10.000 events were collected for 
each analysis. Gating strategies for identification of positive cell population are shown 
in Appendix A. 
2.12 Analysis of haematopoietic colony-forming potential of haematopoietic 
progenitors by CFU Assay  
iPSC-derived haematopoietic progenitor cells were treated with 1X TrypLE™ Express 
for 5-10 minutes at 37°C to obtain a single a cell suspension. TrypLE™ Express is 
diluted in PBS and cells were pelleted by centrifugation at 300g for 3 minutes. Cell 
pellets were resuspended in FACS buffer and cells were counted with a 
haemocytometer. A final amount of 6x104 cells resuspended in 300µl of FACS buffer 
and mixed with 3ml of Methocult™ methylcellulose media enriched with recombinant 
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cytokines (Stem Cell Technologies, Vancouver, BC, Canada) and 1.5 ml were plated 
in duplicate in 35-mm dishes. Colonies were scored after 14 days of culture using light 
microscope according to standard criteria (Coutinho, 1993; Eaves, 1995) and 
averaged between the duplicate dishes. 
2.13 RNA isolation 
RNA from iPSCs and fibroblasts at day-7 of SeV transduction used as positive Sendai 
control was extracted using the ReliaPrepTM RNA Cell Miniprep System (Promega, 
Madison, MA, USA) including DNase I (Promega) treatment for degradation of 
genomic DNA according to the manufacturer’s instructions. 
2.14 Reverse Transcription (RT) 
A total amount of 1 µg of RNA was reverse transcribed into cDNA using the GoScriptTM 
Reverse Transcription System (Promega) and random primers according to the 
manufacturer’s instructions. For each test sample a negative control sample in which 
GoScriptTM Reverse Transcriptase was substituted by nuclease-free water (Promega) 
in order to detect genomic DNA contamination. 
2.15 Polymerase chain reaction (PCR) 
For the PCR reaction mixture, 1µl of cDNA previously generated from 1µg of RNA was 
amplified using 0.5µl 10µM dNTP mix, 5µl 5X Green GoTaq® Reaction Buffer and 
0.2µl GoTaq® DNA polymerase (5u/µl), 17.3µl of nuclease-free water (Promega) and 
0.5µl 10µM primers shown in Table 5 made to a final volume of 25µl. The PCR 
consisted of a 35-cycle program and was carried out using a Mastercycler® thermal 
cycler. The machine was set up to carry out as a sequence of reaction temperatures 
for denaturation, annealing and amplification of reverse transcription enzymes. The 
sequence of 35 cycles begins with 95°C for 30 seconds, 95°C for 30 seconds followed 
by 72°C for 30 seconds and held at 4°C. 
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 Product Primer sequence (5’ → 3’) Size (bp) 
SeV-OCT4 
Forward  CCCGAAAGAGAAAGCGAACCAG 
483 
Reverse AATGTATCGAAGGTGCTCAA 
SeV-SOX2 
Forward  ATGCACCGCTACGACGTGAGCGC 
451 
Reverse AATGTATCGAAGGTGCTCAA 
SeV-Klf4 
Forward  TTCCTGCATGCCAGAGGAGCCC 
410 
Reverse AATGTATCGAAGGTGCTCAA 
SeV-cMYC 
Forward  TAACTGACTAGCAGGCTTGTCG 
532 
Reverse TCCACATACAGTCCTGGATGATGATG 
SeV 
Forward  GGATCACTAGGTGATATCGAGC 
181 
Reverse ACCAGACAAGAGTTTAAGAGATATGTATC 
GAPDH 
Forward  GGATCACTAGGTGATATCGAGC 
151 
Reverse ACCAGACAAGAGTTTAAGAGATATGTATC 
Table 5. List of specific primers used for detecting SeV genome and transgenes by RT-PCR 
2.16 Agarose gel electrophoresis 
Amplification products were visualized by electrophoresis on horizontal 2% agarose 
gels using fluorescent nucleic acid dye GelRedTM Nucleic Acid Stain (Biotium, Fremont, 
CA, USA).  In order to monitor the size and intensity of DNA fragments 5µl of Gene 
Ruler 100bp plus DNA ladder (Thermo Fisher Scientific) was used. Gels were 
electrophoresed at 70-100 volts for 40-60 minutes. DNA bands were visualized and 
photographed by illumination of fluorescent nucleic acid dye by excitation using 
ultraviolet (UV) light, suing a GelDoc-It® 310 imaging system trans-illuminator (UVP, 
Upland, CA, USA) and VisonWorksTM LS software (UVP) for image analysis.    
2.17 Quantitative PCR for Telomere Length measurement  
Telomere length from previously extracted genomic DNA was measured as abundance 
of telomeric template versus a single copy gene (36B4) as previously described 
(Martin-Ruiz et al., 2005) using the primers shown in Table 6.  
  
68 
 
Product Primer sequence (5’ → 3’) 
TelA  CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT 
TelB  GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT 
36B4 
Forward  CAG CAA GTG GGA AGG TGT AAT CC 
Reverse CCC ATT CTA TCA TCA ACG GGT ACA A 
Table 6. List of specific primers used for measurement of telomere length 
Three internal control DNA samples of known telomere length (10.4 kb, 3.9 kb and 
2 kb) were run within each plate to correct for plate–to-plate variation. Measurements 
were performed in triplicate. All PCRs were carried out on an Applied Biosystems 
7900HT Fast Real Time PCR system with 384-well plate capacity. The intra-assay 
coefficient of variation was 2.7% while the inter-assay coefficient of variation was 5.1%. 
2.18 Telomere Repeat Amplification analysis for Telomerase Activity detection  
Telomerase activity in iPSC and iPSC-derived haematopoietic progenitors was 
measured as previously described (Ishaq et al., 2016) using the TeloTAGGG 
Telomerase PCR ELISA kit (Roche, Basel, Switzerland) according to manufacturer’s 
instructions. In brief, cell pellets were lysate using CHAPS lysis buffer (Roche). Total 
protein concentration was measured using Bradford Protein assay (Bio-Rad, Hercules, 
CA, USA) according to manufacturer’s instructions and absorbance at 450 nm was 
measured using an FLUOstar Omega spectrophotometer (BMG Labtech, Ortenberg, 
Germany). Initial amount of 100 ng of protein lysate was used for primer elongation 
and PCR amplification steps using no protein/lysate samples as negative controls and 
4 consecutive dilutions of Hela cells: 100, 10, 1 and 0.1ng as positive controls. 
Hybridization of amplified products to digoxigenin-(DIG)-labeled telomeric repeat-
specific detection and detection of probe by enzyme-linked immunosorbent assay 
(ELISA) were performed according to manufacturer’s instructions and absorbance at 
450 nm was measured using an FLUOstar Omega spectrophotometer (BMG Labtech). 
2.19 Analysis of DNA damage, Proliferation and Apoptosis by Flow Cytometry 
Day 12 iPSC-derived haematopoietic progenitor cells were exposed to 2M 
Hydroxyurea (HU) for 24 hours and collected at different time points (0, 1, 3, 8 and 24 
hours). DNA damage, proliferation and apoptosis induction after HU-treatment was 
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analysed using a flow cytometric kit according to manufacturer’s instructions (Becton-
Dickinson). Briefly, at the specified time points after HU treatment, the cells were 
labelled with 50 µM 5-bromo-2-deoxyuridine (BrdU) for 1 hour and stained later with 
antibody anti-human CD43-FITC. The labelled cells were then fixed, permeabilized 
and labelled with anti-human γH2AX-Alexa Fluor®647, anti-human BrdU- 
PerCPCy™5.5 and anti-human Cleaved PARP (Asp214)-PE according to 
manufacturer’s instructions. DNA content for cell cycle analysis was determined by 
DAPI staining provided by the kit. Size and cell complexity were used to identify cell 
populations in a scatter graph representation and single cells were discriminated using 
FSC-A and FSC-H. The cells were acquired using the LSRII flow cytometer (Becton-
Dickinson) and data analysed using FlowJo software. At least 10.000 events were 
collected for each analysis. Gating strategies for identification of positive cell 
population are shown in Appendix A.          
2.20 Statistical Analysis 
Data are shown as mean ± S.E.M. from at least three independent experiments. The 
significance between means was determined with Multiple t-test using Holm-Sidak 
method and One-way ANOVA when Gaussian distribution was assumed and with 
Kruskal-Wallis test when Gaussian distribution was not assumed. Multiple 
comparisons test for comparison between particular pairs of control and patient groups. 
Statistically significant values were judged as follows: * P ≤0.05, ** P ≤0.01, *** P 
≤0.001, **** P ≤0.0001. Statistical analysis was performed using GraphPad Prism 
version 7.0 software (GraphPad Software, La Jolla, CA, USA) and Minitab 17 statistical 
software (Minitab Inc., State College, Pennsylvania, USA). 
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3 Chapter 3.  Generation of SAA induced pluripotent stem cells 
(SAA-iPSC) 
3.1 Introduction 
iPSC technology has proved to be a powerful tool in disease modelling and therapy 
development as discussed in Chapter 1 (section 1.2.3). Particularly in the study of 
SAA, generation of iPSC lines from SAA patient’s cells could provide an unlimited 
source of haematopoietic progenitors to investigate the contribution of these 
progenitors to the phenotype observed in SAA patients. 
 
During reprogramming, induction of pluripotency is driven by the forced expression of 
the reprogramming transgenes. Transgene expression induces cell proliferation and 
downregulation of the genes specific to the cell type of origin. Later, erasure of the 
existing epigenetic somatic memory and upregulation of the endogenous pluripotency-
associated genes, such as OCT4, SOX2 and NANOG, results in the acquisition of the 
pluripotent state (Plath and Lowry, 2011) . Thus, a percentage of the starting population 
of somatic cells is fully reprogrammed showing established expression of the 
pluripotency transcriptional network and full differentiation potential defined as ability 
to give rise to cells from the three different germ layers (Chan et al., 2009). 
 
However, iPSC technology faces some limitations that may affect the iPSC 
differentiation ability. Constitutive expression of the reprogramming transgenes, 
incomplete reprogramming and introduction of genetic variations during 
reprogramming and/or subsequent in vitro culture are the main challenges that need 
to be addressed to ensure the generation of fully reprogrammed iPSC  suitable for 
downstream applications (Liang and Zhang, 2013) (Figure 20). Additionally, lack of 
robustness observed in some protocols used to differentiate patients’ iPSC introduces 
variation that should be considered when interpreting phenotypic differences, as it will 
be discussed in Chapter 4 (section 4.2.3) (Soldner and Jaenisch, 2012) (Figure 20).  
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The aim of this chapter is to describe the process of generation and characterization 
of control and SAA-iPSC lines generated for this study as follows: 
 Reprogramming to pluripotency of HDF from control and SAA cells by 
transduction with SeV containing reprogramming transgenes.  
 Analysis of residual expression of reprogramming transgenes and SeV 
genome in control and SAA-iPSC lines generated for this study. 
 Assessment of pluripotency of control and SAA-iPSC lines by detection of 
pluripotency marker expression and in vivo differentiation potential. 
 Analysis of major chromosomal abnormalities present in control and SAA-
iPSC lines  
 Authentication of genetic identity of control and SAA-iPSC lines and parental 
fibroblasts 
 
 
Figure 20. Sources of variation during the process of generation and differentiation of iPSC. 
Transduction of somatic cells with the reprogramming factors can lead to the integration of these RTs 
in the genome of the host cells leading to the transgene constitutive expression and mutagenesis in the 
genome. Likewise, incomplete reprogramming due to the inefficient removal of the somatic epigenetic 
marks the introduction of genetic variations at a chromosomal and nucleotide level can also impair the 
differentiation potential of the reprogrammed cells. CNVs: copy number variations, SNVs: single 
nucleotide variations. Adapted from Liang et al (Liang and Zhang, 2013).  
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3.2 Results 
3.2.1 Reprogramming of HDF from SAA patients 
Control and SAA-HDF were obtained from skin biopsy of healthy volunteers and SAA 
patients respectively with appropriate consent and approval from the Great Northern 
Biobank (GNB application GNB-ML4). Table 7 shows the age, gender and clinical 
manifestation of both control (WT1, WT2 and WT3) and SAA patients used in this study. 
SAA patients’ age range from 10 to 24 years old matching the first peak of incidence, 
classified as paediatric and young adult, characteristic in the biphasic distribution of 
SAA (10-25 and over 60 years) (Samarasinghe and Webb, 2012). All the SAA patients 
were classified as severe or very severe according to blood cells counts and bone 
marrow cellularity (Guinan, 2011) and showed different response to IST, which is likely 
to reflect an underlying heterogeneity in the aetiology of SAA. SAA1 patient 
successfully responded to IST whereas SAA2 patient relapsed after IST and failed with 
a second course. This relapse and failure to IST of the SAA2 patient might indicate the 
presence of an underlying defect in the HSPC of this patient. Likewise, response to 
IST in SAA patients does not necessarily imply that pathophysiology of the disease is 
solely due to immuno-mediated BM destruction since it has been previously reported 
that patients with HSC harbouring TERT mutations successfully responded to IST 
(Townsley et al., 2014).     
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Patient 
ID 
Age 
(years) 
Gender 
Phenotype, diagnosis and 
treatment 
Reprogramming 
efficiency 
WT1 Newborn Male Healthy 0.21% 
WT2 51 Male Healthy 0.29% 
WT3 37 Female Healthy 0.14% 
SAA1 16 Male 
Severe AA 
Negative for DEB test 
No clinical features of inherited BMFS 
No family history of SAA 
Responded to IST 
0.11% 
SAA2 24 Male 
Very severe AA 
Negative for DEB test 
No clinical features of inherited BMFS 
No family history of SAA 
Responded to IST 
Developed PNH and relapsed 
Failed with second course of 
immunosuppressors (horse ATG) 
Successful matched unrelated HSCT 
0.10% 
SAA3 10 Female 
Very severe AA and autism 
Negative for DEB test 
No clinical features of inherited BMFS 
No family history of SAA 
Successful matched unrelated HSCT 
0.11% 
SAA4 13 Male 
Very severe AA 
Negative for DEB test 
No clinical features of inherited BMFS 
No family history of SAA 
Successful matched unrelated HSCT 
0.14% 
Table 7. Phenotype of control and SAA patients used in this study. 
DEB, diepoxybutane; BMFS, bone marrow failure syndrome; SAA, severe idiopathic aplastic anaemia; 
IST, Immunosuppressive therapy; PNH, Paroxysmal Nocturnal Haemoglobinuria; ATG, Anti-Thymocyte 
Globulin; HSCT, Haematopoietic stem cell transplantation 
HDF from unaffected donors (3 cell lines) and SAA patients (4 cell lines) were thawed 
and cultured for at least one passage before transduction. An outline of the 
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reprogramming process is shown in Figure 21A. Figure 21B depicts the transition 
from HDFs to iPSC. HDF showed characteristic long, elongated morphology when 
transduced with replication-incompetent SeV encoding the reprogramming factors- 
OCT4, SOX2, KLF4, c-MYC on day 2. Following a 7-day period, the cells began to 
form small colonies containing reduced cytoplasm and large nuclei cells (Figure 21B).  
Over the following three weeks of reprogramming, the cell cultures began to shift from 
a long, elongated conformation to a smaller structure consisting of higher nucleoli to 
cytoplasmic composition. First iPSC colonies showing cells with human ESC-like 
appearance (large nucleus with prominent nucleoli) emerged on day 24 (Figure 21B). 
Human iPSCs typically grow as a thin and flat monolayer forming colonies of 
cobblestone appearance as opposed to singularly existing HDF (Figure 21B). 
Colonies containing partially-reprogrammed cells were also observed during the 
throughout the reprogramming process. These partially-reprogrammed cells presented 
a heterogeneous differentiated morphology not resembling human ESC.  (Figure 21B).  
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Figure 21. Description of the iPSC generation process. 
(A) Timeline of iPSC generation from HDF cells. HDF were plated on day 0. Once fibroblast cultures 
reached 80% confluency (day 2) SeV including the reprogramming transgenes separately were added. 
Transduced HDF were plated on mitotically-inactivated MEF feeder cells on day 9. HDF media was 
replaced by induced pluripotent Stem Cell (iPSC) media to enhance reprogramming. First iPSCs 
showing characteristic human ESC-like morphology emerged around day 20 and were manually picked 
on day 24. Due to feeder cell exhaustion, culture media was replaced by MEF-conditioned iPSC (CM-
iPSC) media from day 20. (B) Representative microscope images of the morphological changes 
observed in the transduced cells during the reprogramming process. Scale bars, 200 µm.  
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Single iPSC colonies containing characteristic human ESC-like cells were picked 
manually and transferred onto fresh MEF feeder cells. Each transferred colony 
represented a clone of the iPSC line. Different numbers of clones were picked and 
expanded in order to ensure the availability of different iPSC clones for each cell line 
(Table 8). Analysis of haematopoietic differentiation variability among clones of the 
same iPSC line will be thoroughly described in Chapter 4. The iPSC lines generated 
(7 total) were expanded mechanically on γ-irradiated MEF for at least 12 passages 
prior to PSC characterization. The reprogramming efficiency for each cell lines was 
calculated using the original number of cells that were transduced using SeV 
containing the reprogramming transgenes on day 0 and the total number of clones 
obtained after 30 days of transduction (Table 8). 
 
Patient ID 
Number of cells 
transduced 
Number of clones 
generated 
Reprogramming efficiency 
WT1 100.000 210 0.21% 
WT2 100.000 290 0.29% 
WT3 100.000 142 0.14% 
SAA1 50.000 63 0.11% 
SAA2 100.000 102 0.10% 
SAA3 100.000 114 0.11% 
SAA4 100.000 141 0.14% 
Table 8. Reprogramming efficiencies for control and SAA cell lines 
Once control and SAA-iPSC lines were generated and maintained I proceeded to the 
characterization of the iPSC lines analysing the presence of SeV genome and 
transgenes in the iPSC lines and assessing the pluripotency, chromosomal stability 
and identity of the iPSC lines generated (Table 9). 
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Analysis Aim Method of detection 
SeV expression 
Detection of residual expression of SeV 
and/or reprogramming transgenes 
RT-PCR 
Assessment of 
pluripotency 
Expression and localization of pluripotency-
associated markers OCT4, NANOG, SSEA4 
and TRA-1-60 
Immunofluorescence 
Quantification of population of cells 
expressing pluripotency-associated markers 
SSEA4 and TRA-1-60 
Flow cytometric analysis 
Induction of teratoma formation in SCID 
mice containing structures characteristic of 
the three germ layers: ectoderm, endoderm 
and mesoderm 
In vivo growth of teratoma 
and histological analysis  
Cytogenetic 
analysis 
Detection of major chromosomal 
abnormalities present in iPSC and parental 
fibroblasts 
SNP analysis  
Genetic 
identity 
Matching genetic identity between iPSC and 
parental fibroblasts 
SNP analysis 
Table 9. Overview of the iPSC characterization process. 
SeV, Sendai virus; RT-PCR, reverse transcriptase- polymerase chain reaction, SCID, severe combined 
immunodeficiency mouse; SNP: single nucleotide polymorphism 
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3.2.2 Detection of SeV genome and reprogramming transgenes in control and SAA-
iPSC generated 
Detection of SeV genome (SeV) and transgenes (SeV-OCT4, -SOX2, -KLF4 and –
cMYC) can be achieved by reverse transcription PCR (RT-PCR), where the primers 
utilized are complementary to both the inserted reprogramming factor gene as well as 
to part of the viral vector genome. Analysis of the PCR products showed expression of 
SeV vector and reprogramming transgenes in 7-day transduced HDF (Sendai positive 
cells) but non-detectable residual expression of both SeV and/or reprogramming 
transgenes in the iPSC lines generated (Figure 22).  
 
Figure 22. Detection of residual SeV genome and reprogramming transgene expression by RT-
PCR. 
Control and SAA-iPSC lines did not show detectable expression of backbone SeV (SeV) or the 
reprogramming transgenes included in the SeV vector (OCT4, SOX2, KLF4 and cMYC). SeV-
transduced HDF were used as a positive control (SeV Positive cells) as recommended by manufacturer 
and nuclease-free water as no-template control (negative Control) to assess the presence of primer-
dimer formation or contamination in the PCR reagents.   
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3.2.3 Assessment of pluripotency of control and SAA-iPSC  generated 
Morphological analysis of iPSC colonies from both control and SAA-iPSC lines 
colonies revealed thin and flat monolayer cell colony with distinct borders characteristic 
of human PSC lines, as well as positive staining for pluripotency-associated markers 
OCT4, NANOG, stage specific embryonic antigen-4 (SSEA4) and tumour-rejection 
antigen 1-60 (TRA-1-60) (Figure 23). It is worth noting the localisation of the 
fluorescence staining for each marker, with staining for surface markers SSEA4/TRA-
1-60 localised in the cell membrane and transcription factors OCT4/NANOG staining 
observed in the cell nucleus as concomitant with the DAPI nuclear stain (Figure 23).  
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Figure 23. Detection of pluripotency-associated markers by immunofluorescence. 
Representative brightfield and immunofluorescence images of control and SAA-iPSC lines showing 
expression of OCT4 (green), NANOG (red), TRA-1-60 (green) and SSEA-4 (red). Nuclei in 
immunofluorescence images were stained with DAPI (blue). Scale bars = 100 µm.  
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The quantification of the population co-expressing the pluripotency-associated surface 
markers SSEA-4 and TRA-1-60 was carried out by multicolour flow cytometric analysis. 
Control and SAA-iPSC  lines analysed prior haematopoietic differentiation showed a 
high percentage of positive cell population co-expressing TRA-1-60 and SSEA-4 
pluripotency-associated markers (Figure 24A) with no statistically significant 
differences in the percentage of SSEA-4+TRA-1-60+ cells between control and patient 
cell lines (Figure 24B).  
 
Figure 24. Detection of pluripotency-associated markers by flow cytometric analysis. 
(A) Representative images of flow cytometric analysis of TRA-1-60/SSEA4 expression in control (WT1, 
WT2 and WT3) and SAA-iPSC lines. (B) Scatter plot showing percentages of SSEA4+TRA-1-60+ cells 
in grouped control (WT) and SAA-iPSC lines. One-way ANOVA with Dunnett’s multiple comparison test 
was used for statistical comparison between grouped control (WT) and SAA-iPSC lines. Data is 
presented as mean of at least 3 independent experiments +/- S.E.M. Data for all control cell lines is 
averaged in one group (WT) 
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Both control and SAA-iPSC lines used in this study successfully induced teratoma 
formation in SCID mice. Table 10 provides detailed information of the number, 
description and time of formation of the teratomae induced by the iPSC lines used in 
this study. Most of the teratomae analysed were solid and presented formation of 
mature tissues. Histology of the teratomae was then taken and stained to reveal germ 
layer specific structures. Histological analysis of the teratomae from both control and 
SAA-iPSC lines revealed the formation of heterogenic tissues consisting of specific 
morphologies from ectoderm (neuroepithellium or pigmented epithelium), mesoderm 
(cartilage, kidney or connective tissue) and endoderm (glandular epithelium, 
gastrointestinal epithelium, primitive intestine or glomeruli structures) (Figure 25). 
However, teratomae from SAA3 and SAA4-iPSC lines failed to display tissues from 
ectoderm and endoderm/mesoderm germ layers respectively (Figure 25).   
 
Patient ID 
Passage 
number 
SCID 
mice 
used 
Number 
teratomae 
induced 
Classification 
by content 
Classification 
by clinical 
criteria 
Time of 
growth 
(weeks) 
WT1-
iPSC 
21 2 2 Solid/Solid Mature/Mature 8 
WT2- 
iPSC 
20 2 2 Solid/Solid 
Mature/ 
Inmature 
benign 
12 
WT3- 
iPSC 
38 2 2 Solid/Solid Mature/Mature 6 
SAA1- 
iPSC 
30 2 1 Solid 
Inmature 
benign 
7 
SAA2- 
iPSC 
9 2 2 Solid/Mixed Mature/Mature 8 
SAA3- 
iPSC 
9 2 1 
Solid 
(encapsulated) 
Mature 8 
SAA4- 
iPSC 
36 2 1 Solid Mature 6 
Table 10. Methodology and description of the teratomae generated by control and SAA-iPSC 
lines 
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Figure 25. Induction of teratoma formation in SCID mice. 
Representative histology images of tissue contained in the teratomae generated from control and SAA-
iPSC lines showing tri-lineage differentiation. No ectoderm and endoderm/mesoderm structures were 
found for SAA3 and SAA4-iPSC lines respectively. Scale bars = 100 µm.   
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3.2.4 Cytogenetic analysis of control and SAA-iPSC and parental HDF 
Cytogenetic analysis by using genomic SNP array was carried out on each set of 
iPSC/parental HDF for both control and SAA-iPSC lines. No chromosomal major 
alterations associated to reprogramming process or long-term culture when compared 
to a human reference genome (hg38) were detected in control-iPSC lines (WT1, WT2 
and WT3) (Table 11). On the other hand, two regions of 1.3Mb and 1Mb with copy-
neutral loss of heterozygosity (CN-LOH) in 3q11.2 and 7q22.1 locus respectively were 
noted in SAA1-iPSC. SAA2 and SAA3-iPSC lines presented different types of 
chromosomal alterations that were also present in the parental HDF (Table 11). SAA4-
iPSC presented a small deletion of 0.14 Mb in locus 16p12.2 that was not present in 
the parental HDF (Table 11).  
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Patient 
ID 
Cell type 
Passage 
number 
Alteration 
(size in Mb) 
Locus 
OMIM 
disease-
causing 
genes 
Karyotype 
WT1 
Fibroblast 4 - - - 
46XY 
iPSC 24 - - - 
WT2 
Fibroblast 7 - - - 
46XY 
iPSC 20 - - - 
WT3 
Fibroblast 7 - - - 
46XX 
iPSC 11 - - - 
SAA1 
Fibroblast 10 - - - 
46XY 
iPSC 14 
CN-LOH 
(1.3 Mb) 
3q11.2  
CN-LOH 
(1.1 Mb) 
7q22.1  
SAA2 
Fibroblast 4 
CN-LOH 
(6.4 Mb) 
11p11.12
-q11 
 
46XY 
iPSC 23 
CN-LOH 
(6.4 Mb) 
11p11.12
-q11 
 
SAA3 
Fibroblast 4 
Del (1.5Mb) 15q13.3 
TRPM1, 
CHRNA7 
46XX 
Duplication 
(1.5 Mb) 
16p13.11 
NDE1, 
MYH11, 
ABCC6 
iPSC 32 
Del (1.5Mb) 15q13.3 
TRPM1, 
CHRNA7 
Duplication 
(1.5 Mb) 
16p13.11 
NDE1, 
MYH11, 
ABCC6 
SAA4 
Fibroblast 9 - - - 
46XY 
iPSC  Del (0.1Mb) 16p12.2 OTOA 
Table 11. Cytogenetic analysis of control and SAA cell lines by SNP array 
Table showing karyotype, cytogenetic alterations observed in HDF and iPSC, location and OMIM 
disease-causing genes included in the altered region. Del, deletion 
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3.2.5 Genetic identity analysis 
Genetic authentication of the iPSC lines is a critical step required to provide reliable 
and reproducible results. By confirming origin I guarantee the genetic identity of the 
iPSC used in the study in order to exclude undesired cross-contamination or switching 
with other iPSC lines therefore avoiding drawing erroneous conclusions derived from 
these mishandlings. For this study high-density SNP analysis of each set of iPSC and 
parental fibroblast cell line of control and SAA patient was carried out. SNP-based 
genetic identity analysis revealed correlation between parental HDF and iPSC lines 
indicating the same genetic profile and authenticity of all the iPSC lines used in this 
study (Figure 26).       
 
Figure 26. Authentication of genetic identity of iPSC and parental fibroblasts. 
Global SNP patterns from parental HDF and iPSC were compared by whole SNP microarray indicating 
perfect genetic identity between iPSC and parental fibroblasts for control and SAA cell lines.   
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3.3 Discussion 
The use of iPSC technology as a disease model represents an excellent opportunity 
to provide insights into the pathophysiology of SAA. Here I provide evidence of the 
successful generation and characterization of control and SAA-iPSC lines that will be 
the basis for further studies focused on investigating the existence of an underlying 
disease-causing genetic defect present in SAA cell lines. With this aim in mind iPSC 
from three control and four SAA HDF cell lines were generated. No dramatic 
differences were observed with regards to the iPSC generation efficiency of cell lines 
from control and SAA patients. These results suggest that neither the age of the 
patients nor the potential presence of a mutation carried by the patients’ cells affected 
the reprogramming process. These results are particularly interesting since it has been 
previously reported that cells isolated from FA patients showed low reprogramming 
efficiencies (Yung et al., 2013; Liu et al., 2014). These low reprogramming efficiencies 
observed in FA cells are due to an impaired ability to repair DNA damage that is 
generated by cellular stress during the reprogramming process via FA DNA repair 
pathway. Thus, this observation might indicate that the potential genetic defect present 
in the SAA cells studied here may not be involved in this specific DNA repair pathway. 
 
The successful generation and identification of iPSC from SAA patients is the first step 
towards the generation of a disease model for this disorder. However, as important as 
to generate SAA-iPSC is to provide proof of the fully reprogramming of the iPSC. To 
do so it is necessary to provide evidence of the pluripotency of the SAA-iPSC lines, 
absence of genetic abnormalities that can affect their differentiation potential and 
freedom from any residual expression of the ectopically applied reprogramming factors. 
As mentioned previously in Chapter 1 (section 1.2.5.1), the generation of integration-
free iPSC has become crucial in order to avoid genotoxicity, activation of any poised 
oncogenic activity via transgene integration and impairment of the differentiation 
potential via constitutive expression of the exogenous reprogramming factors. Vector 
based on SeV has been reported as a non-integrative method with a high efficiency 
induction of human PSCs (Fusaki et al., 2009). The cytoplasmic-residing nature and 
infection-incompetent variant of the vector ensures reduced iPSC cytotoxicity and 
minimal genomic integration. However, even following the use of a non-integrating 
transgene vector such as SeV, the remaining possibility of residual 
mutagenesis/expression requires the transient nature of the vector to still be confirmed. 
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Thus, the generation of integration-free and transgene-free iPSC is essential for this 
project in order to provide a reliable disease model for identifying pathogenic variants 
in paediatric cases of SAA. Control and SAA-iPSC lines showed no amplification of the 
SeV vector or reprogramming transgenes by RT-PCR. Thus, the lack of detection of 
amplicon in the established iPSC lines indicates that SeV transgenes were transiently 
expressed during the first stages of reprogramming but were diluted during prolonged 
culture to undetectable levels or complete absence. These results indicate that the 
control and SAA-iPSC lines generated in this study successfully maintained stable 
regulation of the endogenous pluripotency-associated gene expression activated 
during reprogramming even with the loss of exogenous reprogramming transgene 
expression after several rounds of cell division. 
 
To assess the pluripotent features of iPSCs, there are a number of tests used as 
standard practice originally with human ESCs and, currently, with iPSCs (Pera et al., 
2000; Hoffman and Carpenter, 2005; Takahashi et al., 2007). Besides the 
morphological analysis of the cells and colonies formed, demonstration of the presence 
of pluripotency-associated surface antigens such as cell membrane-localised SSEA4 
and TRA-1-60 as well as nuclear-localised transcription factors such as OCT4 and 
NANOG have been widely reported to validate the pluripotency of cells (Niwa et al., 
2000; Draper et al., 2002; Silva et al., 2009). The expression of these pluripotency-
associated markers in both control and SAA-iPSC lines was assessed by both 
immunocytochemistry and multicolour flow cytometric analysis. Brightfield images 
confirmed the human ESC-like morphology of the control and SAA-iPSCs. Likewise, 
immunocytochemistry analysis to assess the localization of the pluripotency-
associated markers expression revealed positive expression of both pluripotency-
associated transcription factors OCT-4 and NANOG and surface markers SSEA-4 and 
TRA-1-60 of control and SAA-iPSC lines. Nuclear localization of the expression of 
OCT4 and NANOG transcription factors was observed by co-localization of 
fluorescence with DAPI nuclear staining. Likewise, cytoplasmic staining was observed 
in SSEA-4 and TRA-1-60 in accordance with its localization on the cell surface as 
surface antigens.  Flow cytometric analysis was used to quantify the percentage of 
iPSC expressing the selected pluripotency-associated surface markers prior to every 
haematopoietic differentiation experiment as a check point to assess the quality of the 
iPSC lines. Control and SAA-iPSC showed high percentages of iPSC co-expressing 
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SSEA+4 and TRA-1-60+ (≥80%) with no significant differences between control and 
SAA-iPSC lines. Although previous work reported the expression of SSEA-4 and 
NANOG in partially-reprogrammed cells (Chan et al., 2009) and the existence of an 
OCT4 alternative isoform B not related to pluripotency (Wang and Dai, 2010), the 
expression of the four pluripotency-associated markers shown by the control and SAA-
iPSC has been previously described as consistently expressed in PSCs (Draper et al., 
2002; Henderson et al., 2002; International Stem Cell et al., 2007). 
 
One of the most robust tests in human to test pluripotency is via demonstration of in 
vivo differentiation into tissue consisting of derivatives from all three germ layers (De 
Los Angeles et al., 2015). Human PSC injected in SCID mouse induce the formation 
of benign tumours characterized by a rapid growth in vivo consisting of various 
disparate tissues that contain structures of all three germ layers (ectoderm, mesoderm 
and endoderm). This pluripotent ability of the injected cells to form a rich variety of 
mature tissue types from the three germ layers explains why in vivo teratoma-formation 
assay is regarded as the gold standard for validating the pluripotency of human PSCs 
(Zhang Wendy, June 10, 2012). The basic protocol for this assay begins with injection 
of the human iPSC/ESC of interest into a specific site of an SCID mouse. This will 
subsequently be followed by teratoma formation in over 8-12 weeks, derivative of the 
PSC type. Ectoderm, mesoderm and endoderm derived-tissue formation in the 
teratomae can then be examined by observation of the particular germ layer-specific 
microstructures after histological staining. Control and SAA-iPSC successfully 
generated teratomae in SCID mice with different degrees of maturation. Likewise 
teratomae generated by the three control and two of the SAA-iPSC lines displayed 
tissues from the three different germ layers.  However two of the SAA-iPSC (SAA3 and 
SAA4) failed to display tri-lineage differentiation according to results from histological 
analysis. Absence of structures from a specific germ layer observed in these teratomae 
does not necessarily imply the lack of pluripotency of these cell lines since only two 
mice were used for each cell line in this assay. Unfortunately, as suggested by Muller 
et al., the lack of an established standard for the parameters involved in the assay, 
such as the number of cells/injections/animals that should be used in order to establish 
if an iPSC line has functional pluripotent potential, makes difficult to interpret this data 
satisfactorily (Muller et al., 2010). I therefore consider that additional teratoma assays 
most probably would induce teratoma formation displaying tissues from the germ 
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layers absent in this only experiment. Additionally, SAA3 and SAA4-iPSC lines 
successfully generated haematopoietic progenitors, as it will be thoroughly discussed 
in Chapter 5, thence proving the differentiation capacity of these iPSC lines. Likewise, 
it is also important to indicate that current tests are not sufficient and further rigorous 
quantifiable analysis are required to fully provide proof of pluripotency of a PSC line 
since even partially reprogrammed iPSC  lines can show features of pluripotency 
including ability to induce formation of teratoma-like tumours (Chan et al., 2009). 
Recently, different methods have been developed based on the analysis of molecular 
signature and expression levels of specific genes predicting differentiation potential of 
human PSCs lines, offering a more efficient and quantifiable way to evaluate potential 
and quality of human PSCs  (Bock et al., 2011; Tsankov et al., 2015). 
 
One of the major advantages of an iPSC -derived disease model is the ability to 
represent a patient-specific genotype in the in vitro disease tissue, thereby allowing 
study of the exact genetic defects contributing to pathogenesis. However, there is an 
inherent risk of genomic mutation during reprogramming thus reducing translation of 
the patient somatic cell genotype over to the corresponding iPSCs. Acquisition of 
genetic mutation during reprogramming or long-term culture of iPSCs can alter its 
differentiation capacity. Thus, cytogenetic analysis of the iPSC cell lines prior to its 
differentiation is recommended in order to detect any likely chromosomal structural 
variations. Although it has been reported that cells with chromosomal aberrations are 
eliminated via p-53 dependent apoptosis in the early stages of reprogramming, it has 
been shown that aneuploid cells can be successfully reprogrammed, implying that this 
kind of chromosomal aberration is not a barrier to reprogramming (Park et al., 2008; 
Marion et al., 2009). Additionally, as seen previously in Chapter 1 (section 1.1.5.2), 
cytogenetic analysis might be particularly interesting for cells from SAA patients since  
they may present mutations that can affect genes encoding proteins involved in DNA 
repair pathways and telomere length homeostasis leading to accumulation of DNA 
damage, chromosome instability and premature cell senescence. Whereas no clinical 
cytogenetic imbalance was observed in WT1, WT2 and WT3 control-iPSC lines, SAA1-
IPSC line revealed two small regions of CN-LOH in locus 3q11.2 and 7q22.1. CN-
LOHs are stretches of homozygosity that might be particularly detrimental if the 
homozygous region includes recessive mutations. Presence of mutations in both 
alleles would lead to a defective/loss of gene function. However, regions were CN-LOH 
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are located in SAA1-iPSC  have a relative small size with no significant clinical 
relevance since these regions do not include previously described disease-causing 
OMIM genes according to the UCSC Genome Browser database (Kent et al., 2002). 
Both SAA2 and SAA3-iPSC lines presented cytogenetic abnormalities that were also 
present in the parental HDF indicating that these alterations did not arise during the 
reprogramming process or long-term iPSC culture. Finally, SAA4-iPSC presented a 
small deletion of 0.14 Mb not observed in the parental HDF. This deletion is located in 
locus 16p12.2 that includes the disease-causing OMIM gene OTOA. Deafness is the 
main disease phenotype associated with this gene with no association to 
haematological malignancies (Kent et al., 2002). Cytogenetic alterations observed in 
SAA1 and SAA4-iPSC might be due to the reprogramming process since it has been 
previously reported that reprogrammed cells encounter a high replicative stress during 
reprogramming (Hussein et al., 2011). However, it is worth mentioning that several 
authors reported that most of the CNV observed only in iPSC using SNP arrays were 
also detected in the starting populations of fibroblasts when using deep sequencing 
approach (Abyzov et al., 2012; Kwon et al., 2017). This study might suggest that low-
frequency CNV present in parental fibroblasts might be beyond the detection limit of 
the SNP array but they are detected by more sensitive methods such as NGS. Thus, 
we cannot exclude the possibility that alterations detected specifically in SAA1 and 
SAA4-iPSC could have been present in the original fibroblast population in 
undetectable levels by the SNP analysis but, due to later clonal expansion of the 
specific clones of these SAA-iPSC lines were then detected by the SNP array.  
  
92 
 
Taken together these results provide enticing evidence of the successful generation of 
fully-reprogrammed iPSC suitable for further differentiation into haematopoietic 
progenitors as disease model for SAA. The generated control and SAA-iPSC lines 
presented characteristic features associated to PSC with no signs of reprogramming-
associated alterations that could affect their differentiation potential therefore 
introducing bias to the study and distorting results.  
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4 Chapter 4. Differentiation of iPSC into Haematopoietic 
Progenitor Cells 
4.1 Introduction 
HSC from SAA patients would provide the best disease model to study the 
pathogenesis of SAA. However, the SAA disorder is characterized by low numbers of 
HSCs in the bone marrow of SAA patients and ex vivo expansion or pooling of bone 
marrow haematopoietic progenitor cells from SAA patients would be necessary in 
order to generate sufficient samples for disease studies (Zeng et al., 2004). Likewise, 
ex vivo expansion of HSCs remains challenging due to the complexity controlling the 
regulatory networks involved in HSC differentiation (Walasek et al., 2012). Remarkably, 
iPSC technology provides an excellent opportunity to investigate the pathogenesis of 
SAA. Due to the unique features of iPSC, widely discussed in Chapter 1 (section 
1.2.3), these cells can be used to provide a supply of unlimited numbers of patient-
specific haematopoietic progenitor cells. 
 
To date, several elegant methods have reported the generation of haematopoietic 
progenitor cells from human PSCs using different approaches such as directed 
differentiation, with cytokine stimulation and EB formation or co-culture on stromal cells, 
directed conversion or by way of teratomae formation in vivo as described in Chapter 
1 (section 1.3.2.2). However, the generation of functional HSCs with multi-lineage 
reconstitution ability and robust engraftment potential from PSC remains challenging 
(Ackermann et al., 2015; Wahlster and Daley, 2016). Recently, Olivier et al. described 
the development of a robust, simple and highly efficient protocol, reporting the 
generation of 150 haematopoietic progenitor cells generated from a single PSC, 
primarily designed for the generation of erythroid cells from human PSCs but that can 
be also used in the first stages for the differentiation for the generation of HSPCs 
(Olivier et al., 2016).    
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The aim of this chapter is to validate the use of the haematopoietic differentiation 
protocol by analysing: 
 The capacity of the control-iPSC lines to generate the different populations 
of mesodermal, haemato-endothelial precursors and haematopoietic 
progenitor cells by flow cytometric analysis  
 The potential of control-iPSC-derived haematopoietic progenitor cells to 
differentiate into haematopoietic colonies using CFU assays  
 The robustness of the haematopoietic differentiation protocol in order to 
identify sources of variation present during the differentiation of iPSC lines.  
4.2 Results 
4.2.1 Directed differentiation of control-iPSC lines into haematopoietic progenitor 
cells 
The method previously described by Olivier et al. (Olivier et al., 2016) was used to 
differentiate control-iPSC lines into haematopoietic progenitor cells. This method 
promotes the induction of PSCs into mesoderm lineage and later specification of the 
mesodermal precursor into haematopoietic progenitors by combining the use of 
different cytokines and small molecules at specific time points (Figure 27).  
 
 
Figure 27. Differentiation scheme used for the generation of haematopoietic progenitors from 
iPSC 
Protocol designed by Oliver et al (Olivier et al., 2016). 
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As described in Chapter 1 (section 1.3.2.1), different mesodermal and endothelial 
populations emerge during the differentiation of PSCs into haematopoietic progenitors. 
Figure 28 describes visually the process of haematopoietic differentiation from PSCs 
including time points and key stages defining markers I chose to identify the different 
populations of mesodermal, haemato-endothelial precursors and haematopoietic 
progenitor cells, including MkP, Ery/MkP, EryP and myeloid progenitors (MyeP).       
 
 
Figure 28. Schematic representation of the experimental design used to analyze control-iPSC 
haematopoietic differentiation capacity. 
Identification of populations emerging during the process of generation of iPSC-derived haematopoietic 
progenitors was monitored by flow cytometric analysis. On day 3, mesodermal precursors were 
identified by KDR expression. On day 6, haemato-endothelial precursors were identified by CD34 and/or 
CD43 expression. Haematopoietic progenitors were identified at day 12, 16 and 20 by expression of 
CD43 marker including mekaryocytic/erythroid, megakaryocytic, erythroid and myeloid progenitors 
using CD41a and CD235a markers. Colony-forming potential of iPSC-derived haematopoietic 
progenitors was assessed by CFU assay on day 26-34. Myeloid and erythroid colonies were 
enumerated and identified according to size, morphology and cellular composition on day 26-34. CFU, 
colony-forming unit; CFU-GEMM, colony forming unit-granulocyte, erythrocyte, macrophage, 
megakaryocyte; CFU-GM, colony forming unit-granulocyte, macrophage; BFU-E, burst forming unit-
erythroid; CFU-G, colony forming unit-granulocyte; CFU-M, colony forming unit-macrophage; CFU-E, 
colony forming unit-erythroid.  
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WT2 and WT3 control-iPSC lines were used to validate the haematopoietic 
differentiation method published by Olivier et al. By day 3 of differentiation, formation 
of mesodermal cells was identified by expression of KDR marker also known as CD309 
and vascular endothelial growth factor receptor 2 (Figure 29A). Presence of both 
CD34+CD43- endothelial progenitors, including HE cells, and emergence of cells 
expressing the haematopoietic marker CD43+ from the CD34+CD43- endothelial 
population was observed at day 6 of differentiation (Figure 29B).  
 
Figure 29. iPSC differentiation into mesodermal and haemato-endothelial progenitors. 
(A) Flow cytometric analysis of KDR expression in control cell lines on day 3. (B) Flow cytometric 
analysis of CD34 and CD43 expression in control cell lines on day 6. 
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Expression of CD43 has been previously described to confer antiadhesive properties 
interfering with cell-cell adhesion (Ardman et al., 1992). This would explain the 
presence of floating cells budding from loosely attached haemato-endothelial clusters 
firstly observed at day 6 (Figure 30A). An increase in the numbers of these 
budding/floating cells was observed at day 9 (Figure 30B) becoming especially 
prominent at day 12 (Figure 30C).   
 
Figure 30. Appearance of haematopoietic progenitor cell like morphology. 
Cell morphology of non-adherent cells which may be haematopoietic progenitors (red arrow) budding 
from haemato-endothelial clusters (green arrow). (A) Day 6. (B) Day 9. (C) Day 12. Scale bars, left 
column 200µm, right column 100µm.  
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A large population of CD43+ cells was identified by flow cytometric analysis of the 
whole population of cells between days 12 and 20 (Figure 31A). A gradual down-
regulation in the expression of CD34 marker was observed within the CD43+ 
population from day 12, with 47% of CD34+CD43+ cells on day 12, 33% on day 16 
and 27% on day 20.  Likewise, analysis of the CD43+ subpopulations of progenitors 
revealed the generation of MkP (CD41a+CD235a-), Ery/MkP (CD41a+CD235a+), 
EryP (CD41a-CD235a+) and MyeP (CD41a-CD235a-) at day 12 (Figure 31B). A 
decrease in the Ery/MkP and EryP percentages was also observed in day 16 and day 
20 most likely due to a maturation of the progenitors over time.   
 
Figure 31. Identification of CD43+ haematopoietic progenitors and CD41a+/CD235a+ 
subpopulations. 
(A) Flow cytometric analysis of CD34 and CD43 expression in control cell lines on day 12, 16 and 20. 
(B) Flow cytometric analysis of CD41a and CD235a expression in gated CD43+ cells in control cell lines 
on day 12, 16 and 20.   
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Analysis of the colony-forming capacity of the control-iPSC-derived haematopoietic 
progenitors generated at day 12, 16 and 20 was evaluated by CFU assays using 
methylcellulose–based medium enriched with haematopoietic-specific cytokines. This 
assay allows the enumeration of CFU colonies from both erythroid lineage (CFU-E and 
BFU-E), myeloid lineage (CFU-GEMM, CFU-GM, CFU-G and CFU-M) after 14-16 
days of culture according to size, morphology and cellular composition following 
standard criteria (Coutinho, 1993; Eaves, 1995) (Figure 32). Maturation capacity of 
progenitors from megakaryocyte lineages was not evaluated due to the difficulties on 
enumerating CFU-Mk based on morphology and cellular composition using 
methylcellulose-based media.  
 
Figure 32. Morphological appearance of haematopoietic colonies from iPSC-derived 
haematopoietic progenitors formed in CFU-assay. 
Representative colony types of CFU-E, BFU-E, CFU-GEMM, CFU-M, CFU-G and CFU-GM 
haematopoietic colonies obtained from differentiation of control-iPSC-derived haematopoietic 
progenitors. Scale bars, 200µm. 
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CD43+ haematopoietic progenitors obtained from whole population of cells at day 12 
showed a higher colony-forming capacity with increased numbers of CFUs in cytokine-
enriched medium compared to day 16 and day 20 (Figure 33). 
 
Figure 33. Colony-forming potential of iPSC-derived haematopoietic progenitor cells. 
CFU assay showing number of haematopoietic colonies and colony type generated by control-iPSC-
derived haematopoietic progenitor cells on day 12, 16 and 20. 
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4.2.2 Haematopoietic potential of CD43+ subset  
To identify the population of cells at day 12 with haematopoietic colony-forming 
potential, subsets of CD34/CD43 cells obtained from WT3-iPSC line were enriched by 
fluorescence-activated cell sorting (FACS) and assayed for colony-forming potential 
by CFU assay (Figure 34A). As expected, only CD43+ cells showed ability to form 
haematopoietic colonies whereas CD43- populations showed complete absence of 
haematopoietic colonies (Figure 34B). This indicates that only CD43+ fraction displays 
haematopoietic colony-forming potential. Both CD43+ subpopulations, CD34+ and 
CD34-, demonstrated colony-forming potential although it is noteworthy that 
CD34+CD43+ showed a higher number of CFU compared to the CD34-CD43+ 
population although the CD34+CD43+ cells on day 12 showed a lower percentage of 
cells, 16%, compared to the 68% of CD34-CD43+ cells. 
 
 
Figure 34. Colony-forming potential of FACS-sorted CD34/CD43 subsets. 
(A) Flow cytometric analysis of CD34 and CD43 expression in WT3 cell line on day 12. (B) CFU assay 
showing number of haematopoietic colonies and colony type according to the different subpopulations 
sorted with indicated phenotype (+/- chart) generated by WT3-iPSC-derived haematopoietic progenitor 
cells on day 12.  
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4.2.3 Analysis of sources of variation in the haematopoietic differentiation of iPSC 
To identify potential contributors to variability in the differentiation process of the iPSC 
lines into haematopoietic progenitors, I analysed the variation introduced by different 
experimental variables when using the previously described haematopoietic 
differentiation method such as differentiation experiment, passage number of the iPSC 
line (passage), iPSC clone (clone) and iPSC line (genetic background) (Figure 35). 
 
 
Figure 35. Schematic representation of the experimental design to analyse variation in 
generation of haematopoietic progenitor cells from iPSC on day 12. 
Differentiation experiment refers to the variation observed in sample biological repeats (intra-
experimental) (variable is differentiation experiment). Passage refers to the variation observed in 
experiments using an individual clone from the same iPSC line with different passage number (variable 
is passage number). Clone refers to the variation observed in experiments using different clones from 
the same iPSC line with same passage number (variable is clone). Genetic background refers to the 
variation observed in experiments using different iPSC lines with same passage number (variable is 
genetic background between iPSC lines) 
  
103 
 
Percentages of positive cells for the different populations analysed in this experiment 
are shown in Appendix B. By using a test for equal variances for multiple comparisons, 
the different variances obtained for each variable were compared when differentiating 
the iPSC into CD43+ haematopoietic progenitors and the different subpopulations of 
haematopoietic progenitors (Ery/MkP, MkP, EryP and MyeP). No statistical differences 
were observed in the variances obtained from the variables of interest and the 
differentiation experiment variable for any of the haematopoietic progenitor populations 
(Figure 36A-E). However, variance observed in the EryP population was close to 
significance (p value=0.051) (Figure 36D). As shown in Figure 36D, interval of data 
represented for genetic background in EryP barely overlaps with the interval of data 
for differentiation experiment, indicating that differences of both standard deviations 
are close to significance (red rectangle, Figure 36D). This suggests that genetic 
background is the main driver of variation when generating EryP from iPSC lines in our 
study, although the differences observed were not significant. 
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Figure 36. Analysis of variation in the differentiation of WT3-iPSC into haematopoietic progenitor 
cells and subpopulation of progenitors on day 12. 
(A)  Haematopoietic progenitors (CD43+). (B) Ery/MkP. (C) MkP. (D) EryP. Red rectangle indicates 
minimum overlap between differentiation experiment and genetic background variables. (E) MyeP. Test 
for equal variances for multiple comparisons was used for statistical comparison between the different 
variables. Data is presented as mean of at least 3 independent experiments.  
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4.3 Discussion 
The generation of patient-specific SAA haematopoietic progenitor cells represents a 
“disease-in-a-dish” approach that we consider extremely valuable to investigate the 
unknown pathogenesis of SAA. In this chapter, the process of generation and 
identification of haematopoietic progenitors from iPSC is described and the robustness 
of the method used to obtain these progenitors in order to identify potential sources of 
experimental variation is evaluated. By using the method developed by Olivier et al., 
mesodermal KDR+ cells were successfully induced on day 3 from control-iPSCs lines. 
The formation of primitive mesodermal KDR+ cells at this stage is induced by the 
signalling activators BMP4, Activin A and WNT3A used in the differentiation media 
previously described by different studies as essential in establishing posterior streak 
mesoderm progenitors, with haematopoietic and endothelial potential  (Sumi et al., 
2008; Zhang et al., 2008; Wang and Nakayama, 2009). Additionally, stabilization of β-
catenin by GSK3β inhibitor (Inhibitor VII) used in the differentiation media activates 
WNT signalling effect in the formation of mesoderm with haemato-vascular potential 
(Sumi et al., 2008; Olivier et al., 2016). Likewise, addition of VEGF, FGFα and SCF to 
the differentiation media promoted the formation of haematopoietic progenitors via 
haemato-vascular specification of the primitive mesoderm (Pick et al., 2007). Thus, at 
day 6, the formation of endothelial cells was detected by expression of endothelial 
marker CD34 and absence of haematopoietic marker CD43. CD34+ population at this 
stage is heterogeneous including committed endothelial cells and haemogenic 
endothelium (HE) cells, defined as a specialized population of endothelial cells that 
lack of ability to form haematopoietic colonies in semi-solid media but have the capacity 
to form haematopoietic progenitors with erythroid, myeloid and T-lymphoid potential 
when cultured on OP9 mouse stromal cells (Choi et al., 2012; Kennedy et al., 2012). 
We observed that CD34+CD43- cells at day 6 showed very similar pattern and 
percentages to the ones reported by studies using similar differentiation method 
(Kennedy et al., 2012).  Likewise, the first early haematopoietic progenitors emerging 
form the CD34+CD43- cells were detected on day 6 although at low levels. This 
population could be designated as angiogenic haematopoietic progenitors, previously 
described as the first haematopoietic progenitors to emerge at this stage from the 
endothelial population with potential to form haematopoietic colonies (Choi et al., 2012). 
However, CFU assays would be required to confirm the haematopoietic potential of 
this CD43low population.  
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From day 10-12 a burst in the proliferation of cells was observed with an elevated 
presence of floating cells. This could be explained by the use of cytokines and small 
molecules such as SCF, FGF2, TPO, IGF2 and IBMX at later stages in order to enforce 
and enrich the generation of haematopoietic progenitors by enhancing haematopoietic 
proliferation and increasing the transcription of key genes involved in haematopoietic 
specification (Perlingeiro et al., 2003; Zhang et al., 2006; Olivier et al., 2016). As 
described in section 4.2.1, CD43 pan-haematopoietic marker allows the identification 
of the haematopoietic progenitor population generated from PSCs and it has been 
widely used in a high number of studies involving haematopoiesis from PSCs 
(Vodyanik et al., 2006; Timmermans et al., 2009; Choi et al., 2012; Kennedy et al., 
2012; Elcheva et al., 2014; Ronn et al., 2015; Nishizawa et al., 2016) and modelling of 
haematopoietic disorders using iPSCs (Garcon et al., 2013; Mills et al., 2013). Days 
12, 16 and 20 showed similar percentages of CD43+ cells (75% at day 12, 65% at day 
16 and 68 % at day 20) and CD43+ subpopulations including Ery/MkP, MkP, EryP and 
MyeP were also detected. However, CFU assays revealed a higher colony-forming 
capacity of day 12 haematopoietic progenitors and a decreased colony-forming 
potential of the day 16 and day 20 progenitor populations. This could be explained by 
a down-regulation in the expression of CD34 within the CD43+ population observed at 
days 16 and 20 previously described as a sign of commitment to more mature 
progenitors and decreased colony-forming potential (Vodyanik et al., 2006; Kennedy 
et al., 2012). Likewise, the decrease in Ery/MkP and EryP population observed on days 
16 and 20 could be also attributable to a maturation of the progenitors with loss of 
CD43 expression associated to a commitment to erythroid lineages (Remold-
O'Donnell et al., 1987)  
 
To confirm the colony-forming potential of the CD43+ population, CD34/CD43 fractions 
at day 12 were sorted according to surface marker expression and plated in cytokine-
enriched media in order to assess the colony-forming potential of the different fractions. 
As expected, CFU-assays showed the presence of CFUs from both erythroid and 
myeloid lineages only in the CD43+ subsets, CD34+CD43+ and CD34-CD43+, 
confirming that CD43 marker can be used to reliably separate population of progenitors 
with haematopoietic colony-forming potential as previously described by other studies 
(Vodyanik et al., 2006; Timmermans et al., 2009; Kennedy et al., 2012).  Interestingly, 
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CD34+CD43+ fraction generated a higher number of CFU, 170 per 30.000 cells plated, 
compared to CD34-CD43+ fraction, 40 per 30.000 cells plated, with a lower percentage 
of cells at day 12 (16% for CD34+CD43+ vs 68% for CD34-CD43+). These results 
confirm that the loss of CD34 expression is associated to a reduced colony-forming 
potential probably due to a maturation of the progenitors but not a complete lack of 
capacity to form haematopoietic colonies.   
 
As described earlier in Chapter 1 (section 1.2.5) the use of iPSC in disease modelling 
presents important limitations.  Analysis of potential sources of variation introduced 
during the generation of the iPSC lines was addressed in Chapter 3. The results in 
this Chapter 3 demonstrated that the iPSC lines generated for this study presented no 
major complications with regards to reprogramming vector-related alterations, 
incomplete reprogramming or presence of genetic variations due to reprogramming or 
long-term passaging of the cell lines. In this chapter, we address complications related 
to potential heterogeneity induced by the differentiation of iPSC cells into 
haematopoietic progenitors that can diminished the value of iPSC in SAA disease 
modelling. Thus, I analysed the contribution of different sources of variation previously 
described in iPSC-based disease modelling such as passage number variability 
(Nishino et al., 2011), clone-to-clone variability within same iPSC lines (Thatava et al., 
2013) and donor-to-donor variability between iPSC lines due to different genetic 
background (Mills et al., 2013). Cell type of origin has been also previously described 
as potential source of variation suggesting retention of  cell-type epigenetic memory 
that bias the iPSC differentiation potential towards the cell type of origin (Bar-Nur et al., 
2011). However, we did not consider this variable since all the different iPSC lines used 
for this study were generated by reprogramming of the same cell type, HDF. Thus, for 
each variable group, different iPSC lines that differ mainly in the variable of interest 
(passage, clone or genetic background) were differentiated and variances obtained for 
day 12 CD43+ haematopoietic progenitors, including EryP, Ery/MkP, MkP and MyeP, 
were compared to the differentiation experiment variable which is included in each 
variable group. Thus, any statistical significant differences observed when comparing 
variances of any of the variable groups to the differentiation experimentation group 
could be interpreted as variation introduced by the variable and not just experimental 
variability. Results obtained by using the test for equal variances by multiple 
comparisons method indicate that differences in variances between each of the 
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variables and the differentiation experiment variable were not statistically significant for 
any of the haematopoietic progenitor populations since the standard deviations 
calculated for each variable showed overlapping with the differentiation experiment 
variable. However, it is noteworthy that differences in variances for EryP were close to 
significance that might be attributable to the minimum overlap showed by the standard 
deviations of the genetic background variable and the differentiation experiment 
variable. So, it can be hypothesized that genetic background might be acting as a 
source of variation with regards to the generation of EryP from iPSC and a definitive 
answer to this question would require further experiments. These results are in 
agreement with previous studies highlighting the importance of genetic background as 
the main source of variation in iPSC at a transcriptomic and epigenetic level (Rouhani 
et al., 2014; Choi et al., 2015; Kyttala et al., 2016; Carcamo-Orive et al., 2017) and  at 
haematopoietic differentiation potential of iPSCs and ESCs (Mills et al., 2013; Tulpule 
et al., 2013; Kotini et al., 2015; Feraud et al., 2016). Thus, as suggested by Cahan et 
al., it is possible that genetic background variations observed in iPSC differentiation 
are amplified due to the fact that in vitro differentiation methods do not completely 
reproduce aspects of early embryonic development and signalling pathways involved 
in differentiation are less efficiently activated (Cahan and Daley, 2013). The use of 
normal isogenic iPSC lines from same patient or iPSC lines sharing partial genetic 
background, such as parental relatives, would reduce the variation introduced by the 
genetic background. Unfortunately, samples from parental relatives of the SAA 
patients were not available and generation of isogenic iPSC lines from SAA patients is 
not plausible since presence of a genetic defect in these patients remains unknown 
and, therefore, there is no possibility to correct it to generate isogenic iPSC lines. 
Therefore, in the light of these results, in order to include genetic background variation 
when analysing the haematopoietic potential of SAA-iPSC in Chapter 5, I decided to 
use multiple control-iPSC lines to distinguish between phenotypic effects caused by 
disease-causing alterations and normal variation.  
 
In summary, here I provide evidence of the effective generation from PSCs of 
previously described mesodermal/endothelial progenitors and, most importantly, the 
generation of haematopoietic progenitors with colony-forming potential, including Ery-
P, Ery/MkP, MkP and MyeP when using the method published by Olivier et al. These 
results show that haematopoietic progenitors on day 12 have a higher colony-forming 
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capacity compared to later stages of the differentiation. Likewise, we confirmed that 
CD43 expression can be used to identify haematopoietic progenitors with colony-
forming potential. Thus, in accordance with these results, we will base the analysis of 
the haematopoietic potential of the SAA cell lines described in the Chapter 5 in 
investigating the CD43+ population generated by the SAA-iPSC on day 12. Finally, 
when studying the variation introduced by different experimental variables we identified 
genetic background as the variable showing the highest contribution to the variance in 
EryP. This indicates that genetic background variation should be considered when 
investigating the haematopoietic potential of the SAA-iPSC lines by including multiple 
lines from unaffected individuals in order to reduce the risk of misinterpreting 
differences in phenotypes due to genetic variation as disease-related phenotypes.  
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5 Chapter 5. Haematopoietic potential and telomere dynamics of 
SAA cell lines 
5.1 Introduction 
SAA is characterised by peripheral blood pancytopenia and hypocellular bone marrow. 
Several studies have reported reduced numbers of haematopoietic progenitors in the 
bone marrow of SAA patients and impaired differentiation capacity of these progenitors 
by in vitro clonogenic assays (Chapter 1, section 1.1.5.2). Although traditionally 
considered as an immune disorder, the presence of an underlying defect in 
haematopoietic progenitors of SAA patients has been also hypothesised to be 
associated to SAA pathogenesis. However, this stem cell dysfunction has been difficult 
to investigate due to absence of in vitro disease models and unsuitability of current 
animal models (see section 1.1.6). By using iPSC technology, SAA haematopoietic 
progenitor cells could be generated at ease providing an in vitro disease model to 
investigate their properties and potential defects in the absence of immune system 
influence.  
 
Different studies have reported the generation of iPSC from patients with BMFS such 
as FA (Raya et al., 2009; Muller et al., 2012; Yung et al., 2013), DC (Agarwal et al., 
2010; Batista et al., 2011; Wang et al., 2012; Gu et al., 2015), DBA (Garcon et al., 
2013; Ge et al., 2015), SDS (Tulpule et al., 2013) and SCN (Hiramoto et al., 2013; 
Nayak et al., 2015). These patient-specific iPSC models have successfully 
recapitulated the disease phenotype of patients and have been used as disease model 
to investigate the mechanisms associated with the pathogenesis of the disorders.      
 
Excessive telomere attrition in highly proliferative cells such as HSPCs can lead to 
bone marrow failure (Calado and Young, 2008). Due to the up-regulation of telomerase 
function and telomere elongation occurring during the reprogramming process (Marion 
et al., 2009; Zalzman et al., 2010) , IPSC technology has been widely used in the past 
to investigate telomere dynamics in telomeropathies such as DC (Agarwal et al., 2010; 
Batista et al., 2011; Wang et al., 2012; Gu et al., 2015). I decided to investigate the 
telomere dynamics in our SAA-iPSC model since it has been reported that one third of  
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acquired AA patients present short telomeres in leukocytes with only 10% of these 
patients presenting mutations in known telomere-associated genes (Ball et al., 1998; 
Brummendorf et al., 2001; Young et al., 2006).  
 
The aim of this 5th chapter is to assess the feasibility of the iPSC approach to 
recapitulate the AA disease phenotype by analysing: 
 
 The ability of SAA-iPSC to generate haematopoietic progenitor cells including 
mesodermal and haemato-endothelial precursors during haematopoietic 
differentiation 
 The capacity of iPSC-derived haematopoietic progenitor cells to proliferate and 
differentiate into haematopoietic cells. 
 The telomerase activity up-regulation and telomere length during 
reprogramming of SAA-fibroblasts and further SAA-iPSC haematopoietic 
differentiation. 
   
 
5.2 Results 
5.2.1 Generation of haematopoietic progenitor cells from SAA-iPSC lines 
Control (WT1, WT2 and WT3) and SAA-iPSC lines (SAA1, SAA2, SAA3 and SAA4) 
were differentiated into haematopoietic progenitor cells by using the experimental 
design and differentiation protocol described in Chapter 4 (Figure 37).  
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Figure 37. Schematic representation of the experimental design used to analyze the control and 
SAA-iPSC haematopoietic differentiation capacity 
As described in Chapter 1 (section 1.2.5.3), potential epigenetic memory retained in 
iPSC after reprogramming process can result in reduced differentiation capacity 
leading to biased results. Thus, to guarantee erasure of existing somatic epigenetic 
memory, both control and SAA-iPSC lines were cultured for at least 30 passages since 
it has been described that extended passaging of iPSC removes this epigenetic 
memory (Polo et al., 2010). Early stages of mesoderm induction from iPSC cultures 
were monitored on day 3 of differentiation by expression of KDR (FLK1) (Figure 38A). 
No statistically significant differences were observed in the percentage of KDR+ cells 
between control and SAA cell lines indicating that patient-specific iPSC lines did not 
show impaired ability to differentiate into mesodermal lineages (Figure 38B).  
Formation of haemato-endothelial progenitors and the emergence of the first 
haematopoietic progenitors was detected at day 6 using CD34 and CD43, pan-
haematopoietic marker (Figure 38C). SAA1-iPSC showed a significant reduction in 
the percentage of CD34+/CD43+ cells indicating a reduced potential of SAA1-iPSC to 
generate haemato-endothelial progenitors or a delay in the generation of these cells 
from iPSC (Figure 38D).   
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Figure 38. Generation of mesodermal and haemato-endothelial progenitors from control (WT) 
and SAA-iPSC lines. 
(A) Representative images of flow cytometric analysis of KDR expression in differentiating control (WT) 
and SAA cell lines on day 3; (B) Scatter plot showing percentages of KDR+ cells in differentiating 
grouped control (WT) and SAA cell lines on day 3; (C) Representative images of flow cytometric analysis 
of CD34 and CD43 expression in differentiating control (WT) and SAA cell lines on day 6; (D) Scatter 
plot showing percentages of CD34+ and/or CD43+ cells in differentiating grouped control (WT) and SAA 
cell lines on day 6; B, D: One-way ANOVA with Dunnett’s multiple comparison test was used for 
statistical comparison between grouped control (WT) and SAA cell lines. Data is presented as mean of 
at least 3 independent experiments +/- S.E.M. Data for all control cell lines is averaged in one group 
(WT).  
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The presence of CD43+ haematopoietic progenitors including erythroid, 
megakaryocytic and myeloid subpopulations generated from control and SAA-iPSC 
lines was assessed at day 12 by flow cytometric analysis (Figure 39).  
 
Figure 39. Generation of iPSC-derived CD43+ haematopoietic progenitors and Ery/MkP, MkP and 
MyeP subpopulations from control (WT) and SAA cell lines. 
Representative images of flow cytometric analysis of CD34, CD43 expression and CD41 and CD235 
expression for gated CD43+ population. 
Statistical analysis did not reveal a significant reduction in the capacity to generate 
CD43+ haematopoietic progenitors in any of the SAA-iPSC cell lines compared to 
unaffected controls (Figure 40A). However, one of the SAA patient iPSC (SAA1) 
showed a statistically significant reduction in the potential to generate EryP 
(CD43+CD41a-CD235a+) (Figure 40B); whereas no impaired potential to generate 
the Ery/MkP, MkP and MyeP was observed in the other SAA-iPSC lines (Figure 40C-
E). 
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Figure 40. Comparison of haematopoietic differentiation potential of control (WT) and SAA-iPSC 
lines. 
(A) Haematopoietic progenitors (CD43+); (B) Erythroid progenitors (CD43+CD41a-CD235a+); (C) 
Megakaryocytic/erythroid progenitors (CD43+CD41a+CD235a+); (D) Megakaryocytic progenitors 
(CD43+CD41a+CD235a-); (E) Myeloid progenitors (CD43+CD41a-CD235a-);  A, C: Kruskal-Wallis test  
with Dunn’s multiple comparison test was used for statistical comparison between grouped control (WT) 
and SAA cell lines; B, D, E:  One-way ANOVA with Dunnett’s multiple comparison test was used for 
statistical comparison between grouped control (WT) and SAA cell lines; A-E: Data is presented as 
mean of at least 3 independent experiments +/- S.E.M. Data for all control cell lines is averaged in one 
group (WT).  
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5.2.2 Colony-forming potential of SAA-iPSC-derived haematopoietic progenitor cells 
To assess the colony-forming potential of the SAA-iPSC cell lines, we performed CFU 
assays at day 12 by culturing iPSC-derived-haematopoietic progenitors for 14-16 days 
in methylcellulose-based media enriched with recombinant cytokines which promote 
the differentiation into committed erythroid progenitors (CFU-E and BFU-E), and 
myeloid lineage progenitors (CFU-G, CFU-M, CFU-GM and CFU-GEMM) (Figure 37).  
Enumeration of CFU colonies was carried out according to size, morphology and 
cellular composition as indicated in Chapter 4 (section 4.2.1). Two of the patient cell 
lines (SAA2 and SAA3) failed to produce all the different types of CFU colonies usually 
obtained from haematopoietic progenitors (Figure 41). CFU colonies from SAA 
patients displayed similar morphology to CFUs from control cell lines with no apparent 
changes in size or cellular composition (Figure 41). 
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Figure 41. Representative pictures of CFU-GEMM, CFU-E, BFU-E, CFU-GM, CFU-G and CFU-M 
haematopoietic colonies in control (WT) and SAA cell lines. 
No representative pictures for CFU-M/CFU-GEMM and CFU-G/CFU-GEMM were taken for SAA2 and 
SAA3 cell lines respectively due the scant number of colonies. Scale bars, 200 µm. 
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Determination of the number of CFUs revealed that three SAA-iPSC-derived 
haematopoietic progenitors (SAA1, SAA2 and SAA3) showed a significant reduction 
in the total number of CFUs (Figure 42A) indicating an impaired haematopoietic 
colony-forming capacity, including both erythroid and myeloid colony potential (Figure 
42B-C). Of note, the main and common deficiency between the three affected SAA cell 
lines appeared at the stage of erythroid and myeloid colony formation from respective 
progenitor cells, a process which requires extensive cellular replication and 
differentiation.  
 
 
Figure 42. Comparison of the colony-forming potential of control (WT) and SAA-iPSC-derived 
haematopoietic progenitors. 
(A) Total number of CFUs; (B) Erythroid-lineage CFUs; (C) Myeloid-lineage CFUs; A-C: Kruskal-Wallis 
test with Dunn’s multiple comparison test was used for statistical comparison between grouped control 
(WT) and SAA cell lines. Data is presented as mean of at least 3 independent experiments +/- S.E.M. 
Data for all control cell lines is averaged in one group (WT). 
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Analysis of the different haematopoietic colony types generated in CFU assay showed 
a complete absence of CFU-M and CFU-GEMM colony type in SAA2 cell line (Figure 
43). However, these results are difficult to interpret due to the reduced total 
haematopoietic colony number observed in the affected SAA cell lines (Figure 43). 
 
Figure 43. Distribution of haematopoietic colonies types in control (WT) and SAA cell lines 
represented as proportional percentage. 
Data is presented as mean of at least 3 independent experiments. Data for all control cell lines is 
averaged in one group (WT).  
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5.2.3 Telomere dynamics in SAA cell lines 
To assess the ability of the SAA cells to elongate telomeres during reprogramming, I 
measured telomere length in parental fibroblasts and iPSC at different passages by 
qPCR. Control-iPSC and one of the SAA patients (SAA4) showed longer telomeres in 
iPSC than in parental fibroblasts due to telomere elongation during reprogramming, 
corroborating previous reports (Marion et al., 2009). Strikingly, no significant increases 
in telomere length were observed during the reprogramming of three of the SAA cell 
lines (SAA1, SAA2 and SAA3) (Figure 44A). Furthermore, one of the patients (SAA3) 
showed continued telomere shortening during the reprogramming process (Figure 
44A), resulting in iPSC with telomeres which were significantly shorter than parental 
fibroblasts. The control-iPSC lines did not show a significant telomere shortening 
during the 12 day differentiation time course to haematopoietic lineages compared to 
iPSC passage 50; however the three SAA-iPSC lines showing defective telomere 
elongation (SAA1, SAA2 and SAA3) displayed a significant telomere attrition during 
the differentiation process, resulting in iPSC-derived haematopoietic progenitors with 
significantly shorter telomeres than corresponding iPSC passage 50 (Figure 44B).  
 
Figure 44. Telomere length analysis of control (WT) and SAA cell lines. 
(A) Analysis of telomere length in parental fibroblasts (dark grey bars) and iPSC passage 30 (light blue 
bars) and 50 (green bars) in grouped control (WT) and SAA cell lines. One-way ANOVA with Tukey’s 
multiple comparison test was used for statistical comparison between fibroblasts and iPSC passage 30 
and passage 50; (B) Analysis of telomere length in iPSC passage 50 (green bars) and iPSC-derived 
haematopoietic progenitor cells (HPC) differentiated from iPSC passage 50 (light grey bars) in grouped 
control (WT) and SAA cell lines. Multiple t-test using Holm-Sidak method was used for statistical 
comparison between iPSC passage 50 and HPC; A-B: data is presented as mean of at least 3 
independent experiments +/- S.E.M. Data for all control cell lines is averaged in one group (WT). 
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We assessed up-regulation of telomerase activity in iPSC and iPSC-derived-
haematopoietic progenitors by TRAP assay. Telomerase activity was significantly 
increased in iPSC when compared to parental fibroblasts indicating up-regulation of 
telomerase activity during reprogramming of both control and SAA-fibroblasts as 
reported by other studies (Takahashi et al., 2007) (Figure 45A). Analysis of telomerase 
activity in iPSC-derived-haematopoietic progenitors revealed that only one SAA patient 
(SAA2) displayed a significantly reduced telomerase activity compared to iPSC 
passage 50 (Figure 45B). Together, these data indicate an impaired telomere 
elongation during the reprogramming of SAA-fibroblasts which was independent of 
telomerase activity assessed by in vitro TRAP assay. Furthermore, three SAA-iPSC 
lines (SAA1, SAA2 and SAA3) suffered significant telomere attrition during 
differentiation resulting in haematopoietic progenitors with shorter telomeres than 
controls corroborating data obtained with patient specific peripheral blood and bone 
marrow nucleated cells (Brummendorf et al., 2001; Lee et al., 2001; Sakaguchi et al., 
2014; Park et al., 2016). 
 
 
Figure 45. : Telomere activity analysis of control (WT) and SAA cell lines.  
(A) Analysis of telomere activity in parental fibroblasts (dark grey bars) and iPSC passage 30 (light blue 
bars) and 50 (green bars) in grouped control (WT) and SAA cell lines. One-way ANOVA with Tukey’s 
multiple comparison test was used for statistical comparison between fibroblasts and iPSC passage 30 
and passage 50; (B) Analysis of telomere activity in iPSC passage 50 (green bars) and iPSC-based 
haematopoietic progenitor cells (HPC) differentiated from iPSC passage 50 (light grey bars) in grouped 
control (WT) and SAA cell lines. Multiple t-test using Holm-Sidak method was used for statistical 
comparison between iPSC passage 50 and HPC; A-B: data is presented as mean of at least 3 
independent experiments +/- S.E.M. Data for all control cell lines is averaged in one group (WT).  
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5.3 Discussion 
Reduced number of haematopoietic progenitor cells in the bone marrow is the common 
clinical presentation in SAA patients. This reduced number of bone marrow progenitor 
cells has been traditionally associated to an immune-mediated disorder due to the fact 
that 60-70% of SAA patients show response to IST (Young et al., 2006). However, 
there is an increasing recognition that a significant number of young adults may have 
instead a constitutional form of BMFS which affects the haematopoietic stem and/or 
progenitor compartments. In 2003, a study reported that five percent of SAA patients 
cases were undiagnosed cases of constitutional BMFS without the apparent abnormal 
phenotype commonly associated to these disorders (Fogarty et al., 2003). 
Misdiagnosis of SAA in patients actually presenting constitutional defects in 
haematopoietic progenitors may have severe consequences in terms of both diagnosis 
and treatment. Firstly, unnecessary exposure of patients to the toxicity associated to 
IST and inadequacy of the use of these treatments in patients that might not respond 
due to the non-immune-associated nature of the disorder are elements that would 
benefit from the identification of potential genetic defects in SAA patients. Secondly, 
identification of potential genetic defects in SAA patients could also help to identify 
affected ‘silent’ siblings that should not be considered as donors in case of HSCT. 
Lastly, in the longer term, patients with inherited BMFS are predisposed to develop to 
haematopoietic malignancies (Zeng and Katsanis, 2015), necessitating more rigorous 
monitoring for later development and long term follow up of second malignancies.  
Thus, identification of constitutional forms of BMFS in SAA cases would have profound 
clinical implications in SAA patients that would benefit from more accurate diagnosis 
and tailored therapies.                         
 
SAA-iPSC lines generated in this study, as described in Chapter 3, were successfully 
differentiated into haematopoietic progenitors. In the process of haematopoietic 
differentiation, SAA-iPSC lines successfully generated KDR+ mesodermal precursors 
at levels similar to those in control cell lines indicating no impaired capacity to 
differentiate into mesodermal lineages. These results were expected since SAA 
patients do not show defects in cells from mesodermal lineage, other than 
haematopoietic cells, such as endothelial, vascular, bone, cardiac muscle and skeletal 
muscle cells. Mesodermal progenitors generated from SAA cell lines progressed into 
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differentiation and generated CD34+/CD43+ haemato-endothelial progenitors. One of 
the SAA cell lines (SAA1) generated a significantly reduced number of haemato-
endothelial progenitors compared to control cells lines that could be interpreted as an 
impaired capacity to generate haemato-endothelial progenitors.  Flow cytometric 
analysis of CD43+ haematopoietic progenitors on day 12 revealed that SAA cell lines 
did not show a significantly reduced percentage of CD43+ haematopoietic progenitors 
providing evidence of the potential of the SAA-iPSC lines to generate haematopoietic 
progenitors. Thus, generation of CD43+ by SAA1 in similar levels to those in control 
cell lines on day 12 suggest that the formation of CD34+/CD43+ haemato-endothelial 
progenitors occurred later than day 6 and the reduced percentages of these 
progenitors observed on day 6 in SAA1 might be explained by a delay in the generation 
of haemato-endothelial progenitors. However, SAA1 was the only patient cell line 
showing significantly reduced numbers of CD43+CD41a-CD235a+ EryP. These 
results could indicate a reduced capacity of SAA1 to generate progenitors from 
erythroid lineages. However, it is noteworthy that generation of EryP is highly 
influenced by genetic background variability as shown in Chapter 4. Thus, it would be 
important not to rule out the idea that the significant differences observed between 
control and SAA1 cell lines could be attributable to genetic background variation. A 
definite answer to this question would require an increased number of control cell lines 
to include a higher genetic background variation in the control group when comparing 
generation of EryP. 
 
Strikingly, SAA-iPSC-derived haematopoietic progenitors of three of the patient cell 
lines (SAA1, SAA2 and SAA3) exhibited a significantly reduced ability to generate 
haematopoietic colonies, with CFUs from both erythroid and myeloid lineages affected 
equally, accurately recapitulating the phenotype that defines SAA. One of the 
remaining SAA patient cell line (SAA4) did not exhibit a significantly reduced colony-
forming capacity compared to control cell lines suggesting normal functional ability. 
The presence of reduced number and colony-forming capacity of bone marrow 
haematopoietic progenitors in SAA patients has been reported by different studies 
(Marsh et al., 1990; Maciejewski et al., 1994; Scopes et al., 1994; Maciejewski et al., 
1996; Rizzo et al., 2002; Rizzo et al., 2004). These quantitative and qualitative defects 
observed in bone marrow haematopoietic progenitors from SAA patients have been 
traditionally considered to be secondary to immune-mediated stem cell destruction 
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(Young et al., 2006). The in vitro SAA-iPSC model used in this study provides evidence 
of an impaired differentiation capacity in SAA-iPSC-derived haematopoietic 
progenitors in the absence of the immune system in three of the patient cell lines (SAA1, 
SAA2 and SAA3), which is suggestive of a constitutional progenitor cell dysfunction in 
these patient cell lines. Thus, use of this SAA-iPSC model would potentially offer the 
opportunity of identifying SAA patients showing an underlying haematopoietic 
progenitor cell dysfunction away from the influence of immune system that could be 
treated accordingly. Likewise, by recapitulating the SAA disease phenotype, the SAA-
iPSC model presented in this study could be used to identify pathogenic mechanisms 
associated to stem cell dysfunction in SAA disease modelling studies.       
 
Functional reconstruction of telomeres and upregulation of telomerase activity during 
reprogramming represent a hallmark of induction to pluripotency (Takahashi and 
Yamanaka, 2006; Takahashi et al., 2007; Marion et al., 2009). iPSC-based modelling 
of telomeropathies associated with BMFS caused by mutations in telomerase-
associated genes such as TERC, TERT and DKC  have shown defective telomere 
elongation in iPSC due to reduced telomerase function which impacts on the 
maintenance of the pluripotent phenotype and haematopoietic differentiation capacity 
(Batista et al., 2011; Winkler et al., 2013; Gu et al., 2015). In AA, only 10% of patients 
with short telomeres display known mutations in telomere pathway components 
suggesting that mutations in uncharacterised genes might have a role in the disease 
phenotype observed in these patients (Young et al., 2006). For this reason, we set out 
to investigate telomere dynamics in the SAA-iPSC lines and haematopoietic 
progenitors derived therefrom. Variability in telomere length among iPSC lines due to 
passage number and parent cell type has been previously described  (Rohani et al., 
2014). Likewise, it has been reported that telomeres in iPSC are elongated gradually 
with increasing passages and stabilize after prolonged passaging at passage 15-30 
(Marion et al., 2009; Liu, 2017). Both control and SAA-iPSC lines were generated from 
fibroblast cells, minimizing the variability introduced by parental cell type. Additionally, 
in order to reduce the variability in telomere length due to passage number and ensure 
that telomere elongation was completed by the time of measurement, analysis of 
telomere dynamics in control and SAA-iPSC lines was done in iPSC passage 30 and 
50. Our results revealed that three of the SAA-iPSC lines (SAA1, SAA2 and SAA3) 
failed to elongate telomeres during the reprogramming process despite up-regulation 
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of telomerase activity, pointing to an impaired telomere elongation during the 
reprogramming process that cannot be attributed to an absent/reduced telomerase 
activity. In vivo HSC exhibit detectable levels of telomerase activity although this 
activity is down-regulated during the process of in vivo generation of haematopoietic 
cells leading to shortening of telomere as the cells differentiate (Zimmermann and 
Martens, 2008; Hills and Lansdorp, 2009).  Telomeres in control and SAA4 cell lines 
were not significantly shorter compared to the corresponding iPSC passage 50 used 
for differentiation. In contrast, iPSC-derived haematopoietic progenitors in the telomere 
elongation deficient SAA cell lines (SAA1, SAA2 and SAA3) showed excessive 
telomere shortening during haematopoietic differentiation. Thus, I hypothesized that 
the presence of short telomeres due to accelerated telomere attrition may be 
responsible for the impaired haematopoietic differentiation capacity we observed in 
SAA1, SAA2 and SAA3 cell lines as previously described (Winkler et al., 2013). 
Interestingly, SAA4 cell line showed normal colony-forming capacity and telomere 
elongation in iPSC with no accelerated telomere attrition upon iPSC haematopoietic 
differentiation, supporting the hypothesis that impaired haematopoietic differentiation 
capacity observed in SAA1, SAA2 and SAA3 might be attributed to excessive telomere 
shortening.  Alternatively, the short telomeres can be a consequence of reiterative 
rounds of divisions carried out by a smaller number of proliferating haematopoietic 
progenitor cells in SAA patients which was highlighted by our study as a compensatory 
mechanism to maintain homeostasis (Beier et al., 2012). It is difficult to distinguish 
between these possibilities without knowing the genetic defect that may underline the 
pathogenesis of SAA in these patients.  
 
In summary, iPSC-derived haematopoietic progenitors of three of the SAA cell lines 
(SAA1, SAA2 and SAA3) exhibited a reduced capacity to generate haematopoietic 
cells despite an equal ability to generate haematopoietic progenitor cells, thus 
corroborating data obtained from the study of SAA patients. Secondly, SAA cell lines 
with reduced haematopoietic differentiation potential (SAA1, SAA2 and SAA3) showed 
a deficient telomere elongation in iPSC during reprogramming and accelerated 
telomere shortening upon differentiation into haematopoietic progenitors. These 
results suggest an intrinsic link between telomere shortening and haematopoietic 
differentiation; however more work at the gene analysis is needed to establish whether 
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these patients harbour mutations in any of the genes that maintain telomere length and 
telomerase activity. 
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6 Chapter 6. Insights into SAA pathophysiology using molecular 
studies 
6.1 Introduction 
iPSC-derived haematopoietic progenitors generated from three SAA cell lines (SAA1, 
SAA2 and SAA3) exhibited a reduced capacity to generate both erythroid and myeloid 
cells in CFU assays as described in Chapter 5. Likewise, these three SAA cell lines 
showed defective telomere elongation during reprogramming and, most importantly, 
accelerated telomere attrition upon haematopoietic differentiation of the iPSC lines. 
Progressive telomere shortening leads eventually to cell cycle arrest and apoptotic cell 
death (Harley et al., 1990; Blasco, 2005). Extensive replication associated with 
haematopoietic differentiation may lead to accumulation of DNA damage, which, if 
unrepaired, can induce replicative senescence or apoptosis of HSPCs (Zeman and 
Cimprich, 2014; Moehrle and Geiger, 2016). Impaired DNA damage repair capacity in 
HSPCs has been associated with inherited BMFS such as FA (Dokal and Vulliamy, 
2010).  
 
In this chapter I set out to investigate whether the observed impaired haematopoietic 
differentiation potential of SAA-iPSC derived haematopoietic progenitors of the three 
affected SAA cell lines could be associated to a haematopoietic progenitor cell 
dysfunction such as abnormal proliferation, apoptosis rate and DNA repair capacity. 
To this end, SAA-iPSC-derived haematopoietic progenitors were cultured under 
replicative-stress conditions in order to synchronize cell cycle for subsequent 
proliferation analysis. Ability to repair DNA damage and apoptosis rate in normal and 
replicative-stress conditions in SAA-iPSC-derived haematopoietic progenitor cells 
were determined using flow cytometric analysis and CFU assays.  
 
As discussed in Chapter 1 (section 1.2.4.1), one of the main advantages that iPSC 
technology offers is the possibility of testing the efficacy of drugs and provide insights 
into the drug mechanism of action in patient specific iPSC-derived cells. Several 
studies have demonstrated the use of iPSC technology as disease model to identify 
drugs that can rescue the disease phenotype in patient-derived iPSC cells (Huang et 
al., 2011; Cooper et al., 2012). Recently, it has been reported that EP, a TPO receptor 
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agonist, stimulates bi- and tri-lineage haematopoiesis by increasing platelet and 
neutrophil counts and haemoglobin levels with overall response in 40% of SAA patients 
at 3-4 months (Desmond et al., 2014) (Chapter 1, section 1.1.4.2). Thus, in view of 
these findings, I investigated whether the observed reduced colony-forming potential 
and proliferation of the affected SAA-iPSC-derived haematopoietic progenitors could 
be rescued by the addition of EP to the differentiation media. 
 
The aim of this 6th chapter is to investigate the following: 
 The proliferation of SAA-iPSC-derived haematopoietic progenitors  
 The ability of SAA-iPSC-derived haematopoietic progenitors to repair DNA 
damage under normal and replicative-stress conditions 
 The apoptosis of SAA-iPSC haematopoietic progenitors under normal and 
replicative-stress conditions 
 The effect of EP in colony-forming potential, proliferation and DNA repair 
capacity of SAA-iPSC-derived haematopoietic progenitors under normal and 
replicative-stress conditions 
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6.2 Results 
6.2.1 Proliferative capacity of SAA-iPSC-derived haematopoietic progenitors 
To analyse proliferation capacity, I synchronized the iPSC-derived haematopoietic 
progenitors from control cell lines in G1/S phase by treatment with ribonucleotide 
reductase inhibitor hydroxyurea (HU) for 24 hours (Figure 46A). This was followed by 
culture in HU-free media and pulsing with 5-bromo-2-deoxyuridine (BrdU) for 1hour. 
Flow cytometric analysis of DNA content and incorporation of BrdU in control-iPSC-
derived-haematopoietic progenitors indicated a high percentage of cells arrested in 
G1/S phase at 1 and 3 hours post-release from HU due to depletion of 
deoxyribonucleotide pools (Figure 46B). These arrested cells re-entered the cell cycle, 
progressed through S-phase and showed a similar cell cycle profile to that of untreated 
cells at 24 hours post treatment (Figure 46B-C), indicating that iPSC-derived 
haematopoietic progenitors require at least 24 hours to restore normal cell-cycle profile.  
 
Next, I analysed the proliferation rate of the synchronized control- and SAA-iPSC-
derived haematopoietic progenitors (marked by CD43 expression) by comparing the 
percentage of BrdU-incorporating cells (S-phase) at 24 hours post-release from HU. 
Interestingly, SAA-iPSC-derived-haematopoietic progenitors from the three affected 
SAA cell lines  (SAA1, SAA2 and SAA3) showed a significant reduction in the number 
of BrdU-incorporating cells (proliferative cells) compared with control counterparts, 
indicating a reduced proliferative capacity (Figure 46D). IPSC-derived haematopoietic 
progenitors from SAA4 showed no significant differences in the percentages of 
proliferative cells compared to control cell lines, indicating normal proliferative capacity 
(Figure 46D).     
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Figure 46. Analysis of proliferative capacity of control and SAA-iPSC-derived haematopoietic 
progenitors. 
(A)  Schematic of the experimental design used to analyse the proliferation, DNA repair capacity and 
apoptosis in iPSC-derived-haematopoietic progenitor cells (HPC); (B) Flow cytometric analysis of BrdU 
and DAPI incorporation in untreated, 1 hour HU recovery, 3 hour HU recovery, 8 hour HU recovery and 
24 hour HU recovery control-iPSC-derived haematopoietic progenitor cells; (C) Analysis of cell cyle in 
untreated (dark blue bars) and 24 hour HU recovery (red bars) control-iPSC-derived haematopoietic 
progenitor cells. Multiple t-test using Holm-Sidak method was used for statistical comparison between 
untreated and 24 hour HU recovery WT cells; (D) Analysis of BrdU-incorporating cells in control (WT) 
and SAA-iPSC-derived-haematopoietic progenitors. One-way ANOVA with Dunnett’s multiple 
comparison test was used for statistical comparison between WT and SAA cell lines. B-D: data is 
presented as mean of at least 3 independent experiments +/- S.E.M. Data for all control cell lines is 
averaged in one group (WT).  
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6.2.2 Ability to repair DNA damage associated to replicative stress in SAA-iPSC-
derived haematopoietic progenitors 
Induction of replicative stress by depletion of deoxyribonucleotide pools with long 
exposure to HU leads to stalled replication forks and accumulation of DNA damage 
(Petermann et al., 2010). To address whether the reduced haematopoietic potential of 
SAA-iPSC-derived-haematopoietic progenitors might be attributed to an impaired 
ability to repair DNA damage associated with replicative stress, I analysed the 
percentage of DNA damage induced by HU treatment by flow cytometric analysis in 
proliferating (BrdU+) and non-proliferating cells (BrdU-). First, to assess the 
reversibility of the DNA damage induced by HU exposure, I measured the formation of 
the phosphorylated histone variant H2AX at serine 139 (γH2AX) at 1, 3, 8 and 24 hours 
after HU release in control-iPSC-derived-haematopoietic progenitors. This analysis 
indicated accumulation of γH2AX+ in BrdU+ cells at 1 and 3 hours after HU release 
indicating accumulation of DNA damage in replication forks after HU replication arrest 
(Figure 47A). The γH2AX foci progressively disappeared showing similar levels of 
γH2AX levels to those of untreated cells at 24 hours (Figure 47A). Thus, analysis of 
accumulation of DNA damage in proliferating (γH2AX+BrdU+) and non-proliferating 
(γH2AX+BrdU-) iPSC-derived-haematopoietic progenitors showed that control cell 
lines were able to repair the induced DNA damage after 24 hours release from HU 
(Figure 47B-C).  
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Figure 47. DNA damage induced by replicative stress (HU) in control-iPSC-derived 
haematopoietic progenitors. 
(A) Flow cytometric analysis of BrdU incorporation and γH2AX detection in untreated, 1 hour, 3 hours, 
8 hours and 24 hours post-HU recovery; (B) Analysis of γH2AX in BrdU+ untreated, 1 hour, 3 hours, 8 
hours and 24 hours post-HU recovery. Student’s t-test was used for statistical comparison between 24h 
untreated and 24 HU recovery groups; (C)  Analysis of γH2AX in BrdU- untreated, 1 hour, 3 hours, 8 
hours and 24 hours post-HU recovery. Student’s t-test was used for statistical comparison between 24h 
untreated and 24 post-HU recovery groups. A-C: data is presented as mean of at least 3 independent 
experiments +/- S.E.M. 
To investigate the ability of SAA cell lines to repair DNA damage associated to 
replicative stress, I then analysed the accumulation of γH2AX in proliferating (BrdU+) 
and non-proliferating (BrdU-) in SAA-iPSC-derived-haematopoietic progenitors at 1 
and 24 hours after HU release. No significant increase in the accumulation of 
γH2AX+BrdU+  was observed at 1 hour post HU release in SAA-iPSC-derived 
haematopoietic progenitors (Figure 48A), unlike the control counterparts which 
showed a significant accumulation of DNA damage at 1 hour post HU release. Of note, 
low levels of DNA damage observed in BrdU+ 1h after replicative stress in SAA1, SAA2 
and SAA3 iPSC-derived haematopoietic progenitors points to a reduced proliferation 
capacity likely due to a reduced formation of replication forks, in agreement with our 
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previous results showing a significantly reduced number of BrdU-incorporating cells in 
SAA1, SAA2 and SAA3 cell lines  (Figure 46D). Thus, higher levels of γH2AX+BrdU+ 
cells were observed in control-iPSC-derived haematopoietic progenitors compared to 
those in SAA cell lines, likely due to a higher number of replication forks, although the 
differences were not statistically significant (Figure 48B).  
 
 
Figure 48. DNA damage induced by replicative stress (HU) in proliferating iPSC-derived 
haematopoietic progenitors. 
(A) Analysis of γH2AX in BrdU+ cells in untreated (dark blue bars), 1 hour after HU recovery (beige bars) 
and 24 hours after HU recovery (red bars) iPSC-derived-haematopoietic progenitors. One-way ANOVA 
with Tukey’s multiple comparison test was used for statistical comparison between untreated cells and 
1 hour after HU recovery and 24 hours after recovery; (B) Analysis of γH2AX in BrdU+ cells in control 
(WT) and SAA-iPSC-derived-haematopoietic progenitors. One-way ANOVA with Dunnett’s multiple 
comparison test was used for statistical comparison between control (WT) and SAA cell lines. A-B: data 
is presented as mean of at least 3 independent experiments +/- S.E.M. Data for all control cell lines is 
averaged in one group (WT). 
Interestingly, analysis of DNA damage in non-proliferative (BrdU-) progenitors revealed 
a significant increase in the level of γH2AX at 24 hours post HU release in two of the 
patient-derived-haematopoietic progenitors (SAA2 and SAA4) compared to equivalent 
cells generated from the controls (Figure 49A), suggesting an impaired ability to 
restore normal levels of DNA damage after HU treatment in non-proliferating iPSC-
derived haematopoietic progenitors. Notwithstanding this, the percentage of 
γH2AX+BrdU-cells in the haematopoietic progenitors derived from these two patient 
iPSC lines was not significantly higher when compared to equivalent cells generated 
from the unaffected controls (Figure 49B). Together these data indicate that 
proliferating SAA-iPSC-derived-haematopoietic progenitors from the three affected 
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patient cell lines (SAA1, SAA2 and SAA3) tend to accumulate less DNA damage soon 
after HU treatment most likely as a result of their reduced proliferation. Furthermore, a 
subset of SAA-iPSC-derived-haematopoietic progenitors may be slower or have an 
impaired ability to restore DNA damage in the non-proliferative compartment. However, 
the overall level of DNA damage induced in response to replicative stress is not 
significantly different compared to control-derived-haematopoietic progenitors, 
excluding DNA damage accumulation as a key factor underlying the impaired 
haematopoietic differentiation of SAA-iPSC lines. 
 
 
Figure 49. DNA damage induced by replicative stress (HU) in non-proliferating iPSC-derived 
haematopoietic progenitors. 
(A) Analysis of γH2AX in BrdU- cells in untreated (dark blue bars), 1 hour post-HU recovery (beige bars) 
and 24 hours post-HU recovery (red bars) iPSC-derived-haematopoietic progenitors. One-way ANOVA 
with Tukey’s multiple comparison test was used for statistical comparison between untreated cells and 
1 hour post-HU recovery and 24 hours post-recovery; (B) Analysis of γH2AX in BrdU- cells in control 
(WT) and SAA-iPSC-derived-haematopoietic progenitors. One-way ANOVA with Dunnett’s multiple 
comparison test was used for statistical comparison between control (WT) and SAA cell lines. A-B: data 
is presented as mean of at least 3 independent experiments +/- S.E.M. Data for all control cell lines is 
averaged in one group (WT). 
6.2.3 Apoptosis rate in SAA-iPSC-derived haematopoietic progenitors under normal 
and replicative-stress conditions 
To investigate whether apoptosis was increased in SAA-iPSC-derived-haematopoietic 
progenitors, I measured the presence of cleaved Poly (ADP-ribose) polymerase-1 
(PARP) under normal and replicative-stress conditions by flow cytometric analysis. 
Reduced presence of apoptotic cells in both control and SAA cell lines was observed 
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in the analysis of cleaved-PARP in iPSC-derived haematopoietic progenitor cells 
cultured under normal conditions (Figure 50A). However, a significant increase in the 
percentage of apoptotic cells was observed in SAA-iPSC-derived haematopoietic 
progenitors derived from one of the patients (SAA2) when compared to control cells 
(Figure 50B), which suggests an increased apoptosis rate in this patient. However, 
these results are difficult to interpret due to the extremely low number of apoptotic cells 
detected.  
 
  
Figure 50. Analysis of apoptotic cells in SAA-iPSC-derived haematopoietic progenitors in normal 
conditions. 
(A) Flow cytometric analysis of γH2AX and cleaved-PARP (PARP) detection in control (WT) and SAA-
iPSC-derived haematopoietic progenitor cells (HPC) under normal conditions; (B) Analysis of cleaved 
PARP in control (WT) and SAA-iPSC-derived haematopoietic progenitor cells in non-replicative-stress 
conditions. One-way ANOVA with Dunnett’s multiple comparison test was used for statistical 
comparison between control (WT) and SAA cell lines. A-B: data is presented as mean of at least 3 
independent experiments +/- S.E.M. Data for all control cell lines is averaged in one group (WT).  
136 
 
Levels of apoptotic cells remained low in haematopoietic progenitor cells from control 
and SAA cell lines when subjected to replicative-stress conditions (Figure 51A). Thus, 
no significant increase was observed in the apoptosis rate of SAA-iPSC-derived 
haematopoietic under replicative stress when compared to control cells (Figure 51B). 
In summary, these findings provide no convincing evidence of increased apoptosis in 
SAA cell lines under normal or after replicative stress excluding this mechanism as 
potential haematopoietic progenitor cell dysfunction associated to impaired 
haematopoietic differentiation potential in SAA cell lines.      
 
 
Figure 51. Analysis of apoptotic cells in control and SAA-iPSC-derived haematopoietic 
progenitors under replicative stress conditions. 
(A) Flow cytometric analysis of γH2AX and cleaved-PARP (PARP) detection in control (WT) and SAA-
iPSC-derived haematopoietic progenitor cells (HPC) under replicative-stress conditions (HU-treated); 
(B) Analysis of cleaved PARP in control (WT) and SAA-iPSC-derived haematopoietic progenitor cells 
under replicative-stress conditions (HU-treated). One-way ANOVA with Dunnett’s multiple comparison 
test was used for statistical comparison between control (WT) and SAA cell lines. A-B: data is presented 
as mean of at least 3 independent experiments +/- S.E.M. Data for all control cell lines is averaged in 
one group (WT). 
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6.2.4 Effect of EP in SAA-iPSC-derived haematopoietic progenitors   
To assess the impacts of EP on iPSC-derived haematopoietic progenitors, SAA cell 
lines showing impaired haematopoietic potential (SAA1, SAA2 and SAA3) were 
cultured under normal and replicative-stress conditions in the presence and absence 
of EP from day 6 of differentiation and tested for colony-forming potential by CFU assay 
at day 14 of differentiation (Figure 52).  
 
 
Figure 52. Schematic of the experimental design used to analyse the effect of EP on the colony-
forming potential, proliferation and DNA repair capacity in SAA-iPSC-derived haematopoietic 
progenitor cells. 
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First, I performed pilot experiments in control-iPSC-derived haematopoietic progenitors 
to validate the effect of EP. Generation of CD43+ cells with a high presence of erythroid 
progenitors (CD43+CD41a-CD235a+) was observed in the control-iPSC-derived 
haematopoietic progenitors cultured in the presence of EP (Figure 53A). Thus, 
addition of EP to TPO-containing differentiation media induced a significant increase 
in the percentage of erythroid progenitors (CD43+CD235a+CD41a-) at the expense of 
megakaryocytic progenitors (CD43+CD235a-CD41+) compared to the control group 
containing only TPO in differentiation media (Figure 53B). These results are very 
similar to what has been reported in CD34+ bone marrow cells (Jeong et al., 2015) 
and indicate that EP is biologically active in our iPSC differentiation system. 
 
 
Figure 53. Validation of the effect of EP in control-iPSC-derived haematopoietic progenitors. 
(A) Representative images of flow cytometric analysis of CD34 and CD43 expression and CD41 and 
CD235 expression for gated CD43+ population in control-iPSC-derived haematopoietic progenitor cells; 
(B) Analysis of the different haematopoietic progenitor cell (HPC) subpopulations, megakaryocitic 
(CD41a+CD235a-), megakaryocytic/ertythroid (CD41a+CD235a+), erythroid (CD41a-CD235a+) and 
myeloid (CD41a-CD235a-), in DMSO-treated and EP-treated groups. Multiple t-test using Holm-Sidak 
method was used for statistical comparison between DMSO-treated and EP-treated. A-B: data is 
presented as mean of at least 3 independent experiments +/- S.E.M.   
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CFU assay results did not show significant differences between DMSO- and EP-
treated groups in the total number of CFU colonies (Figure 54A) or in the number of 
erythroid lineage (Figure 54B) and myeloid lineage colonies (Figure 54C) generated 
from SAA-iPSC-derived-haematopoietic progenitors cultured in absence of HU.  
 
 
Figure 54. Colony-forming capacity of SAA-iPSC-derived haematopoietic progenitors in the 
presence and absence of EP in normal conditions. 
Analysis of CFUs generated in DMSO (dark blue bars) and EP-treated (orange bars) iPSC-derived-
haematopoietic progenitors in control (WT) and SAA cell lines in non-replicative-stress conditions; (A) 
Total CFUs, (B) erythroid-lineage CFUs, (C) myeloid-lineage CFUs. A-C: Multiple t-test using Holm-
Sidak method was used for statistical comparison between DMSO and EP groups. Data is presented 
as mean of at least 3 independent experiments +/- S.E.M. Data for all control cell lines is averaged in 
one group (WT). 
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Similarly, no differences in the total number of CFU colonies (Figure 55A) or in the 
number of erythroid lineage (Figure 55B) and myeloid lineage colonies (Figure 55C) 
were observed when EP was added in parallel to replicative stress inducing agent, HU. 
 
 
Figure 55. Colony-forming capacity of SAA-iPSC-derived haematopoietic progenitors in the 
presence and absence of EP in replicative-stress conditions (HU). 
Analysis of CFUs generated in DMSO (red bars) and EP-treated (grey bars) iPSC-derived-
haematopoietic progenitors in control (WT) and SAA cell lines in replicative-stress conditions; (A) Total 
CFUs, (B) erythroid-lineage CFUs, (C) myeloid-lineage CFUs. A-C: Multiple t-test using Holm-Sidak 
method was used for statistical comparison between DMSO and EP groups. Data is presented as mean 
of at least 3 independent experiments +/- S.E.M. Data for all control cell lines is averaged in one group 
(WT). 
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EP favours the proliferation and DNA double-strand break (DSB) repair after γ-
irradiation in human HSPCs (Sun et al., 2012; Cheruku PS, 2015). To investigate 
whether EP is affecting the proliferative and DNA damage repair capacity of the SAA-
iPSC-derived-haematopoietic progenitors under conditions of replicative stress 
induced by HU, flow cytometric analysis for BrdU incorporation and accumulation of 
γH2AX was carried out after EP treatment. No significant differences were observed 
in the percentage of BrdU+ cells, indicating that EP does not affect the proliferation of 
control or SAA-iPSC-derived haematopoietic progenitors (Figure 56A). Similarly, no 
significant changes were observed in the percentage of proliferating and non-
proliferating control-and SAA-iPSC-derived-haematopoietic progenitors with γH2AX 
foci (Figure 56B-C). Together these data indicate that EP does not affect the 
proliferative capacity or DNA repair ability of SAA-iPSC-derived-haematopoietic 
progenitor cells. In summary, these findings demonstrate that SAA-iPSC-derived 
haematopoietic progenitors generated in this study do not respond to EP treatment 
suggesting that the potential underlying haematopoietic progenitor defect observed in 
the SAA patients analysed herein might not be associated with TPO signalling or other 
effects of EP independent of TPO receptor stimulation.   
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Figure 56. Analysis of proliferation and DNA repair capacity of control and SAA-iPSC-derived 
haematopoietic progenitors in the presence and absence of EP under replicative-stress 
conditions. 
(A) Analysis of BrdU-incorporating cells in DMSO (red bars) and EP-treated (grey bars) iPSC-derived-
haematopoietic progenitors in control (WT) and SAA cell lines; (B) Analysis of γH2AX in BrdU+ cells in 
DMSO (red bars) and EP-treated (grey bars) iPSC-derived-haematopoietic progenitors in control (WT) 
and SAA cell lines; (C) Analysis of γH2AX in BrdU- cells in DMSO (red bars) and EP-treated (grey bars) 
in iPSC-derived-haematopoietic progenitors in control (WT) and SAA cell lines. A-C: Multiple t-test using 
Holm-Sidak method was used for statistical comparison between DMSO and EP groups. Data is 
presented as mean of at least 3 independent experiments +/- S.E.M. Data for all control cell lines is 
averaged in one group (WT). 
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6.3 Discussion 
Qualitative and quantitative defects such as reduced colony-forming capacity (Marsh 
et al., 1990; Rizzo et al., 2002; Rizzo et al., 2004) and presence of very low numbers 
of haematopoietic progenitors (Maciejewski et al., 1994; Scopes et al., 1994; 
Maciejewski et al., 1996) as measured by colony assays have been described in SAA 
patients. Presence of low numbers of progenitors in SAA patients and potential 
influence of the patient’s immune system makes it difficult to investigate whether these 
defects are associated to a dysfunctional immune response, as described in many SAA 
patients, or to presence of an underlying haematopoietic progenitor cell defect. iPSC 
approach offers two main advantages: 1) SAA patient-specific iPSC-derived 
haematopoietic progenitors can be generated at ease enabling the use of these 
progenitors for disease modelling studies and 2) enables the study of SAA 
haematopoietic progenitors in an in vitro setting, therefore in the absence of patient’s 
immune system influence, consequently removing one of the variables potentially 
associated to SAA pathophysiology. 
 
Previous studies have shown the potential use of iPSC approach in disease modelling 
to provide insights into pathological mechanisms of BMFS (Chapter 1, section 
1.3.4.2). One of the most recent examples of the use of iPSC technology in DC disease 
modelling was reported by Gu et al. showing that dysregulation of WNT signalling in 
DC-iPSC may contribute to the DC pathogenesis (Gu et al., 2015). Thus, in view of the 
impaired haematopoietic differentiation capacity of the SAA-iPSC-derived 
haematopoietic progenitors and defective telomere maintenance observed in three of 
the SAA cell lines in Chapter 5, I decided to use the SAA-iPSC model to investigate 
potential mechanisms in order to provide evidence of an underlying haematopoietic 
progenitor cell dysfunction. 
 
Defective telomere maintenance can lead to presence of short telomeres resulting in 
reduced numbers of haematopoietic cells in DC patients (Calado and Young, 2009). It 
has been previously described that the presence of critically short telomeres can result 
in the activation of DNA damage checkpoint pathway leading to senescence and 
blocking entry of haematopoietic progenitors into the cell cycle (Allsopp et al., 2003; 
d'Adda di Fagagna et al., 2003; Zimmermann and Martens, 2008). For this reason, I 
decided to investigate the proliferation rate of SAA-iPSC-derived-haematopoietic 
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progenitors. Our results revealed a significantly reduced proliferative capacity in the 
iPSC-derived haematopoietic progenitors of the three SAA cell lines displaying 
excessive telomere shortening (SAA1, SAA2 and SAA3). This reduced proliferation 
might be secondary to the presence of short telomeres as reported previously (Allsopp 
et al., 2003; Raval et al., 2015). Interestingly, SAA4-iPSC-derived haematopoietic 
progenitors showed levels of proliferative cells similar to those in control cell lines. As 
shown in Chapter 5, SAA4 displayed normal haematopoietic colony-forming potential 
and no excessive telomere shortening in iPSC-derived haematopoietic progenitors. 
These results support the idea that reduced proliferation observed in SAA1, SAA2 and 
SAA3-iPSC-derived haematopoietic progenitors is associated to the presence of short 
telomeres in the progenitors of these cell lines. Whether this reduced proliferation is 
specific of the iPSC-derived haematopoietic progenitors is worth investigating. 
Analysis of the proliferation capacity of the affected SAA-iPSC lines would provide an 
answer to this question and would support the hypothesis that the reduced proliferation 
observed in the affected SAA-iPSC-derived haematopoietic progenitors is secondary 
to the presence of short telomeres. Replicative senescence induced by telomere 
shortening leads to an increased activity and expression of the lysosomal hydrolase β-
galactosidase (Bernadotte et al., 2016). Thus, it would be interesting to determine β-
galactosidase activity in iPSC-derived haematopoietic progenitor cells to provide more 
evidence of the link between reduced proliferation and telomere shortening observed 
in the affected SAA cell lines. It has been described that the presence of short 
telomeres activates DNA damage responses leading to up-regulation of p21 and 
blocking cell cycle in G1 (Herbig et al., 2004; Deng et al., 2008). Hence, it is worth 
analysing the expression levels of p21 and G1 arrest of the affected SAA-iPSC-derived 
haematopoietic progenitors in order to provide more evidence of a potential telomere 
dysfunction in these SAA cell lines. Likewise, short telomeres are detected by the cell 
as double-stranded DNA breaks activating the recruitment of γH2AX in dysfunctional 
telomeres, the so-called telomere-induced foci (TIF), and DNA-damage checkpoint 
factors (d'Adda di Fagagna et al., 2003; Takai et al., 2003). In this setting, analysis of 
co-localization of γH2AX and telomeres would be useful to indicate an increased 
telomeric damage pointing to dysfunctional telomeres that could potentially explain the 
reduced proliferation and consequent impaired haematopoietic differentiation in the 
affected SAA cell lines. Another future line of investigation that remains interesting 
would be to analyse the expression of cell cycle regulators as described in Chapter 1 
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(section 1.1.5.2).  Zeng et al. showed that proliferation and cell cycle control genes 
such as CDK6, which is mainly involved in G1/S transition (Malumbres and Barbacid, 
2001), were down-regulated in haematopoietic progenitors from SAA patients (Zeng et 
al., 2004). Of note, up-regulation of p21 expression in cells with short telomeres leads 
to the down-regulation of CDK cell cycle stimulator proteins (Harper et al., 1993; Harper 
et al., 1995), so it is likely that potential CDK6 down-regulation observed in SAA 
haematopoietic progenitors might be secondary to presence of dysfunctional 
telomeres.    
 
Next, to investigate the DNA damage associated to increased proliferation during 
haematopoietic differentiation, SAA-iPSC-derived haematopoietic progenitors were 
subjected to replicative-stress conditions by deoxynucleotide depletion with HU leading 
to arrested replication forks. HU is mainly active in the S-phase of the cell cycle, 
affecting mainly proliferative cells, and prolonged exposure at lower doses can lead to 
collapsed forks generating DNA strand breaks and oxidative stress (Singh and Xu, 
2016). Thus, analysis of accumulation of DNA damage in stalled replication forks 
induced by HU revealed that proliferating (BrdU+) SAA-iPSC-derived haematopoietic 
progenitor cells did not show higher levels of H2AX phosphorylation under conditions 
of replicative stress, most likely indicating a reduced formation of replication forks 
(Gagou et al., 2010; Zeman and Cimprich, 2014). These results corroborate the 
reduced proliferative capacity findings of SAA-iPSC-derived-haematopoietic 
progenitors and exclude the accumulation of replicative stress- induced DNA damage 
as a causative factor for impaired haematopoietic differentiation. However, these 
results do not provide information regarding the ability of SAA cell lines to repair DNA 
damage since no replicative stress-associated DNA damage was observed due to the 
reduced number of proliferative cells. Therefore, it would be interesting to determine 
the ability of the SAA cell lines to repair different types of DNA lesions such as DSB or 
DNA crosslinks with agents such as ionizing radiation and bifunctional alkylators (i.e. 
cisplatin and mitomycin C). Depending on the nature of the DNA lesion different DNA 
repair pathways are activated. Thus, double-strand breaks induced by ionizing 
radiation are mainly repaired by non-homologous end joining (NHEJ), whereas DNA 
crosslinks induced  by cisplatin or mitomycin C are repaired by homologous 
recombination (HR) or FA pathway (Helleday et al., 2008). Tilgner et al. reported the 
use of a ligase IV-iPSC model to highlight the role of NHEJ-mediated-DSB repair in 
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the survival and differentiation of ligase IV-iPSC-derived haematopoietic progenitors 
after induction of DNA damage with ionizing radiation (Tilgner et al., 2013). Thus, it 
would be interesting to use the SAA-iPSC model to determine the DNA repair capacity 
of the SAA cell lines to specific DNA damage by performing a similar analysis.     
 
EP is a non-peptide molecule mimetic to TPO that stimulates bi- and tri-lineage 
haematopoiesis with 40% of the SAA patients responding to EP treatment at 3-4 
months (Olnes et al., 2012; Desmond et al., 2014). However, the mechanism by which 
EP is promoting the generation of blood cells and impacting HSPC in AA patients is 
not fully understood. I studied the ability of EP to rescue the impaired haematopoietic 
differentiation capacity in our SAA-iPSC model. Interestingly, SAA-iPSC-derived 
haematopoietic progenitors did not show a significant increase in the number of 
erythroid or myeloid-lineage CFUs, proliferative capacity or DNA damage repair 
capacity under conditions of replicative stress, upon adding EP during the 
differentiation process. Given the complete lack of any cellular improvements in the 
presence of EP, it is likely that the potential underlying stem cell dysfunction present 
in our SAA cell lines is not associated with the TPO signalling pathway. Interestingly, 
it has been reported that EP failed to improve severe thrombocytopenia in patients with 
inherited BMFS including DC and DBA (Trautmann et al., 2012). Thus, this lack of 
response to EP by DC patients supports our hypothesis that constitutional defects in 
the telomere-associated genes may be at the root of the impaired haematopoietic 
differentiation observed in the SAA-iPSC-derived haematopoietic progenitors. 
Different authors have hypothesized with the idea that EP might be involved in immune 
cell function by modulating regulatory T cell function in SAA patients (Desmond et al., 
2014; Marsh and Mufti, 2014) as observed in chronic ITP patients treated with EP  (Bao 
et al., 2010). Although Desmond et al. did not find significant changes in regulatory T 
cell subsets in 25 SAA patients treated with EP (Desmond et al., 2014), the lack of 
response to EP observed in the SAA cell lines using the iPSC model might suggest 
that EP could have an underlying immune-regulatory function and therefore showing 
no effect on SAA cases with haematopoietic progenitors displaying defects associated 
to telomere maintenance. Nonetheless, it would be also of interest to investigate if this 
group of patients will respond to other available therapies, for example danazol, 
although, to date, it is unclear whether danazol related improvements are due to 
upregulation of telomerase activity through an increase in TERT expression or to a 
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telomerase-independent elongation of telomeres (Calado et al., 2009; Townsley et al., 
2016b). 
 
Taken together, these findings indicate, first, a reduced proliferative capacity in the 
SAA-iPSC-derived haematopoietic progenitors, likely associated with excessive 
telomere shortening observed in these haematopoietic progenitors. Second, in line 
with these findings, affected SAA-iPSC-derived haematopoietic progenitors exhibited 
reduced replicative-stress-associated DNA damage suggesting a reduced formation of 
replication forks. Third, apoptosis was not increased in SAA-iPSC-derived 
haematopoietic progenitors cultured under normal conditions and under replicative-
stress conditions, excluding apoptotic death as potential dysfunctional mechanisms 
causing the reduced differentiation potential observed in the affected SAA patient cell 
lines. Lastly, addition of EP did not improve the proliferative capacity or rescue the 
disease phenotype observed in the affected SAA-iPSC-derived haematopoietic 
progenitors implying that EP signalling is probably not associated to the potential 
haematopoietic progenitor dysfunction present in the affected SAA cell lines. Thus, 
these results suggest that the presence of dysfunctional telomeres observed in SAA1, 
SAA2 and SAA3 cell lines could cause the reduced proliferation of the SAA-iPSC-
derived haematopoietic progenitors observed in this study leading to impaired 
haematopoietic colony-forming capacity.  
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7 Chapter 7. Summary and future work 
7.1 Summary 
IPSC technology offers an excellent opportunity to study the complex pathophysiology 
of SAA for various reasons. First, it provides an unlimited source of SAA patient-
specific haematopoietic progenitor cells that can be used in disease modelling studies 
and assessment of drug effectiveness and toxicity. This is especially relevant in the 
context of SAA due to the difficulties of obtaining haematopoietic progenitors from SAA 
patients for study of disease biology due to their reduced number in the patient’s bone 
marrow. Second, it provides a disease model that enables the study of SAA patient-
specific haematopoietic progenitors in the absence of immune system and 
identification of underlying haematopoietic progenitor dysfunction. Despite the fact that 
SAA is considered immune in nature, there is an increasing recognition that a subgroup 
of patients diagnosed with SAA might actually have underlying genetic defects. Thus, 
use of SAA-iPSC-derived haematopoietic progenitor cells in disease modelling studies 
would allow the identification of underlying dysfunction in these SAA progenitor cells 
in an in vitro setting opening a door to the study of the cellular pathways involved in 
this dysfunction. Identification of constitutional HSPC defects may have profound 
clinical implications on systematic diagnosis and treatment of SAA patients. Correct 
diagnosis of constitutive cases of SAA displaying haematopoietic progenitor 
dysfunction would lead to appropriate treatment with either HSCT, androgen or other 
newly emerging therapies (Miano and Dufour, 2015), avoiding toxicities from 
inappropriate and costly therapies, such as ATG, to which most show no or only 
transient response (Song et al., 2013). Likewise, patients presenting genetic defects 
associated with BMFS have a predisposition towards haematological malignancies 
(Zeng and Katsanis, 2015), therefore rigorous follow-up studies of these patients would 
be imperative. Finally, identification of constitutional haematopoietic progenitor cell 
defects would ultimately lead to family screenings including testing of siblings to avoid 
using affected ‘silent’ siblings that might carry the same genetic defect as donors. This 
body of work was designed firstly to generate a SAA-iPSC model that could 
recapitulate the disease phenotype observed in SAA patients and, secondly, to 
investigate the existence of a potential haematopoietic progenitor cell dysfunction in 
cells from SAA patients by using this model.  
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The main conclusions inferred from this study are summarised as follows: 
 
 iPSC from the four SAA patients (three paediatric and 1 young adult) and 
three unaffected volunteers generated for this study met all the standard 
criteria of pluripotency, including expression of pluripotency markers and 
formation of trilineage teratomae. Moreover, presence of reprogramming 
transgenes or chromosomal abnormalities was not detected, providing 
additional evidence of the fully-reprogramming of the generated iPSC.   
 
 Haematopoietic progenitor cells, marked by expression of CD43 and 
capacity to generate haematopoietic colonies in CFU assays, and 
subsequent progenitor populations (erythroid, megakaryocytic, 
erythroid/megakaryocytic and myeloid) were successfully generated from 
iPSC lines by using a haematopoietic differentiation protocol previously 
described (Olivier et al., 2016).  
 
 SAA-iPSC showed similar potential to generate haematopoietic progenitor 
cells to control cell lines. However, iPSC-derived haematopoietic progenitor 
cells from three of the SAA cell lines (SAA1, SAA2 and SAA3) failed to 
generate mature haematopoietic colonies in CFU assays in similar levels 
than those in control cell lines pointing to a reduced haematopoietic colony-
forming potential in these SAA cell lines. This reduced haematopoietic 
differentiation potential observed in the affected SAA-iPSC-derived 
haematopoietic progenitor cells successfully mirrors characteristic SAA-
associated cytopenia observed in patients, therefore, confirming the 
capacity of iPSC technology to generate a bona fide SAA disease model.  
 
  Telomere length measurement revealed a reduced reprogramming-induced 
telomere elongation in iPSC of three SAA cell lines (SAA1, SAA2 and SAA3) 
despite up-regulation of telomerase activity. Moreover, these affected SAA-
iPSC cell lines displayed an excessive telomere shortening upon 
differentiation towards haematopoietic progenitor cells. 
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 SAA1, SAA2 and SAA3 iPSC-derived haematopoietic progenitor cells 
showed a reduced number of BrdU-incorporating cells indicating reduced 
proliferation whereas SAA4 showed proliferation capacity similar to that in 
control cell lines. Additionally, a reduced number of replication-induced DNA 
damage was observed in the affected SAA cell lines suggesting a reduced 
formation of replication forks and, therefore, confirming previous observation 
of reduced proliferation in these SAA cell lines. 
 
 Addition of EP to cell culture media failed to rescue the affected SAA cell 
lines (SAA1, SAA2 and SAA3) from impaired haematopoietic differentiation 
capacity or increase the proliferative capacity of these cell lines. These 
findings suggest that potential haematopoietic progenitor cell dysfunction 
present in these affected SAA cell lines is not associated with TPO signalling 
or alternative effects of EP independent of TPO stimulation. 
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Based on these findings, I hypothesized that the impaired haematopoietic colony-
forming capacity observed in the iPSC-derived haematopoietic progenitors of SAA1, 
SAA2 and SAA3 cell lines is caused by a defective telomere maintenance leading to 
dysfunctional telomeres in these haematopoietic progenitor cells. This hypothesis is 
supported by the absence of reprogramming-induced telomere elongation in the 
affected SAA-iPSC lines and excessive telomere shortening upon differentiation into 
haematopoietic progenitors most likely due to extensive cellular replication required in 
this process. This accelerated telomere attrition would lead to dysfunctional telomeres 
and subsequent induction of replicative senescence as cellular response to avoid 
genome instability, ultimately resulting in reduced formation of haematopoietic colonies 
in CFU assays. The fact that the remaining SAA cell line, SAA4, did show telomere 
elongation in iPSC, colony-forming potential and proliferation at similar levels than 
control cell lines most likely indicates that the SAA-disease phenotype in this patient 
might not be caused by stem cell dysfunction. However, much more work will be 
required to test the validity of this hypothesis as it is discussed in the next section. A 
representation of the proposed model is presented in Figure 57 in a visual format.  
 
Accelerated telomere shortening in SAA patients has been associated to increased 
proliferative stress observed in the first years following allogeneic HSCT due to 
increased HSPC turnover to replenish the bone marrow stem cell compartment 
(Gadalla and Savage, 2011). It is also plausible that SAA-iPSC derived haematopoietic 
progenitors show a defective proliferation capacity as the primary cause of the 
impaired haematopoietic colony-forming potential. As described in Chapter 1, section 
1.1.5.2, Zeng et al. reported the up-regulation of genes associated with inhibition of 
cell cycle entry and down-regulation of cell proliferation and cell-cycle progress-
enhancing genes (Zeng et al., 2004). Thus, telomeres shortening observed in the 
affected SAA cell lines would be a consequence of an increased compensatory 
proliferation in a smaller number of non-defective SAA-iPSC derived haematopoietic 
progenitors to compensate for the loss of progenitors as reported by others (Beier et 
al., 2012). However, this possibility would imply the presence of a heterogeneous 
population containing defective and non-defective haematopoietic progenitors which 
seems unlikely if a constitutional defect is considered. Likewise, proliferation analysis 
did not show presence of proliferative SAA-iPSC derived haematopoietic progenitors 
in the affected SAA cell lines as it would be expected if the non-defective underwent 
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replicative stress as compensatory mechanism. Based on the data generated in this 
study is difficult to distinguish between these two possibilities and further experiments 
would be required to identify the primary cause associated to the impaired colony-
forming potential of the affected SAA cell lines.     
  
 
Figure 57. Proposed model for the role of telomere maintenance dysfunction found in three of 
the SAA-iPSC lines. 
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The potential defective telomere maintenance would imply the presence of genetic 
defects in telomere-associated genes in the affected SAA cell lines. SAA-iPSC lines 
were originally derived from HDF from SAA patients, underscoring the inherited nature 
of these genetic defects. Patients used for this study were diagnosed with SAA after 
exclusion of inherited BMFS suggesting absence of mutations in known genes 
associated with these syndromes. However, the majority of SAA patients with short 
telomeres lack mutations in previously characterized telomere-associated genes, 
suggesting the existence of undescribed mutations and genes that could contribute to 
defective telomere maintenance (Vulliamy et al., 2005; Calado and Young, 2008; 
Walne and Dokal, 2009; Zeng and Katsanis, 2015; Allegra et al., 2017). Novel 
mutations in genes associated with telomere pathway are rapidly emerging in 
syndromes characterized by short telomeres underscoring the complexity associated 
with telomeric function and regulation and blurring the historical clear distinction 
between SAA and inherited BMFS (Young, 2013; Gandhi et al., 2015; Martinez and 
Blasco, 2015). Thus, assuming that the abnormal phenotype is caused defects by a 
single gene mutation, iPSC technology would provide a model to investigate as-yet-
unknown constitutional defects in telomere-associated genes for further genetic 
studies. This would include correction of gene mutations in SAA-iPSC lines or 
introduction of specific mutations into non-affected control-iPSC lines with genome 
engineering to confirm causal relationship between genetic defect and disease 
phenotype (Musunuru, 2013)  
 
In summary, these data provide evidence for the usefulness of iPSC-based disease 
modelling to replicate key phenotypes associated with SAA. Likewise, SAA-iPSC 
model provides a good platform to identify potential haematopoietic progenitor 
dysfunction, facilitating the identification of cryptic BMFS over acquired/immune-type 
AA. This in turn could prove extremely useful when applied in studies with a larger 
number of patients who are subsequently followed up with exome sequencing to 
uncover specific genetic variants associated with SAA. With current advances in 
genetic medicine, such information can easily be incorporated into diagnostic tests for 
patients and families with SAA, allowing the timely provision of the appropriate 
treatment modality. In conclusion, SAA-iPSC model stands out as an excellent tool for 
the identification of constitutional HSPC defects and uncovering novel constitutional 
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defects for further genetic studies. Further, this model can help SAA patients by 
predicting patient specific drug efficacy and safety in vitro. 
 
I acknowledge that the use of iPSC technology in disease modelling of haematopoietic 
disorders presents some limitations that should be considered in order to avoid 
identification of phenotype due to reprogramming/differentiation artefacts as disease-
relevant phenotype. Variability introduced during the reprogramming and 
differentiation process, either by clonal heterogeneity or genetic background, and the 
lack of protocols that enable the robust generation of bona fide HSCs are among the 
factors that could diminish the utility of iPSC for modelling haematopoietic diseases 
with a late onset. In the next section I discussed different approaches that could help 
overcome some of these hurdles. 
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7.2 Future work 
The work described so far describes the feasibility of using iPSC technology to create 
a SAA disease model to study SAA pathogenesis. In this section, I suggest additional 
studies that would be necessary to improve this SAA-iPSC model to identify underlying 
SAA haematopoietic progenitor dysfunction and the cellular pathways involved in this 
abnormal behaviour:  
 Identification of fully-reprogrammed iPSC clones.  
Successful identification of fully-reprogrammed iPSC clones is one of the 
main challenges associated with iPSC generation in order to avoid the so-
called clonal heterogeneity. Conventional methods used in the 
characterization of iPSC are not sufficient in many aspects due to lack of 
standardization and ability to specifically identified bona fide iPSC clones 
(Asprer and Lakshmipathy, 2015). Interestingly, different studies have 
reported recently the successful identification of markers such as 
IGF2/TRIM58 and CHCHD2 to predict the differentiation potential of iPSC 
lines towards haematopoietic (Nishizawa et al., 2016) or neuroectodermal 
lineages (Zhu et al., 2016) respectively. Thus, Nishizawa et al. reported that 
downregulation of IGF2 and/or aberrant DNA methylation of TRIM58 during 
the reprogramming process would lead to a reduced haematopoietic 
differentiation potential in iPSC clones. Therefore, it would be interesting to 
determine the levels of expression of IGF2 and methylation pattern of 
TRIM58 to confirm that the impaired haematopoietic differentiation potential 
observed in affected SAA-iPSC lines is associated to a haematopoietic 
progenitor cell dysfunction and not as consequence of clonal heterogeneity 
due to aberrant DNA methylation acquired during the reprogramming 
process.   
 
 Genetic background variability 
As discussed in Chapter 4, genetic background has been reported as the 
main driver of variation at a transcriptional, epigenetic and haematopoietic 
differentiation level. In this study, three different control-iPSC lines from 
unaffected individuals were used in order to include genetic background 
variation when comparing with SAA-iPSC lines. However, in order to identify 
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true biological phenotypes rather than just differences in phenotype due to 
genetic background, it would be more appropriate to use iPSC generated 
from unaffected parents/siblings, therefore minimizing variation introduced 
by genetic background. This might be especially relevant for sporadic 
disorders such as SAA in which differences in phenotype might be smaller 
than classical monogenic diseases with more apparent clinical manifestation 
(Bird, 2000).        
 
Likewise, I discussed here further analysis that would be required to support the 
formulated hypothesis proposing defective telomere maintenance as underlying 
dysfunction in affected SAA-iPSC-derived haematopoietic progenitors leading to 
impaired colony-forming capacity of these progenitors. 
 
 Dysfunctional telomeres in SAA-iPSC-derived haematopoietic progenitor 
cells 
Presence of dysfunctional telomeres in SAA-iPSC-derived haematopoietic 
progenitor cells would lead to induction of senescence and formation of TIF 
by accumulation of γH2AX in telomeres as DNA damage response to DSB. 
Detection of β-galactosidase activity would assess the induction of 
senescence (Bernadotte et al., 2016) whereas formation of TIF would be 
detected by co-localization of γH2AX and telomeres by 
immunofluorescence staining (d'Adda di Fagagna et al., 2003). Likewise, 
analysis of expression of p53 by Western blotting and p21 mRNA levels by 
quantitative RT-PCR would provide evidence of the activation of DNA 
damage response and induction of cellular senescence by dysfunctional 
telomeres (Herbig et al., 2004; Deng et al., 2008).  
 
 Genomic studies to identify pathogenic variants  
With the advent of NGS technology, identification of pathogenic genetic 
variants in patients is progressing rapidly. NGS has enabled the 
identification of more than 100 causative genes in Mendelian disorders 
(Rabbani et al., 2012), including MPL (Rabbani et al., 2012; Keel et al., 2016), 
TP53 (Keel et al., 2016) and SRP72 (Kirwan et al., 2012) as causative gene 
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in SAA. Our group performed a whole exome sequencing (WES) analysis of 
SAA patient’s HDF. Unfortunately, no DNA samples from siblings or parents 
of these SAA patients were available which would provide critical information 
for the detection of de novo mutations. WES results revealed that SAA1, 
SAA2 and SAA3 patients did not show DC-associated mutations previously 
described in patients. However, presence of deleterious mutations in other 
telomere-associated genes such as RPA2, NCL, POLD3, TEP1, YLMP1, 
PIF1 and ERCC4 in which no mutations in patients have been described to 
date were detected in SAA1, SAA2 and SAA3 but not in SAA4 (Data not 
shown). Interestingly, the replication Protein A (RPA) has been reported to 
be necessary for telomere maintenance due to its role in unfolding of 
telomeric G-quadruplexes and preventing replication-fork stalling 
(Kobayashi et al., 2010) whereas NCL codifies for the RNA chaperone 
nucleolin that regulates the nuclear localization of telomerase (Khurts et al., 
2004).  Likewise, overexpression of Ylpm1 in mouse ESCs leads to down-
regulation of telomerase activity and telomere shortening resulting in 
reduced proliferation and hematopoietic differentiation ability (Armstrong et 
al., 2004). In line with this, Batista et al. reprogrammed DC fibroblasts 
harbouring mutations in TCAB1 gene, a protein involved in the trafficking on 
the telomerase complex along the telomeric ends, resulting in iPSC with very 
short telomeres despite upregulation of TERT, TERC and dyskerin (Batista 
et al., 2011). These results would support the hypothesis that underlying 
telomere-associated genetic defects observed in our SAA-iPSC model 
would result in primary defective telomere elongation and telomere 
shortening and subsequently impact the proliferation and clonogenic 
capacity of iPSC-derived-hematopoietic progenitor. Thus, it would be 
interesting to carry out WES analysis of a larger cohort of SAA patients in 
order to confirm the prevalence of these variants in other affected individuals 
and identify common pathogenic genes. This approach is especially relevant 
for cases in which the abnormal phenotype is caused by single gene defects. 
However, it is more limited for cases in which the disease is caused by 
interplay of genetic and environmental factors.  
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 Gene-editing approach to correct potential pathogenic mutations. 
The correlation observed between telomere shortening and reduced colony-
forming capacity in the SAA-iPSC derived haematopoietic progenitor cells of 
SAA1, SAA2 and SAA3 cell lines points to a dysfunction in telomere 
maintenance as the underlying cause in the pathogenesis of SAA in these 
patients. However, correlation does not imply causation and the definitive 
experimental evidence of pathogenicity due to underlying telomere 
dysfunction in the affected SAA cell lines would imply functional assays 
correcting the genetic defect and rescue of the SAA-iPSC-derived 
haematopoietic progenitors from the impaired haematopoietic capacity by 
restoring functionality in telomeres. Different studies have reported the 
successful combination of iPSC platform with recently developed gene 
editing technologies to correct disease phenotypes in BMFS such as FA and 
DC (Rio et al., 2014; Osborn et al., 2015; Bluteau et al., 2016; Woo et al., 
2016). Thus, given that the list of previously identified deleterious variants in 
candidate telomere-associated genes using NGS approach may involve 
more than 10 candidates, it would be necessary to perform a proof-of-
principle screen experiment to introduce the relevant wild-type gene using 
genetic manipulation by using lentiviral systems in affected SAA-iPSC lines. 
Genetically-modified SAA-iPSC lines would be differentiated towards 
haematopoietic progenitors in small scale differentiation experiments and 
followed by measurements of telomeres and CFU assays to confirm the 
restoration of telomere functionality and, subsequently, haematopoietic 
colony-forming capacity. If introduction of wild-type gene of interest by 
lentivirus systems successfully reverses the in vitro SAA cellular phenotype, 
it would be interesting to proceed with the correction of the identified 
deleterious variants in the selected candidate genes of the affected SAA-
iPSC cell lines using clustered regularly interspaced short palindromic 
repeats (CRISPR)-CRISPR associated protein 9 (Cas9) genome editing 
technology and CRISPR corrected SAA-iPSC lines would be subjected to 
haematopoietic differentiation to confirm the rescue of the disease 
phenotype as described previously. Likewise, in order to ensure the reliable 
identification of the SAA disease-causing mutations, SAA-disease-
phenotype would be induced in non-disease affected wild-type iPSC lines 
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by introducing the identified mutations using CRIPS/Cas9 systems. These 
approaches would enable in turn the generation of isogenic iPSC lines with 
the correction/introduction of the mutation as only variable minimizing 
variability due to genetic background which can be particularly important in 
the study of sporadic diseases in which phenotypic differences between 
unaffected and affected cell lines are anticipated to be subtle (Shi et al., 2017)  
  
 Follow-up studies  
SAA patients displaying short telomeres are more predisposed to develop 
clonal disorders such as MDS and PNH after receiving IST (Scheinberg et 
al., 2010). Patient SAA1 and SAA2 were treated with IST with different 
outcome (Table 7). SAA2 relapsed and developed PNH, associated with 
clonal evolution. This could be explained by the presence of dysfunctional 
telomeres as pointed out by different authors (Afable et al., 2011; Calado et 
al., 2012; Dumitriu et al., 2012). On the other hand SAA1 responded to IST. 
This contrasts with the possibility that this patient might actually present a 
constitutional telomere-associated defect since it has been reported that 
patients with inherited BMFS show reduced/lack of response to IST (Song 
et al., 2013; Allegra et al., 2017). However, it has been also described that 
patients with defects in TERT can show some response to standard IST 
(Young, 2013; Townsley et al., 2014). Thus, due to the potential defective 
telomere maintenance observed in this patient using the SAA-iPSC model, 
it would be interesting to investigate if this patient has developed a clonal 
disorder that could provide more evidence of the presence of dysfunctional 
telomeres. 
   
 Efficacy of danazol to correct telomere dysfunction 
Danazol, a synthetic sex hormone, has been reported to improve blood 
counts and elongate telomeres in blood leukocytes from patients with 
telomere diseases (Townsley et al., 2016a). It has been hypothesized that 
danazol induces TERT upregulation similarly to that using sex hormones in 
human primary haematopoietic cells (Calado et al., 2009). However, this still 
remains speculative and danazol mechanism of action have not been fully 
elucidated (Grossmann, 2016).  Therefore, even though SAA-iPSC lines 
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showed an upregulation of telomerase activity induced by reprogramming, it 
would be interesting to investigate other possible mechanisms of action of 
danazol and its effect on telomere maintenance in order to correct telomere 
dysfunctionality and potentially rescue affected SAA cell lines from the 
impaired haematopoietic differentiation capacity.  
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9 APPENDIX A: Gating strategies for flow cytometric analysis 
Positive population for SSEA-4 and TRA-1-60 markers on day 0 of haematopoietic 
differentiation was gated using Fluorescence Minus One controls for each specific 
marker (Figure 58). 
 
Figure 58. Gating strategy for analysis of SSEA-4 and TRAA-1-60 markers on day 0 of 
haematopoietic differentiation. 
(A) iPSC Fluorescence Minus One control for SSEA-4 marker (blue) and iPSC cells stained with 
PerCPCy™5.5 anti-human SSEA-4 (red); (B)  iPSC Fluorescence Minus One control for TRA-1-60 
marker (blue) and iPSC cells stained with FITC anti-human SSEA-4 (red). 
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Positive population for KDR marker on day 3 of haematopoietic differentiation was 
gated using PE-Mouse IgG1 isotype control to identify unspecific staining (Figure 59). 
 
Figure 59. Gating strategy for analysis of KDR marker on day 3 of haematopoietic differentiation.  
Differentiated iPSC on day 3 were stained with either PE mouse IgG1 k Isotype Control (blue) or PE 
anti-human KDR (red). 
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Positive population for CD34, CD43, CD41a and CD235a markers on day 6 and day 
12 of haematopoietic differentiation was gated using Fluorescence Minus One controls 
for each specific marker (Figure 60A-D). 
 
Figure 60. Gating strategy for analysis of CD34, CD43, CD41a and CD235a markers on day 6 and 
12 of haematopoietic differentiation. 
(A) Differentiated iPSC Fluorescence Minus One control for CD34 marker (blue) and differentiated iPSC 
cells stained with APC anti-human CD34 (red); (B) Differentiated iPSC Fluorescence Minus One control 
for CD43 marker (blue) and differentiated iPSC cells stained with FITC anti-human CD43 (red); (C) 
Differentiated iPSC Fluorescence Minus One control for CD41a marker (blue) and differentiated iPSC 
cells stained with APCH7 anti-human CD41a (red); (D) Differentiated iPSC Fluorescence Minus One 
control for CD235a marker (blue) and differentiated iPSC cells stained with BV421 anti-human CD235a 
(red). 
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Positive population for CD43, BrdU, γH2AX and Cleaved PARP markers on day 14 of 
haematopoietic differentiation for analysis of proliferation, DNA damage and apoptosis 
of haematopoietic progenitors was gated using Fluorescence Minus One controls for 
each specific marker (Figure 61A-D). 
 
Figure 61. Gating strategy for analysis of CD43, BrdU, γH2AX and Cleaved-PARP markers on day 
14 of haematopoietic differentiation. 
(A) Differentiated iPSC Fluorescence Minus One control for CD43 marker (blue) and differentiated iPSC 
cells stained with FITC anti-human CD43 (red); (B) Differentiated iPSC Fluorescence Minus One control 
for BrdU marker (blue) and differentiated iPSC cells stained with  PerCPCy™5.5 anti-human BrdU (red); 
(C) Differentiated iPSC Fluorescence Minus One control for γH2AX marker (red) and differentiated iPSC 
cells stained with Alexa Fluor® 647 anti-human γH2AX (blue); (D) Differentiated iPSC Fluorescence 
Minus One control for Cleaved-PARP marker (blue) and differentiated iPSC cells stained with PE anti-
human Cleaved-PARP (red). 
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10 APPENDIX B: Data used for analysis of variation in differentiation of iPSC into haematopoietic 
progenitors  
Variable Sample % CD43+ % Ery/MkP % MkP % EryP % MyeP 
Differentiation 
experiment 
WT3-iPSC Clone 1 p42 #1 59 10.5 15.4 15.6 17.5 
WT3-iPSC Clone 1 p42 #2 78.3 19.5 23.7 15.3 19.8 
WT3-iPSC Clone 1 p42 #3 77.9 22.2 24.4 14.7 16.5 
Passage 
WT3-iPSC Clone 1 p32 #1 86.8 15.7 24.2 31.7 15.2 
WT3-iPSC Clone 1 p32 #2 79.9 13.5 23 23.5 19.8 
WT3-iPSC Clone 1 p32 #3 88.9 20.3 21.3 32.4 15 
WT3-iPSC Clone 1 p42 #1 59 10.5 15.4 15.6 17.5 
WT3-iPSC Clone 1 p42 #2 78.3 19.5 23.7 15.3 19.8 
WT3-iPSC Clone 1 p42 #3 77.9 22.2 24.4 14.7 16.5 
WT3-iPSC Clone 1 p52 #1 60.7 11.4 26.8 14.9 7.6 
WT3-iPSC Clone 1 p52 #2 60.1 12.6 26.5 12.9 8.16 
WT3-iPSC Clone 1 p52 #3 41.5 8.19 19 9.14 5.22 
Clone WT3-iPSC Clone 1 p42 #1 79.5 18.3 26.8 14.3 20.1 
195 
 
WT3-iPSC Clone 1 p42 #2 73.9 16.8 20.1 17.4 19.6 
WT3-iPSC Clone 1 p42 #3 69.8 16.4 20.2 14.1 19.1 
WT3-iPSC Clone 4 p42 #1 64 4.26 31.4 19.6 4.77 
WT3-iPSC Clone 4 p42 #2 75.9 9.78 24.8 35.1 6.17 
WT3-iPSC Clone 4 p42 #3 79.4 11.1 26 36.5 5.88 
WT3-iPSC Clone 5 p42 #1 47.1 12.7 10.9 10.9 12.7 
WT3-iPSC Clone 5 p42 #2 57.6 17.4 12.4 16.1 11.7 
WT3-iPSC Clone 5 p42 #3 59.2 15.8 13.1 13.5 16.8 
Genetic 
background 
WT1-iPSC Clone 1 p42 #1 76.1 22 29.1 6.57 18.5 
WT1-iPSC Clone 1 p42 #2 70.8 24.6 22.9 7.15 16.1 
WT1-iPSC Clone 1 p42 #3 71.7 20.8 24.1 8.27 18.5 
WT2-iPSC Clone 1 p42 #1 57.6 1.82 10.8 37 8.06 
WT2-iPSC Clone 1 p42 #2 43.1 1.97 7.88 29 4.23 
WT3-iPSC Clone 1 p42 #1 65.8 18.3 26.8 14.3 20.1 
WT3-iPSC Clone 1 p42 #2 57.3 16.8 20.1 17.4 19.6 
WT3-iPSC Clone 1 p42 #3 57.2 16.4 20.2 14.1 19.1 
Table 12. Percentages of the different populations of haematopoietic progenitors obtained for the different parameters analysed in the variation during 
haematopoietic differentiation of iPSC 
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